



**Effect Of Nigella Sativa Seed Extract On Glucose,
Lipid Profile, Liver Function Tests, Oxidative Stress and
Histological Changes In Pancreas, Kidney, Liver and
Tibial Nerve In Normal and Streptozotocin
Induced Diabetic Rats**

Thesis submitted to the

BLDE UNIVERSITY, VIJAYAPURA, KARNATAKA, INDIA.

Under the faculty of

MEDICINE

For the award of

DOCTOR OF PHILOSOPHY

In ANATOMY

By

Shaik Hussain Saheb

Reg. No-11PhD 014

Department of Anatomy

Shri B M Patil Medical College, Hospital & Research Centre

Vijayapura-586103

2017



BLDE UNIVERSITY

Vijayapura, Karnataka, India

CERTIFICATE

This is to certify that this thesis entitled "*Effect Of Nigella Sativa Seed Extract on Glucose, Lipid Profile, Liver Function Tests, Oxidative Stress and Histological Changes in Pancreas, Kidney, Liver and Tibial Nerve in Normal and Streptozotocin Induced Diabetic Rats*" is a bonafide work of Mr. Shaik Hussain Saheb and was carried out under our supervision and guidance in the Department of Anatomy, Shri B. M. Patil Medical College, Hospital & Research Centre, Vijayapura, Karnataka, India.

Professor of Physiology
BLDE University's Shri B.M. Patil
Medical College, Bijapur.

Dr. Kusal K. Das
Co-Guide

Professor of Physiology
Shri B. M. Patil Medical College,
Hospital & Research Center
Vijayapura, Karnataka.
Visiting Professor
Tulane University, USA.

Dr. S D Desai
Guide,
Principal

& Professor, Department of Anatomy
Shridevi Institute of Medical Science
& Research Centre, Tumkur, Karnataka

PRINCIPAL
Shridevi Institute of Medical Sciences
& Research Hospital,
NH-4, Sira Road, TUMKUR-5

Dr. G. F. Mavishettar

Professor of Anatomy
J. J. M. Medical College

DAVANGERE-577 004

Dr. G.F. Mavishettar
Co-Guide

Professor of Anatomy
JJM Medical College,
Davangere, Karnataka.

Dr. B M Bannur
Professor & Head

Department of Anatomy
Shri B. M. Patil Medical College, Hospital
& Research Centre
Vijayapura, Karnataka

Professor & H.O.D.

Dept. Of Anatomy

B.L.D.E. University's

Shri B M Patil Medical College

Vijayapura-586103.

Dr. S.P. Guggarigoudar
Principal & Dean, Faculty of Medicine
Shri B. M. Patil Medical College, Hospital
& Research Centre,

Vijayapura,
Karnataka

PRINCIPAL,

B.L.D.E. University's
Shri. B. M. Patil Medical College
Hospital & Reserach Centre,
VIJAYAPUR.

DECLARATION

I declare that the thesis entitled "*Effect Of Nigella Sativa Seed Extract On Glucose, Lipid Profile, Liver Function Tests, Oxidative Stress and Histological Changes In Pancreas, Kidney, Liver and Tibial Nerve In Normal and Streptozotocin Induced Diabetic Rats*" has been prepared by me under the guidance of Dr. S D Desai, Department of Anatomy, BLDE University's Shri B. M. Patil Medical College, Hospital and Research Centre, Vijayapura, Karnataka, India. No part of this thesis has formed the basis for the award of any degree or fellowship previously.

Shaik Hussain Saheb
Ph.D. Scholar
Department of Anatomy,
BLDE University's
Shri B. M. Patil Medical College, Hospital & Research Centre
Vijayapura, Karnataka-586103

Date :28/07/2017
Place : Vijayapura

2017

DEDICATED WITH AFFECTION &
GRATITUDE

To

Lord Almighty

My Teachers

&

My Family Members

ACKNOWLEDGEMENT

The endless thanks goes to Lord Almighty for all the blessings he has showered onto me, which has enabled me to write this last note in my research work.

During the period of my research, as in the rest of my life, I have been blessed by Almighty with extraordinary people who have spun a web of support around me. I am not having enough words in expressing how I am very grateful to those excellent people in my life who made this thesis possible. I would like an attempt to thank them for making my time during my research period I will treasure.

I am deeply indebted to my research Guide Dr. S. D. Desai Principal, and Professor in Dept of Anatomy, Shridevi Institute of Medical Sciences, Tumkur, for his valuable guidance, scholarly inputs and constant encouragement I received throughout the research work. This feat was possible only because of the unconditional support provided by him. He has always made himself available to clarify my doubts despite his busy schedules and I consider it as a great opportunity to do my doctoral program under his guidance and to learn from his research expertise.

It is with sincerity and deep sense of gratitude that I thankfully acknowledge my honored co-guide and beloved teacher Dr. Kusal K Das Professor, Laboratory of Vascular Physiology & Medicine, Dept. of Physiology, Shri B M Patil Medical College Hospital & Research Centre, Vijayapura, Visiting Professor, School of Medicine, Tulane University, USA for his guidance. He has guided me with invaluable suggestions, lightened up the way in my darkest times and encouraged me to carry out the work.

It gives me an immense pleasure to express my deep and heart full gratitude and humble and sincere thanks to Dr. G.F. Mavishettar, Professor of Anatomy, JJM Medical College, Davangere for his guidance in carryout the work, valuable advice, constant support and encouragement during the entire academic and research carrier.

I am very much thankful to our college management Shri. Dr. Shamanur Shivasankarappa, MLA, Davangere(South), Shri. Shamanur Maliikarjun, Cabinet Minister, Govt of Karnataka, for providing opportunity to serve JJMMC, Davanagere and providing facilities to carryout Ph.D work.

I owe my most sincere gratitude to Dr. Manjunath Alur, Principal, JJMMC, Davangere, for providing an excellent research environment and facilities to work in the institute and his constant encouragement in academic career.

I express my heart full thanks to Dr. C.M. Ramesh, Former Principal, Sapthagiri Medical College, Bangalore, for his support in academic career and whole process of Ph.D. course.

I am immensely thankful to Great teacher Sir S.T. Thomas, for his valuable suggestions in academic career and during Ph.D. work. He thought me how to write a manuscript for publishing in journals, his support to me in throughout job career cannot explainable in words.

My sincere gratitude to the Dr. S.P. Guggarigoudar, Principal, Shri B. M. Patil Medical College, Hospital & Research Centre, BLDE University, who was a constant source of inspiration during my entire thesis. He had rendered constant support in academic and administration matters.

I am thankful to Dr. Tejaswini Vallabha, Vice- Principal and Chairman of Ph.D. committee, BLDE University, for her constant support, guidance, valuable advises, during Ph.D. course. I am thankful to all the members of Ph.D. committee, BLDE University, for their constant support, guidance, valuable advises, during entire Ph.D. course.

I would like to express the deepest appreciation to Dr. B M Bannur, Professor and Head, Dept. of Anatomy, BLDEU's Shri B.M. Patil Medical College, Vijayapura for his constant support during the course of my study all along the way. I express my heart full thanks to all faculty members of Department of Anatomy.

I extend my thanks to Dr. Manjunath Aithal Prof. HOD Physiology for his needed help during progress report presentations, his guidance and moral support.

I would like express my sincere gratitude to Mr. Satish B. Patil, Deputy Registrar, BLDE university, Vijayapura, for his advises and instruction of all academic proceedings, during entire Ph.D. course.

I express my thanks to Dr. H.R. Chandrashekar, Former principal of JJMMC, for his constant encouragement in academic career.

I express my thanks to Dr. S.B. Muruges, Professor & HOD, Department of Dermatology, for his constant encouragement in academic career.

I offer my gratitude to Dr. A.P. Basavarajappa, Principal, Dr. J.H. Mruthunjaya, Dr. K.V.Ashok Kumar professors, Bapuji Pharmacy college, Davangere, for their support in chemical supply and preparing seed powder.

I would like to offer my special thanks to Dr.Manjunath.M.Tembad, Prof. HOD Biochemistry, JJMMC, Davangere, for providing the facilities to work in their laboratory. My special gratitude to Dr. Gautham and Dr. Chaithanya for their great contribution and assistance during the biochemical investigations.

I would like to offer my special thanks Dr.B.Nikethan Associate Professor of Pathology, JJMMC and Dr. Madhusankari, Professor & HOD of Oral pathology for their help in Histopathology related work. It would be injustice if I don't express my gratitude to the great contribution by Mr. Mahadevappa, Mr. Revansiddappa, Mr. Thares, for their technical help in preparation of histology blocks and sliding.

I express my heart full thanks to Dr. Hadimani. G.A, Dr. Ambudas, who had supported me in all the steps of Ph.D course.

Advice given by Mrs Vijaya Sorganvi and Dr Shahnawaz, Statisticians of Department of Community Medicine was really a great help in data analysis and data interpretations.

I express my heart full thanks to Dr. T. Vivian Samuel and Dr. Smilee Johny, for their constant support during selection of topic and throughout Ph.d course.

I wish to acknowledge the help provided by my all colleagues of Dept of Anatomy, JJMMC, Davngere and I extend my thanks to all the non-teaching staff too for assistance during my thesis. I wish to acknowledge the help provided all staff of Dept of Anatomy, Shri B. M. Patil Medical College, Hospital & Research Centre and I extend my thanks to all the non-teaching staff too for assistance during my thesis.

I would like to offer my special thanks Dr. Muradhilir P Shepur Assistant Professor of Anatomy, Gulbarga govt medical college, for his help in ph.d work, without his help it would have not possible. I express my thanks to Dr.Premchand, for his adjustment in academic curriculum during my Ph.D. work.

I would like to address special thanks to Dr. Somashekar, Dr.Khaji Nissar Ahmed, Mr. Lokesh, department of pharmacology, JJMMC , Davangere, for their great help for providing animals and handling of the animals. My utmost respect goes to my animals without which this study wouldn't have come into existence.

I express my thanks to Dr. P.G. Naveen Kumar, Professor and HOD of Community dentistry, CODS, Davangere, for his suggestions whenever I am in need.

I express my heart full thanks to BLDE University's central Library staff, especially Mr. Shivakumar, Asst Librarian for his help in checking of plagiarism.

I express my thanks to Safa Honey co, Bangalore, for providing Nigella sativa seeds for research work.

I express my thanks to my parents Mr. Shaik Hussain Miya and Shaik Muntaz begum to bring to this level. I would express my deep sense of gratitude to the affection and support shown to me by my Co-Brother and Sister in Law Mr.Rhamath Shaik and Shameena Rahamath. I thank to my brother inlaws Mr. Chowshan Basha and Mr. Khalandhar for their support. I express my special heart full thanks to my mother in-law and father in-law Mrs. Ameerun and Mr. Mahaboob Basha for their financial support for my Ph.D work. The warmest of thanks to my wife Mrs. Haseena Shaik, for her support in each and every way. I also thanks to my two cute little stars Safwana and Madeeha for their contribution in my happiness.

Mr. Shaik Hussain Saheb

Date: 28/07/2017

CONTENTS

Chapter	Content	Page No
	List of Tables	xii
	List of Figures	xiii
	List of Symbols, Abbreviations and Nomenclature	xv
	Abstract	xviii
CHAPTER I INTRODUCTION		
1.1.	Diabetes Mellitus	02
1.2.	Risk factors for type diabetes	03
1.3.	Effect of diabetes on various biochemical Parameters	04
1.4.	Diabetes – Herbal care	07
1.5.	Nigella Sativa	08
	Bibliography – Introduction	13
CHAPTER II REVIEW OF LITERATURE		
2.1.	Diabetes Mellitus	
2.1.1.	Historical background	20
2.1.2.	Types of diabetes Mellitus	20
2.1.3.	Mechanism of diabetes mellitus and its complication	24
2.1.4.	Management of diabetes mellitus	25
2.2.	Nigella Sativa	27
2.2.1.	Historical background	27
2.2.2.	Morphological features of Nigella Sativa	29
2.2.3.	Chemical composition of Nigella Sativa	29
2.2.4.	Nutritional value of Nigella Sativa	31
2.3.	Effects of Nigella Sativa related to diabetes	31
2.3.1.	Effect of Nigella Sativa on blood glucose	32
2.3.2.	Insulinotropic effect of Nigella Sativa	32
2.3.3.	Nigella Sativa and histopathology of pancreatic β -cells	34
2.3.4.	Effect of Nigella sativa on lipid profile Lipid Peroxidation and Anti-oxidant	35
2.3.5.	Effect of Nigella Sativa on liver function tests	38
2.3.6.	Effect of Nigella sativa on kidney, liver and nerve	39
	Bibliography – Review of literature	44
CHAPTER III HYPOTHESIS, AIMS & OBJECTIVES		59

CHAPTER IV MATERIALS AND METHODS

4.1.	Procurement and rearing of experimental animal	62
4.2.	Preparation of Nigella sativa seed powder	62
4.3.	Thymoquinone	62
4.4.	Streptozotocine Induced Diabetes	63
4.5.	Gravimetry	65
4.6.	Method of euthanasia	65
4.7.	Blood & Tissue collection	66
4.7.1.	Blood collection	66
4.7.2.	Tissue collection	67
4.7.3.	Analysis of Biochemical Assay	68
4.7.4.	Histopathology	91
4.8.	Grouping of Animals	95
4.9.	Statistics Analysis	95
	Bibliography – Materials and Methods	96

CHAPTER V RESULTS

5.1.	Gravimetry	101
5.1.1.	Weight gain	101
5.1.2.	Organosomatic index	101
5.2.	Biochemistry	103
5.2.1.	Glucose	103
5.2.2.	Insulin	104
5.2.3.	Oral Glucose Tolerance Test	105
5.2.4.	Oxidant – Malondialdehyde(MDA)	107
5.2.5.	Antioxidants (SOD, Vitamin – C &E)	108
5.2.6.	Lipid profile	110
5.2.7.	Liver function tests	112
5.3.	Histopathology	113
5.3.1.	Histopathology of Pancreas	113
5.3.2.	Histopathology of Liver	116
5.3.3.	Histopathology of Kidney	119
5.3.4.	Histopathology of Nerve	123

Chapter	Content	Page No
CHAPTER VI DISCUSSION		
6.1.	Gravimetry	126
6.1.1.	Weight gain	126
6.1.2.	Organosomatic index	126
6.2.	Biochemistry	127
6.2.1.	Glucose Homeostasis	127
6.2.2.	Oxidative stress and Anti-oxidative markers	130
6.2.3.	Lipid Profile	132
6.2.4.	Liver function tests	135
6.3.	Histopathology	138
6.3.1.	Pancreas	138
6.3.2.	Liver	140
6.3.3.	Kidney	142
6.3.4.	Nerve	144
	Bibliography – Discussion	145
CHAPTER VII SUMMARY & CONCLUSION		157
	Limitation of the study	161
	Scope for future work	161
ANNEXURE -I		
	List of Publications	162

List of Tables

TABLE NO	DESCRIPTIONS	PAGE NO
Table 1	Procedure of Glucose estimation	69
Table 2	Procedure of MDA estimation	70
Table 3	Procedure of SOD estimation	71
Table 4	Procedure for standardization of vitamin –C	74
Table 5	Vitamin C estimation Procedure	75
Table 6	Procedure for standardization of vitamin E	77
Table 7	Analysis of - tocopherol procedure	78
Table 8	Analysis of - tocopherol procedure	79
Table 9	Analysis of - tocopherol procedure	79
Table 10	Procedure for cholesterol estimation	83
Table 11	Procedure for Triglycerides	84
Table 12	Procedure for HDL Cholesterol	85
Table 13	Procedure for ALP estimation	90
Table 14	Procedure for manual tissue processing	92
Table 15	Results of initial, final body weight & gain in each group	102
Table 16	Results of organosomatic index of Pancreas, Liver, Kidney	103
Table 17	Results of Glucose(mg/dl)	104
Table 18	Results of Insulin (mu/L)	105
Table 19	Results of HDL-C, LDL-C, VLDL-C, TC and TG.	111
Table 20	Results of liver Function Tests parameters	113

List of Figures

FIGURE NO	LEGEND	PAGE NO
Figure 1	Nigella Sativa Plant, Flower and Seeds	9
Figure 2	Mechanism of Streptozotocin	64
Figure 3	Oral glucose tolerance test	106
Figure 4	Graph – MDA (nmol/ml)	107
Figure 5	Graph – SOD(U/ml)	108
Figure 6	Graph – Vitamin C(μ g/ml)	109
Figure 7	Graph – Vitamin E(μ g/ml)	109
	Histopathology of Pancreas	
Figure 8	Normal control rat(H&E 10X)	115
Figure 9	Normal rat treated with nigella sativa (H&E 10X)	115
Figure 10	Normal rat treated with thymoquinone(H&E 10X)	115
Figure 11	STZ diabetic control rats (H&E 10X)	115
Figure 12	STZ diabetic rats treated with nigella sativa (H&E 10X)	115
Figure 13	STZ diabetic rats treated with thymoquinone (H&E 10X)	115
Figure 14	Normal control rat (H&E 20X)	116
Figure 15	STZ diabetic control rat (H&E 20X)	116
Figure 16	STZ diabetic rats treated with nigella sativa (H&E 20X)	116
Figure 17	STZ diabetic rats treated with thymoquinone (H&E 20X)	116
	Histopathology of Liver	
Figure 18	Normal control rat(H&E 10X)	118
Figure 19	Normal rat treated with nigella sativa (H&E 10X)	118
Figure 20	Normal rat treated with thymoquinone (H&E 10X)	118
Figure 21	STZ diabetic control rats (H&E 10X)	118
Figure 22	STZ diabetic rats treated with nigella sativa (H&E 10X)	118
Figure 23	STZ diabetic rats treated with thymoquinone (H&E 10X)	118
Figure 24	Normal control rat (H&E 20X)	119
Figure 25	STZ diabetic control rat (H&E 20X)	119
Figure 26	STZ diabetic rats treated with nigella sativa (H&E 20X)	119
Figure 27	STZ diabetic rats treated with thymoquinone (H&E 20X)	119

FIGURE NO	LEGEND	PAGE NO
-----------	--------	---------

Histopathology of Kidney

Figure 28	Normal control rat(H&E 10X)	121
Figure 29	Normal rat treated with nigella sativa (H&E 10X)	121
Figure 30	Normal rat treated with thymoquinone (H&E 10X)	121
Figure 31	STZ diabetic control rats (H&E 10X)	121
Figure 32	STZ diabetic rats treated with nigella sativa (H&E 10X)	121
Figure 33	STZ diabetic rats treated with thymoquinone (H&E 10X)	121
Figure 34	Normal control rat (H&E 20X)	122
Figure 35	Normal rat treated with nigella sativa (H&E 20X)	122
Figure 36	Normal rat treated with thymoquinone(H&E 20X)	122
Figure 37	STZ diabetic control rat (H&E 20X)	122
Figure 38	STZ diabetic rats treated with nigella sativa (H&E 20X)	122
Figure 39	STZ diabetic rats treated with thymoquinone (H&E 20X)	122

Histopathology of nerve

Figure 40	Normal control rat(H&E 10X)	123
Figure 41	Normal rat treated with nigella sativa (H&E 10X)	123
Figure 42	Normal rat treated with thymoquinone(H&E 10X)	123
Figure 43	STZ diabetic control rats (H&E 10X)	123
Figure 44	STZ diabetic rats treated with nigella sativa (H&E 10X)	124
Figure 45	STZ diabetic rats treated with thymoquinone (H&E 10X)	124

List of Symbols, Abbreviations and Nomenclature

SYMBOLS	ABBREVIATIONS & NOMENCLATURE
A	Absorbance
ADP	Adenosine Diphosphate
ALT	Alanine Transaminase
ANOVA	one-way analysis of variance
AST	Aspartate Transaminase
ATP	Adenosine tri phosphate
B	Blank
BW	Body weight
CE	Cholesterol ester
CHE	Cholesterol Esterase
CCL4	Carbon Tetrachloride
CHOD	Cholesterol dehydrogenase
CLIA	Chemiluminescence immunoassay
CPCSEA	Committee For the Purpose of Control and Supervision of Experiments on Animals
CVD	Cardiovascular diseases
DPA	Dihydroxyacetone phosphate
DC	Diabetic Control rats
D-GAL N	D-Glactosamine
DHB	Dichloro hydroxyl benzene sulfonic acid
DI	Deci liter
DM	Diabetes Mellitus
DNA	Deoxy ribo nucleic acid
DNS	Diabetic rats treated with Nigella sativa seed powder
DPX	Distyrene plasticizer and xylene
DTQ	Diabetic rats treated with thymoquinone
DW	Distil Water
EDTA	Ethylene diamine tetra acetic acid
ELISA	Enzyme Linked Immuno Absorbent Assay
FeCl ₃	Ferric Chloride
GAA	Glacial Acetic Acid
GK	Glycerol Kinase
GLUT2	Glucose transporter 2
GSH	Glutathione
H ₂ O ₂	Hydrogen peroxide
H ₂ So ₄	Sulphuric acid
HbA1c	Glycated Hemoglobin
HCL	Hydrochloric acid
HDL	High Density Lipoproteins
IAEC	Institutional Animal Ethics Committee
IU	International Unit
LDH	Lactate dehydrogenase
LDL	Low Density Lipoproteins
LPO	Lipid Peroxidation
LPS	Lipo polysaccharide
LFT	Liver function tests

SYMBOLS	ABBREVIATIONS & NOMENCLATURE
MDA	Malondialdehyde
MDH	Malate dehydrogenase
mg	Milli Gram
mg ²	Magnesium
Min	Minute
mL	Milli Liter
NAD	Nicotinamide Adenine Dinucleotide
NADH	Nicotinamide Adenine Dinucleotide Hydrogenase
NaNO ₃	Sodium Nitrate
NC	Normal control rats
nm	Nano meter
NO	Nitric oxide
NNS	Normal rats treated with Nigella sativa seed powder
NS	Nigella Sativa
NTQ	Normal rats treated with thymoquinone
OD	Optical density
OGTT	Oral glucose tolerance test
OSI	Organosomatic Index
PH	Potential of hydrogen
POD	Peroxidase
RNS	Reactive Nitrogen Species
RLU	relative light units
ROS	Reactive Oxygen Species
S	Standard
Sec	Second
SGOT	Serum Glutamate Oxaloacetate Transaminase
SGPT	Serum Glutamate Pyruvate Transaminase
SOD	Super oxide dismutase
SOP	Standard Operating Procedure
Std.	Standard
STZ	Streptozotocin
T	Test
TBA	Thio Barbituric Acid
TCA	Tri Chloro Acetic Acid
TG	Triglycerides
TQ	Thymoquinone
THQ	Thymohydroquinone
U	Unit
USD	United State Dollars
Vit-C	Vitamin-C
Vit-E	Vitamin-E
VLDL	Very Low Density Lipoproteins
B-cells	Beta cells of Islet of Langerhans
μL	Micro Liter
4AAP	4-Aminoantipyrine

ABSTRACT

ABSTRACT

Introduction: Diabetes is a group of metabolic diseases in which there are high sugar levels over a prolonged period. Symptoms of high glucose levels lead to increased thirst, hunger and frequent urination. If left untreated, diabetes can cause many complications. Acute complications include diabetic ketoacidosis and nonketotic hyperosmolar coma. Serious long-term complications include stroke, kidney failure, cardiovascular disease, diabetic foot and diabetic retinopathy. Diabetes is due to either the pancreas not producing enough insulin or the cells of the body not responding properly to the insulin produced. Diabetes can be treated by medically, diet balance and physical activities. However plant-derived and herbal remedies continue to be popular alternative for diabetes treatment. *Nigella sativa* is an extensively used herb in Arab medicine and Indian system of medicine Ayurveda. The present study was conducted to assess the effect of *Nigella sativa* seed and thymoquinone (major bio-active component of *Nigella sativa* seed) in the treatment of streptozotocin induced diabetic albino Wister rats.

Material and Methods: Laboratory bred adult albino Wister rats weighing between 175 - 250gm were used in the study. The acclimatized animals were divided into six groups of six rats each. Group I rats were normal control rats; group II were normal rats treated with *Nigella sativa* seed powder (300mg/kg body weight); group III were normal rats treated with thymoquinone(4mg/kg body weight); group IV were streptozotocin induced diabetic control rats; group V were streptozotocin induced diabetic rats treated with *Nigella sativa* seed powder(300mg/kg body weight) and group VI were

streptozotocine induced diabetic rats treated with thymoquinone(4mg/kg body weight). The duration of study was 45 days. At the end of 45 days blood was collected for biochemical tests such as glucose, insulin, MDA, SOD, Vitamin C & E, lipid profile and liver function tests. Oral glucose tolerance test (OGTT) was performed at the end of 45 days of study in all the groups. For the histopathological observations pancreas, liver, kidney and nerve tissues were collected and processed. IAEC was taken and CPESEA guide lines were followed.

Results: The diabetic untreated rats showed significant increase in serum glucose, total cholesterol, LDL – cholesterol, VLDL – cholesterol, triglycerides, AST, ALT, ASP and MDA compared with normal control rats. After treatment with *Nigella sativa* seed powder and thymoquinone in induced diabetic rat groups the above mentioned parameters were lowered significantly. Insulin, SOD, Vitamin C, Vitamin E and HDL – cholesterol were decreased significantly in diabetic untreated group. After treatment with *Nigella sativa* seed powder and thymoquinone the same parameters were increased significantly in induced diabetic rat groups. The diabetic rat groups treated with *Nigella sativa* seed powder and thymoquinone showed tolerance to oral glucose tolerance test (OGTT) compared with diabetic control rats. There was no significant change of any parameter between normal control rat groups and normal rat groups treated with *Nigella sativa* seed powder and thymoquinone. Histopathological observations of pancreas, liver and kidney of induced diabetic treated rat groups revealed that treatment with *Nigella sativa* seed powder and thymoquinone reversed the histopathological changes seen in induced diabetic control rats. There was no significant histopathological changes

observed between normal control rats and normal rat group treated with *Nigella sativa* seed powder and thymoquinone. This indicates nontoxicity of *Nigella sativa* seed and thymoquinone.

Conclusion: The biochemical parameters in induced diabetic rats were normalised with treatment of *Nigella sativa* seed powder and its major bioactive component thymoquinone. There was no toxic effect observed in normal groups treated with *Nigella sativa* seed powder and thymoquinone. This observation was supported by non-significant changes in biochemical parameters between normal control rats and normal rat groups treated with *Nigella sativa* seed and thymoquinone and furthermore supported by histological observations. The biochemical results and histopathological observations clearly showed beneficial effect of *Nigella sativa* seed powder and thymoquinone in diabetic treated groups. Hence these phytochemical substances may be considered as antidiabetic agents as well as beneficial to the overall diabetic health.

Key words: *Nigella sativa* seed, Thymoquinone, Diabetes mellitus, Streptozotocin, Hyperglycaemia, Antioxidants, Dyslipidaemia, Liver enzymes.

CHAPTER 1

INTRODUCTION

1.1.Diabetes mellitus

Diabetes mellitus (DM) is usually known to as diabetes and it is a group of metabolic disorders in which mainly there are high glucose levels over a long period. Symptoms of high glucose levels lead to increased thirst and hunger and frequent urination. If left untreated, diabetes can cause many complications. Acute complications include diabetic ketoacidosis and nonketotic hyperosmolar coma. Serious long-term complications includes stroke, kidney failure, cardiovascular disease, diabetic foot and diabetic retinopathy. The reason for diabetes is either the pancreas is not releasing sufficient insulin or the cells of the body are not responding properly to the insulin^{1,2}.

In diabetes mellitus there are three important types:

- Type 1 DM due to pancreas failing to produce sufficient insulin. Earlier it was called as ``insulin-dependent diabetes mellitus``.
- Type 2 DM in which the cells of the body fail to respond to insulin properly due to insulin resistance. As the disease progresses, a lack of insulin may also develop. Earlier it was called as "non-insulin dependent diabetes mellitus". The primary cause is excessive body weight and not enough exercise¹.
- Gestational diabetes which occurs in pregnant women. In this type there need not any previous history of diabetes but a high glucose level is developed in pregnancy period³.

Prevention and treatment of diabetes involve a healthy diet, physical exercise, weight management and avoiding smoking. The diabetic persons should control

the blood pressure and proper care of their foot is very important. Type 1 DM may be managed with insulin injections¹. Type 2 DM may be treated with proper medications, with or without insulin and proper physical workouts³. Gestational diabetes usually resolves after the birth of the baby⁴. In 2014, an estimated 387 million people had diabetes throughout world⁵, out of which Type2 DM were about 90%. This represent 8.3% of the adult population, with equal rates in both women and men⁶. In between 2012 and 2014, diabetes resulted in an estimated 1.5 to 4.9 million deaths each year⁵. Diabetes at least doubles a person's risk of death¹. The number of people with diabetes is expected to increase to 592 million by 2035⁵. The economic cost of diabetes worldwide in 2014 was estimated around 612 billion USD⁷.

1.2. Risk Factors for Type 2 Diabetes^{8,9}

People who develop type 2 diabetes are more likely to have the following characteristics:

- Age 45 years or more
- Overweight or obese
- Physically inactive
- Parent or sibling with diabetes
- History of giving birth to a baby weighing more than 9 pounds
- History of gestational diabetes
- High blood pressure—140/90 or above—or being treated for high blood pressure

- High-density lipoprotein (HDL) cholesterol below 35 milligrams per deciliter (mg/dL) or a triglyceride level above 250 mg/dl
- Polycystic ovary syndrome also called PCOS
- Prediabetes— HbA1C level of 5.7 to 6.4 %; fasting plasma glucose level of 100–125 mg/dl, called impaired fasting glucose; or 2-hour oral glucose tolerance level of 140–199, called impaired glucose tolerance
- History of cardiovascular disease.

1.3. Effect of diabetes on various biochemical parameters

Homeostasis of blood glucose levels

Glucose is the main source of energy for the cells in our body, but it is too big to simply diffuse into the cells by itself. Instead, it needs to be transported into the cells. Pancreas is producing the hormone Insulin which facilitates glucose transport into the cells. Insulin helps in glucose transport into the cells from the bloodstream, thus lowering blood sugar level. In fact, insulin actually stimulates glycogen formation from glucose. All these functions of insulin help to lower sugar level in the blood. In general the glucose level in the blood is estimated in terms of milligrams per decilitre (mg/dl), with the normal range of 70 to 110 mg/dl. In general, if glucose level is out of this range, the amount of insulin and glucagon released by the pancreas will be used to bring sugar levels back within the normal range. In normal individuals that insulin and glucagon signalling are having not all-or-nothing responses. When the system is functioning

properly, there is always some insulin and some glucagon being produced by the pancreas that is acting to bring a balance between glucose release into the blood and glucose uptake into cells^{10, 11}.

Many studies have proved that oxidative stress is to participate in the progression of diabetes which plays an important role during diabetes, including impairment of insulin action and elevation of complication incidence. Antioxidants have very good roll in the treatment of diabetes both Type 1 and Type 2. Increase in the levels of oxygen and nitrogen free radicals (ROS/RNS) has been linked with non-enzymatic glycation of proteins, oxidation of glucose and lipid peroxidation which lead to diabetes mellitus and its complications. Most of the studies have shown the oxidative stress effect in diabetes and with the complications related to eye, heart, kidney and liver. Thus, oxidative stress is a more worrying factor in metabolic disorders specially diabetes Type 2^{12, 13, 14}.

In diabetic conditions oxidative stress is produced and is likely involved in progression of pancreatic beta-cell dysfunction. This may be due to low levels of antioxidant enzymes, pancreatic beta-cells being very vulnerable to oxidative stress. Pancreatic beta-cell dysfunction leads to lower levels of insulin, resulting in hyperglycaemia and the cells show intolerance to glucose. Higher levels of glucose lead to increased percentage of HbA1c¹⁵.

Lipids

Diabetes mellitus produces disturbed changes in the lipid profile, which leads to the cells more susceptible to lipid peroxidation¹⁶. Experimental studies show that the

presence of polyunsaturated fatty acids in cell membrane leads to attack by free radicals due to the presence of multiple bonds¹⁷. Lipid hyperperoxides (LHP) through intermediate radical reactions produce such fatty acids that generate highly reactive and toxic lipid radicals that form new lipid hyperperoxides¹⁸. A critical biomarker of oxidative stress is lipid peroxidation which is the most explored area of research when it comes to ROS¹⁹. Malondialdehyde (MDA) is formed as a result of lipid peroxidation that can be used to measure lipid peroxides after reacting it with thiobarbituric acid²⁰. These conditions lead to increased levels of MDA, total cholesterol, triglycerides, LDL-C, VLDL-C, ratio between total cholesterol and HDL-C, ratio between total HDL-C and LDL -C and decreased levels of HDL-C.

Vitamins

Vitamins are very important because they play important role in different biochemical processes. Vitamin A, C and E act as antioxidants by detoxifying the free radicals. The changes in vitamin levels are significant biomarkers of oxidative stress. The more utilization of these vitamin levels leads to decreased levels of same vitamins¹⁸.

Superoxide dismutase (SOD)

Superoxide dismutase provides first line defence against ROS mediated cell injury by catalysing the proportion of superoxide, the primary ROS in oxygen metabolism, to molecular oxygen and peroxide. This condition leads to lower levels of SOD in diabetes²¹.

Liver function tests

Theories behind liver function test parameters elevation in diabetes state that the liver helps to maintain normal blood glucose concentration in the fasting and postprandial states. Loss of insulin effect on the liver leads to glycogenolysis and increase in production of hepatic glucose. Abnormalities of triglyceride storage and lipolysis in insulin-sensitive tissues such as the liver are an early manifestation of conditions characterized by insulin resistance and it also can be detectable earlier than fasting hyperglycaemia, the precise genetic, environmental and metabolic factors and sequence of events that lead to the underlying insulin resistance²². The excess in free fatty acids found in the insulin-resistant state is known to be toxic to hepatocytes. Putative mechanisms include high concentration of cell membrane disruption, toxin formation, mitochondrial dysfunction and inhibition and activation of key steps in the regulation of metabolism²³. Other potential explanations for elevated transaminases in insulin-resistant states include peroxisomal beta-oxidation, recruited inflammatory cells and oxidant stress from reactive lipid peroxidation.

1.4. Diabetes – Herbal care

There are two important principles in the management of Type 2 diabetes: one is to increase the production and effectiveness of insulin as a part of therapeutic management and the other is to decrease the glucose load to the body as part of dietary management. The drugs are of two types: some drugs are managing the diabetes by increasing the insulin production from pancreatic β -cells (Sulphonylurea) and some drugs are working

like insulin (Biguanides). These drugs play very important role in treatment of diabetes, but due to failures in achieving ideal result and increasing side effects, there has always been a need and desire for a natural, more effective and economically feasible alternative with fewer side effects. Herbs are the main say in the alternative treatments, as there are very satisfying for the patients to get their ailments treated with traditional recipes. These are safe and easy to be administrated, provided these are properly recognized and their pharmacological properties established.

1.5. NIGELLA SATIVA

Scientific classification ^{24, 25 ,26 ,27}

Kingdom	: Plantae
Division	: Angiosperms
Class	: Eudicots
Order	: Ranunculales
Family	: Ranunculaceae
Genus	: Nigella
Species	: Nigella Sativa



Fig 1: Nigella Sativa Plant, Flower and Seeds

Common Names

English : Black-caraway, Black-cumin, Fennel-flower, Roman-coriander.

Hindi : Kalonji, Kalajira,

Sanskrit : Mugrela, Upakuncika, Kalajaji

Kannada : Kari jirige

Bengali : Kalo jira

Among the traditional remedies, prescriptions of *Nigella sativa* for the treatment of various diseases are well-known since prehistoric era and especially its seeds for over 4000 years all over the world²⁸. It is commonly known as black seed or black cumin. Pre-Islamic Arabian world knew the seed well, as the Egyptians used to keep the black seeds with mummies in their tombs, thinking that it would help them in the life thereafter. This indicates that *Nigella sativa* was used by Egyptians in different walks of their lives. The Holy Prophet Muhammad (PBUH) appreciated the use of black seed as a remedy for every illness except the death²⁹. The plant of *Nigella sativa* is half a meter tall, having blue flowers and triangular black seeds with pungent smell²⁸. Seeds contain a considerable amount of fixed and volatile oils³⁰, proteins, alkaloids and saponins³¹.

Modern trials have proved that its seeds alone or in combination with other drugs are highly effective in diabetes mellitus³², vitiligo, skin diseases³³, inflammation³⁴ and improve lipid profile through increasing HDL cholesterol and decreasing LDL cholesterol and triglycerides³⁵. Therapeutic effects of *Nigella sativa* are thought to be due to nigellone and thymoquinone contents. The reported pharmacological properties include protection against disease and chemical induced renal and hepatic toxicity, anti-inflammatory, analgesic, antipyretic, anti-microbial and antineoplastic activities. The oil decreases blood pressure, cholesterol, triglycerides and glucose and increases respiration, haemoglobin and packed cell volume. In diabetics, it has insulinotropic action³⁶ and decreases hepatic gluconeogenesis³⁷, thus lowering blood glucose³⁸. Increased intensity of staining for insulin and preservation of beta-cell numbers are the evidences to this effect^{39,40}. *Nigella sativa* has been tried as anti-diabetic mostly in rats and other Type 2 like animal models with considerable efficacy³⁷.

Many previous studies proved that *Nigella sativa* seed is indeed a true panacea, having the capacity to treat everything from small allergies to hypertension and diabetes. A study is relating *Nigella sativa* to multi-drug resistant bacteria. This is very important because these multi-drug resistant bacteria are becoming more dangerous to public health⁴¹. According to a study, the important phytochemicals present in *Nigella sativa* seed are thymoquinone (TQ), thymohydroquinone (THQ) and thymol. This study proved the antifungal nature of *Nigella sativa* components, thymol, TQ and THQ against 30 human pathogens⁴².

Thymoquinone is one of most important components which have been studied since five decades. Many previous studies proved thymoquinone having anti-oxidant, anti-inflammatory and anticancer properties and used in encephalomyelitis, diabetes, asthma and carcinogenesis⁴³. Thymoquinone is acting as an effective superoxide radical scavenger. In addition it also helps to preserve antioxidant enzymes glutathione peroxidase and glutathione-S-transferase. These are major detoxifiers and play important role in cellular antioxidant defence systems because of their hepatoprotective nature from toxins^{43,44}.

Thymohydroquinone is important natural acetylcholinesterase(AChE) inhibitors. These inhibitors are chemicals that stop enzyme activity and these play very important role in treatment of Alzheimer's disease, autism, glaucoma, neurodegenerative conditions, schizophrenia, and Parkinson's disease^{45,46}.

Thymol is one of the active ingredients of *Nigella sativa* seed which acts as natural monoterpene that has a number of useful qualities^{47,48}. It is used as a tuberculocide and medical and general purpose disinfectant. A study of antitumor activity of thymoquinone and thymohydroquinone proved that the two phytochemicals in *Nigella sativa* seed can reduce the tumour cells up to 52%⁴⁹.

A study demonstrated the hepatoprotective nature of *Nigella sativa* seed and thymoquinone⁵⁰. Another research study stated that *Nigella sativa* and thymoquinone can cause partial regeneration of pancreatic beta-cells and these can increase the lowered

serum insulin levels and decrease the elevated sugar levels⁵¹. The same study stated that *Nigella sativa* seed can act like as metformin, which can increase glucose tolerance.

Hence the present study was an attempt to investigate the effects of *Nigella sativa* seed powder and its major bioactive component, thymoquinone on various biochemical parameters and histopathological changes in metabolic organs in normal and streptozotocine induced diabetic rats.

BIBLIOGRAPHY

1. "Diabetes Fact sheet N°312". WHO. October 2013. Retrieved 25 March 2014.
2. Shoback, edited by David G. Gardner, Dolores. "Chapter 17". Greenspan's basic & clinical endocrinology. 2000. 9th ed. New York: McGraw-Hill Medical.
3. Rippe, edited by Richard S. Irwin, James M. Manual of intensive care medicine. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. 5th ed. 2010. p. 549.
4. Cash, Jill Family Practice Guidelines. Springer. 2005. 3rd ed. P.396.
5. "Update 2014". IDF. International Diabetes Federation. Retrieved 29 November 2014.
6. Shi, Yuankai; Hu, Frank B. "The global implications of diabetes and cancer". The Lancet. 2012; 383 (9933): 1947–8.
7. IDF Diabetes Atlas. International Diabetes Federation. 6th edi. 2013. p. 7.
8. Grant RW, Moore AF, and Florez JC. Genetic architecture of type 2 diabetes: recent progress and clinical implications. Diabetes Care. 2009; 32(6):1107–1114.
9. Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009; 374(9702):1677–1686.

10. Ebey Soman, Scienceray. Regulation of Glucose by Insulin. May 4, 2009. Retrieved November 1, 2009.
11. Fortes RC, Novaes MR, Recôva VL, Melo AL. "Immunological, hematological, and glycemia effects of dietary supplementation with *Agaricus sylvaticus* on patients' colorectal cancer." *Exp Biol Med* (Maywood). 2009; 234 (1): 53–62.
12. Ayepola, O.R., Brooks, N.L., Oguntibeju, O.O. *Oxidative Stress and Diabetic Complications: The Role of Antioxidant Vitamins and Flavonoids*. 2014.
13. Bansal, A.K., Bilaspuri, G.S. Impacts of oxidative stress and antioxidants on semen functions (review article). 2011; *Vet. Med. Int.*
14. Kangralkar, V.A., Patil, S.D., Bandivadekar, R.M. Oxidative stress and diabetes: a review. *Int. J. Pharm. Appl.* 2010;1 (1), 38–45.
15. Kajimoto Y¹, Kaneto H. Role of oxidative stress in pancreatic beta-cell dysfunction. *Ann N Y Acad Sci.* 2004; 1011:168-76.
16. Patricia, P.M. Reactive species and diabetes: counteracting oxidative stress to improve health. *Curr. Opin. Pharmacol.* 2009; 9: 771– 779.
17. Butterfiel et al. Structural and functional changes in proteins induced by free radical- mediated oxidative stress and protective action of the antioxidants N-tert-butyl-alpha-phenylnitronone and vitamin E. *Ann. N.Y. Acad. Sci.* 1998;854: 448–462.
18. Maritim, A.C., Sanders, R.A., Watkins, J.B. Diabetes, oxidative stress, and antioxidants: a review. *J. Biochem. Mol. Toxicol.* 2003; 17 (1):24–38.

19. Hatice, P. et al. Lipid peroxidation and resistance to oxidation in patients with type 2 diabetes mellitus. *Tohoku J. Exp. Med.* 2004; 203:211–218.
20. Esterbauer, H., Schaur, R.J.r., Zollner, H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. *Free Rad. Biol. Med.* 1991; 11 (1):81–128.
21. Tiwari, B.K. et al. Markers of oxidative stress during diabetes mellitus. *J. Biomarkers.* 2013.
22. Lewis GF, Carpentier A, Khosrow A, Giacca A: Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. *Endocr Rev* 2001;23:201–229.
23. Neuschwander-Tetri BA, Caldwell S: Nonalcoholic steatohepatitis: summary of AASLD single topic conference. *Hepatology.* 2003; 37:1202–1219.
24. "BSBI List 2007". Botanical Society of Britain and Ireland. Archived from the original (xls) on 2015-02-25. Retrieved 2014-10-17.
25. Heiss, Andreas. "The oldest evidence of *Nigella damascena* L. (Ranunculaceae) and its possible introduction to central Europe". *Vegetation History and Archaeobotany.* 2005;14 (4): 562–570.
26. Zohary, Daniel; Hopf, Maria. *Domestication of plants in the Old World* (3 ed.). Oxford University Press. 2000: 206p.
27. Saliha B, Sipahib T, Oybak Donmez, E. "Ancient *Nigella* seeds from Boyalı Hoyuk in north-central Turkey". *Journal of Ethnopharmacology.* 2009;124 (3): 416–20.

28. Malcolm Stuart. *The Encyclopedia of Herbs and Herbalism*, Macdonald and Co. Turin, Italy. 1987.
29. Bukhari, M. *Sahih Bukhari Sharif*. Reprint. Lahore Pakistan: Maktaba Rehmania Urdu Bazar, 1985;3: p312.
30. Nickavar, B., F. Mojab, K. Javidnia, and M. A. Amoli. Chemical composition of the fixed and volatile oils of *Nigella sativa* L. from Iran. *Z Naturforsch [C]*. 2003; 58 (9): 629-631.
31. Al-Ghamdi, M. S. Protective effect of *Nigella sativa* seeds against carbon tetrachloride- induced liver damage. *Am. J. Chin. Med.* 2003;31 (5):721-728.
32. Al-Rowais, N. A. Herbal medicine in the treatment of diabetes mellitus. *Saudi Med. J.* 2002; 23 (11):1327-1331.
33. Khan, A., I. Ahmad and Z. M. Wazir. Epidemiological studies of diabetes mellitus in the North West Frontier Province of Pakistan. *J. Med. Sci.* 1993;3 (3): 35-44.
34. Hajhashemi, V., A. Ghannadi and H. Jafarabadi. *Phytother Res.* 2004;18 (3): 195-199.
35. Kalus, U., A. Pruss, J. Bystron, M. Jurecka, A. Smekalova, J. Lichius and H. Kieseewetter. Effect of *Nigella sativa* (black seed) on subjective feeling in patients with allergic diseases. *Phytother Res.* 2003;17 (10):1209-1214.
36. Rchid, H., H. Chevassus, R. Nmila, C. Guiral, P. Petit, M. Chokairi and Y. Sauvaire. *N. sativa* seed extracts enhance glucose-induced insulin release

- from rat-isolated Langerhans islets. *Fundam. Clin. Pharmacol.* 2004;18 (5): 525-529.
37. Fararh, K. M., Y. Atoji, Y. Shimizu, T. Shiina, H. Nikami, T. Takewaki. Mechanisms of the hypoglycemic and immunopotentiating effects of *Nigella sativa* L. oil in streptozotocin-induced diabetic hamsters. *Res. Vet. Sci.* 2004;77 (2): 123-129.
38. Al-Rowais, N. A. Herbal medicine in the treatment of diabetes mellitus. *Saudi Med. J.* 2002;23 (11):1327-1331.
39. Kanter, M., I. Meral, Z. Yener, H. Ozbek, H. Demir. Partial regeneration/proliferation of the beta-cells in the islets of Langerhans by *Nigella sativa* L. in streptozotocin-induced diabetic rats. *Tohoku J. Exp. Med.* 2003;201 (4): 213-219.
40. https://en.wikipedia.org/wiki/Nigella_sativa. Retrived on 15/04/2017.
41. <https://www.niaid.nih.gov/topics/antimicrobialResistance/understanding/Pages/quickFacts.aspx>. Retrived on 20/04/2017.
42. Taha, M.; Azeiz, A. Z. Abdel; Saudi, W. Antifungal Effect Of Thymol, Thymoquinone And Thymohydroquinone Against Yeasts, Dermatophytes And Non-Dermatophyte Molds Isolated From Skin And Nails Fungal Infections. *Egyptian Journal of Biochemistry & Molecular Biology.* 2010;28(2):109.

43. Woo CC, Kumar AP, Sethi G, Tan KH. Thymoquinone: potential cure for inflammatory disorders and cancer. *Biochem Pharmacol.* 2012 Feb 15;83(4):443-51.
44. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. *Crit Rev Biochem Mol Biol.* 1995;30(6):445-600.
45. Jukic M, Politeo O, Maksimovic M, Milos M, Milos M. . In vitro acetylcholinesterase inhibitory properties of thymol, carvacrol and their derivatives thymoquinone and thymohydroquinone. *Phytother Res.* 2007 Mar;21(3):259-61.
46. https://en.wikipedia.org/wiki/Acetylcholinesterase_inhibitor. 12/01/2017.
47. Hu D, Coats J. Evaluation of the environmental fate of thymol and phenethyl propionate in the laboratory. *Pest Manag Sci.* 2008 Jul;64(7):775-9.
48. <https://www.epa.gov/oppsrrd1/REDS/factsheets/3143fact.pdf>: 12/01/2017.
49. Ivankovic S, Stojkovic R, Jukic M, Milos M, Milos M, Jurin M. The antitumor activity of thymoquinone and thymohydroquinone in vitro and in vivo. *Exp Oncol.* 2006 Sep;28(3):220-4.
50. Hamed MA, El-Rigal NS, Ali SA. Effects of black seed oil on resolution of hepato-renal toxicity induced by bromobenzene in rats. *Eur Rev Med Pharmacol Sci.* 2013 Mar;17(5):569-81.
51. Murli L. Mathur, Jyoti Gaur, Ruchika Sharma, Kripa Ram Haldiya. Antidiabetic Properties of a Spice Plant *Nigella sativa*. April 2011;1(1):1-8.

CHAPTER 2

REVIEW OF LITERATURE

2.1 Diabetes Mellitus

2.1.1. Historical Background

The history on the discovery of Diabetes Mellitus is fascinating. Papyrus ebers of ancient Egypt (1500 BC) mentioned a number of remedies for combating the passing of too much urine (polyuria). In Ayurveda it recorded that insects and flies were attracted to the urine of some people that the urine tasted sweet and this was associated with certain diseases. Susruta (1000 BC) diagnosed Diabetes Mellitus. Greeks like Aristaeus, Celsius and Galen described the pathological condition of diabetes. Aristaeus was the first person to differentiate between diabetes insipidus and diabetes mellitus. Paul of Aegina refined further the diagnosis of "dypsacus" (diabetes), considered the dehydration in diabetes due to weakness of the kidneys and excess moisture from the body. Apollonius of Memphis probably coined the name "diabetes" sometime around 250 BC. The literature of those days reflects the early understanding of a disease that drained patients of more fluid than they consume. In the first century AD, the Greeks described diabetes as a melting down of the flesh and limbs into urine. Mellitus means in Latin honey and gradually the word "mellitus" word was appended to diabetes because of its link with sweet urine. It was not until 1798 that John Rollo actually documented excess sugar in the blood as well as the urine^{1,2,3}.

2.1.2. Types of Diabetes Mellitus

Diabetes Mellitus (DM) is a metabolic disorder. The characteristic features are the presence of chronic hyperglycemia accompanied by greater or lesser impairment in the metabolism of carbohydrates, lipids and proteins. There are three

types of diabetes, Type 1 diabetes, Type 2 diabetes and gestational diabetes. All these three types of diabetes mellitus have some common features. Normally, our body breaks down the sugars and carbohydrates we eat into a special sugar called glucose. Glucose fuels the cells in our body. The cells need insulin, a hormone, in our bloodstream in order to take in the glucose and use it for energy. In diabetes mellitus, either the pancreas does not secrete enough insulin or the body cannot use the insulin it produces or a combination of both. Since the cells cannot take in the glucose, it builds up in blood. High levels of blood glucose can damage the tiny blood vessels in kidneys, heart, eyes or nervous system. That is why diabetes if left untreated can eventually cause heart disease, stroke, kidney disease, blindness and damage to nerves in the feet.

Type 1 Diabetes: It is a more severe form and is insulin-dependent. Previously it was also called as juvenile diabetes, because Type 1 diabetes usually develops in children and teenagers but it can develop at any age. In Type 1 diabetes, pancreas does not produce insulin. This type is an autoimmune condition and it is due to body attacking its own pancreas with antibodies. In Type 1 diabetic patients, the pancreas is damaged and it cannot produce insulin. This type of diabetes may be caused by a genetic disorder. Type1 diabetes can affect major organs in body including heart, blood vessels, nerves, eyes and kidneys. Keeping blood glucose level in control can dramatically reduce the risk of many complications. When this type of diabetes is untreated it can develop long-term complications gradually. Management of healthy blood glucose can help lower the risk of complications. The major long term complications of type 1 diabetes are atherosclerosis, neuropathy, nephropathy,

diabetic retinopathy and diabetic foot damage. Treatment for type 1 diabetes involves subcutaneous injection of insulin^{4,5}.

Type 2 Diabetes: Type 2 diabetes is a progressive condition and it is most common, accounting for 95% of diabetic cases in adults. Type 2 diabetes was called adult-onset diabetes but with the epidemic of obese and overweight kids, more teenagers are now developing Type 2 diabetes. Type 2 diabetes was also called non-insulin dependent diabetes. Often it is considered that Type 1 diabetes is more dangerous than Type 2 diabetes. Nevertheless, Type 2 diabetes can still cause major health complications, particularly in the smallest blood vessels in the body that nourish the kidneys, nerves and eyes. Type 2 diabetes also increases the risk of heart disease and stroke. In Type 2 diabetes, the pancreas usually produces small amount of insulin, but either the amount produced is not enough for the body's needs or the body's cells are resistant to it. Insulin resistance or lack of sensitivity to insulin happens primarily in fat, liver and muscle cells. People are at high risk of developing type 2 diabetes, particularly the overweight or obese people who are having more than 20% over than their ideal body weight. The overweight people have insulin resistance. When With insulin resistance, the pancreas has to work more hard to produce more insulin, but still there is not enough insulin to keep sugars normal. There is no cure for diabetes. Type 2 diabetes can be controlled by increasing physical activity, nutrition and weight management. Type 2 diabetes tends to progress and medications are often needed. The effect of diabetes 2 on body, glucose builds up in the blood instead of going into cells, the cells are not able to function properly. Associated problems along with hyperglycaemia includes, dehydration -

the increased glucose in the blood leads to excess glucose in the urine because the kidneys can't deal with the high sugar levels. The increase glucose in urine draws frequent urination and it is causing dehydration. Diabetic coma – the dehydration in type 2 diabetes causes heavy fluid losses, they may develop this life-threatening complication. Damage to the body tissues –the treated or long time expose of higher blood glucose levels may damage the nerves and capillaries cause stroke, cardiac and renal diseases. The Symptoms of diabetes type 2 includes, increased hunger, increased thirst, dry oral cavity, frequent urination, unusual weight loss, weakness, blurred vision, recurrent infections^{4,5}.

Gestational Diabetes

Diabetes that is triggered by pregnancies is called gestational diabetes. Gestational diabetes is usually diagnosed during late pregnancy. Because high blood sugar in the mother is circulated through the placenta to the baby, gestational diabetes must be controlled to protect the baby's growth and development. If the mother is diagnosed with diabetes earlier in her pregnancy, she may have had diabetes before she became pregnant. Treating gestational diabetes can help both mother and baby stay healthy. The hyperglycaemic condition of mother's blood circulated through the placenta to the baby can affect the health of baby and growing tissues, risks to the unborn baby are even greater than risks to the mother. The risks in gestational diabetes to baby include abnormal weight before birth, respiratory problems at birth and higher obesity and diabetes risk later in life. In gestational diabetes mother can face risks like damage to heart, kidney, nerves, eye and overweight baby may lead to cesarean section^{4,5}.

Other Forms of Diabetes

A few rare kinds of diabetes can result from specific conditions. For example, diseases of the pancreas, certain surgeries and medications or infections can cause diabetes. These types of diabetes account for only 1% to 5% of all cases of diabetes⁶.

2.1.3. Mechanism of diabetes mellitus and its complications

Carbohydrates, the major component of our food are broken down into simpler sugars like glucose and then absorbed into the body. Glucose is a source of energy, is transported into the blood and it has to enter into the cell for metabolism. Insulin facilitates the entry of glucose into the cell, where it burns through Krebs cycle in the mitochondria under the influence of multiple enzymes and energy is released in the form of adenosine triphosphate (ATP). Body tissues like muscles get energy from ATP to execute mechanical functions. In the absence of or ineffective insulin or a disturbance at the insulin receptor level or its destruction by the antibodies, the body is deprived of energy as it cannot use the ideal source of energy, the glucose. When insulin is absent from the body it is Type 1 diabetes mellitus and when it is scanty or ineffective it is Type 2 diabetes mellitus. The result is underutilization of glucose, which leads to its accumulation in the blood leading to hyperglycemia, a hallmark of diabetes mellitus. The body constantly requires energy to perform different functions like walking, working as well as sleeping and sitting. Even in sleep the organs are constantly at work like digesting food and breathing and all these functions need energy. In diabetes mellitus being unable to use glucose, the body resorts to other sources of energy like lipids, fats and proteins. When lipids and

fats are used in more quantity, their breakdown products are produced in abundance like cholesterol and triglycerides. The excess of cholesterol accumulates in blood. A close relationship exists between levels of blood cholesterol or other lipids and the development of atherosclerosis. In this disorder, plaques containing cholesterol are deposited on the walls of arteries, it happens usually in small and medium sized vessels and it leads to reduce in the diameter of lumen and the flow of blood. Clotting of blood, as in the coronary arteries which causes heart attack, is most likely to develop at places where arterial walls are roughened by such plaques. This blockage of the blood vessels is the main cause of the complications of diabetes mellitus. The chronic condition requires careful management to avoid multi-organ damage and derangements of lipid metabolism, thus preventing its complications including cardiovascular diseases, nephropathy, blindness and nerve damage^{7,8}.

2.1.4 Management of Diabetes Mellitus

Type 1 diabetes mellitus can be treated by insulin therapy only.

In Type 2 diabetes efforts are made to convert the supply of insulin or reduce the glucose load to the body, an attempt to decrease the insulin. Thus the following principles of management of diabetes can be proposed and practiced.

- Providing alien insulin to the body through injections like Humulin or NPH insulin etc.
- Increasing the production of effective insulin within the body, which can be achieved through.
 - Drugs that stimulate the production of insulin from the β -cells of islets of Langerhans in pancreas like Sulphonylureas. These act mainly by

augmenting insulin secretion and consequently are effective only when some residual pancreatic beta-cell activity is present. During long term administration they also have an extra pancreatic action causing hypoglycaemia. But this is uncommon and usually indicates excessive dosage. The hypoglycaemia may persist for many hours and must always be treated in hospital.

- Use of herbs which increases the production of insulin by maintaining the health and integrity of insulin producing cells and modulating the immune function.
- Use of drugs that increase the glucose utilization like Biguanides- metformin which works effectively by decreasing gluconeogenesis and by increasing peripheral utilization of glucose. Since it acts only in the presence of endogenous insulin it is effective only when there are few active functioning beta cells present in pancreas.
- Decreasing the production of glucose from non-carbohydrate sources like amino acids and fat, gluconeogenesis especially in the liver.
- Decreasing the glucose load to the body by
 - Restricting the carbohydrates in the diet.
 - Decreasing the absorption of glucose from the gut by Acarbose an inhibitor of intestinal alpha glucosidases which delays the digestion and absorption of starch and sucrose⁹.

2.2. Nigella sativa

2.2.1. Historical Background

Nigella sativa was first discovered in Tutankhamen's tomb. It played an important role in ancient Egyptian practices. Although its exact role in Egyptian culture is not known, items entombed with a king were carefully selected to help him in the after life^{10, 11}. The earliest reference to Nigella sativa seed is found in the book of Isaiah in the bible. The black cumin is not threshed with a threshing sledge, nor a cart wheel rolled over the cumin. It is beaten out with a rod¹². The Hebrew word for Nigella sativa seed, "ketsah," refers to Nigella sativa, belongs to the order Ranunculaceae which cultivates in Egypt and Syria for its seed, this was clarified in Easton's Bible Dictionary¹³. Dioscoredes, the Greek physicist at unity century, reported that black seed is used to treat headaches, nasal congestion, toothache and intestinal worms. In addition it is also used to promote menstruation and increase milk production in nursing mothers¹⁴. A-Biruni who composed a treatise on the early origin of Indian and Chinese drugs, mentions that the black seed is a kind of grain called alwanak in the Sigzi dialect¹⁵. Later, this statement was justified by Suhar Bakht who explained that the black seed as habb-i-Sajzi (viz. Grains Sigzi) allows people to use it as a nutritional ingredient in the 10th and 11th century. In a medical system in Greco-Arab/Unani-Tibb, which originated from Hippocrates, Galen and Ibn Sina, black seed is a valuable remedy in treating gastrointestinal dysfunction and hepatitis and is described as a stimulant to different conditions and high fever reliever¹⁶. Ibn Sina, in his book "The Canon of Medicine" described the black seed as "stimulating the body's energy and helping recovery from fatigue or lack of spirit"¹⁷. Black seed is also included in the list of natural drugs of Al-Tibb al-Nabawi

and the traditional saying is "Hold on to the use of the black seed for it has a remedy for every illness except death." This prophetic reference in describing black seed as "having a remedy for all illnesses" may not be so exaggerated as it at first appears. Many research studies conducted recently has provided evidence which indicates that *Nigella sativa* seed having an ability to improve and boost human immune system significantly if used over a time of period. The prophetic phrase, "hold on to the use of the seed" also emphasizes consistent usage of the seed¹⁸.

In the Middle and Far East countries for centuries *Nigella sativa* seeds has been used traditionally and successfully to treat ailments including rheumatism and related inflammatory diseases, bronchial asthma and bronchitis, to treat digestive disturbances, to increase milk production in nursing mothers, to support the body's immune system, to promote digestion, elimination and to fight parasitic infestation. Its oil has been used to treat skin conditions such as eczema and boils and is used tropically to treat cold symptoms. The many uses of black seed have earned for this medicinal herb the Arabic approbation ``habbatul barakah`` meaning "the seed of blessing"^{19, 20}.

Nigella sativa has been used as a natural remedy for many ailments parts of Asia and Africa for centuries and is now well known in the USA and Europe. Seeds of *Nigella sativa* had been in use for over 4000 years all over the world^{21, 22}. According to Birdwood, *Nigella sativa* is the black cumin of Bible, Melanthine of Hippocrates and Dioscorides and Gith of Pinty. Analic mentioned its use as carminative external application for skin eruptions, seasoning for food and protection for linen against insect²³. The ancient Greek and Roman clinicians were aware of the beneficial effects of *Nigella sativa* and used it in combination with honey^{24, 25}.

Although native place of *Nigella sativa* is not exactly known, this herbaceous plant belongs to countries around the Mediterranean Sea like Egypt, Turkey and Italy²⁶. Roxburgh believes this plant to be a native of India so also called as *Nigella indica*²⁷.

2.2.2. Morphological features of *Nigella sativa*

Nigella sativa is a pretty erect herb, 30-60 cm high. Its leaves are alternate and bipinnately dissected. The stipules are small. The flowers are terminal, pedunculated and whitish blue or purplish in color. Sepals are five, regular, deciduous, imbricate and petaloid. Petals are five with long claws and small bifid limbs. Stamens are numerous. Carpals are 3-10, sessile, connate below and, each with several horizontal ovules. Two seriates on the suture and style is usually long. Fruit is a capsule, dehiscent along ventral suture of free portion of individual carpel. Dried fruit and seeds are the main plant components and are mostly used medically. Seeds of *Nigella sativa* are black in color and triangular in shape. The seed is about one eighth inch long having a rough interior and a white oily kernel. On rubbing, the seed diffuses a pleasant odor of lemon with a slight suspicion of carrot²⁸.

2.2.3. Chemical Composition of *Nigella sativa*

According to Ahmed Aftab et al²⁹ many active compounds have been isolated, identified and reported in different varieties of black seeds. The most important active compounds are thymoquinone, dithymoquinone, thymoquinone (30%-48%), 4-terpineol (2%-7%), sesquiterpene longifolene (1%-8%) -pinene, t-anethol (1%-4%), p-cymene (7%-15%), carvacrol (6%-12%) and thymol etc. Black seeds also contain some other compounds in traces. These contain two

different types of alkaloids; isoquinoline alkaloids like nigellicimine- N-oxide and nigellicimine and indazole ring bearing alkaloids or pyrazol alkaloids like nigellicine and nigellidine. The seeds also contain alpha-hederin, a water soluble pentacyclic triterpene and saponin, a potential anticancer agent³⁰. Other compounds like carvone, limonene, and citronellol are also found in traces. Most of the pharmacological properties of *Nigella sativa* are mainly due to quinone constituents, out of which thymoquinone is the most important quinone constituent and main reason behind medicinal properties of seed. On storage, thymoquinone yields dithymoquinone and higher oligocondensation products. The seeds of *Nigella sativa* contain protein (26.7%), fat (28.5%), carbohydrates (24.9%), crude fibre (8.4%) and total ash (4.8%). Various vitamins and minerals like Cu, P, Zn and Fe also contents of *Nigella sativa* seed in good amount. The seeds contain carotene which is converted by the liver to vitamin A. Root and shoot are reported to contain vanillic acid³¹. Many previous studies reported that the *Nigella sativa* seeds to contain a fatty oil rich in unsaturated fatty acids, mainly linoleic acid, eicodadienoic acid, oleic acid and dihomolinoleic acid. In *Nigella sativa* seed saturated fatty acids also present about 30% or less. -sitosterol is a major sterol which accounts for around 55% of the total sterols of black seed and stigmasterol one of the major sterol after -sitosterol^{32, 33}. In some studies it is reported that the other components includes nigellone, avenasterol-5-ene, avenasterol- 7 - ene , camp esterol, cholesterol , citrostadieno 1 , cycloeucalenol, gramisterol, lophenol, obtusifoliol, stigmastanol, stigmasterol-7-ene, -amyrin, butyro- spermol, cycloartenol, 24-methylenecycloartanol, taraxerol, tirucallol, volatile oil (0.5-1.6%), fatty oil (35.6-41.6%), oleic acid, esters of unsaturated fatty acids with C15 and higher terpenoids, esters of dehydrosteari,

hederagenin glycoside, aliphatic alcohol, linoleic acid, melanthin, melanthigenin, - unsaturated hydroxy ketone, tannin, resin, reducing sugar, glycosidal saponin and protein^{34,35,36}.

2.2.4. Nutritional Value of *Nigella sativa*

The earlier studies have shown *Nigella sativa* to have a high nutritional potential i.e. protein (22%), fat (38 - 40%) and carbohydrates (32%)³⁷. Haq et al mentioned in their study that the whole black seed proteins have also been fractionated and characterized by sodium dodecyl sulphate polyacrylamide gel electrophoresis³⁸. The mineral and vitamin contents per kg seeds are iron (105 rag), copper (18 rag), zinc (60 mg), phosphorus (527 rag), calcium (1860 rag)³⁹, thiamin (15.4 rag), niacin (57 mg), pyridoxine (5.0 rag) and folic acid (160 pg)⁴⁰. A qualitative study of *Nigella sativa* and a number of other plant extracts of Saudi origin used in folk medicine has revealed the presence of sterols, triterpenes, tannins, flavonoids, cardiac glycosides, alkaloids, saponins, volatile oils, coumarins, volatile bases, glucosinolates and anthraquinones⁴¹.

2.3. Effects of *Nigella sativa* on diabetes

Of the traditional remedies, prescriptions of *Nigella sativa* for the treatment of various diseases are well known since prehistoric era. *Nigella sativa* is one of the plants commonly used in Moroccan folk medicine for treatment of various ailments including diabetes mellitus. Previous studies found that its anti-diabetic effect is multifaceted like regulating blood glucose, insulinotropic, prevention of

gluconeogenesis, preserving the integrity of beta cells of islets of Langerhans in pancreas etc⁴².

2.3.1. Effect of Nigella Sativa on Blood Glucose

El-Dakhakhny et al⁴³ studied the effect of Nigella sativa on blood glucose concentrations in streptozotocin diabetic rats. They also studied the effect of nigellone and thymoquinone on insulin secretion of isolated pancreatic islets in the presence of 3, 5.6 or 11.1 mM glucose. Their results showed Nigella sativa significantly lowering blood glucose concentrations in diabetic rats after 2, 4 and 6 weeks. In an experimental study, Alsaif⁴⁴ reported that blood glucose lowering effect of black seed was due to improved insulin insensitivity in diabetic rats. Abdelmeguid et al⁴⁵ reported that the anti-hyperglycemic effect of black seed and its active component thymoquinone could be due to reduction of oxidative stress, thus preserving pancreatic β -cell integrity lead to insulin levels increase. The black seed oil also contains many bioactive constituents such as thymoquinone, p-cymene, pinene, dithymoquinone and thymohydroquinone⁴⁶. In a study, Khanam M⁴⁷ reported that Nigella sativa showed the lowering of blood glucose in diabetic group but the change was not statistically significant. In studies of Salama RH⁴⁸, Qidwai W et al⁴⁹, Sabzghabae AM et al⁵⁰ and Datau EA et al⁵¹ were also found similar findings in diabetic treated groups with Nigella sativa.

2.3.2. Insulinotropic Effect of Nigella sativa

Fararh et al⁵² reported that Nigella sativa seed extract given orally has insulinotropic properties; it increases the production of insulin from the β -cells of the Islets of Langerhans. This effect has been extensively studied in Streptozotocin and

Nicotinamide induced diabetic animal models. This was evidenced by the increase in serum insulin as measured by enzyme immunoassay and increased staining areas with positive immuno-reactivity for the presence of insulin in Islets of Langerhans by immunohistochemical staining method in which anti-insulin monoclonal antibody was used. Studies of Omar et al⁵³ and Rchid et al⁵⁴ have shown significant decrease in blood glucose level and increased Islet cell regeneration as evidenced by insulin immunohistochemical staining. Oxidative stress is believed to play a role in its pathogenesis. Nigella sativa extract decreases lipid peroxidation and serum NO and increases antioxidant enzyme activity, thus ameliorating pancreatic β -cell integrity and their numbers. Studies of Kanter et al^{55,56}, Badary et al⁵⁷ and Hajhashemi et al⁵⁸ showed the evidence of insulinotropic effect on increased intensity of staining for insulin and preservation of β -cell numbers in the Nigella sativa treated diabetics. Its anti-inflammatory effect also plays a role in preserving the integrity of β -cells. Moneim et al⁵⁹ reported that the Nigella sativa and sulphonilureas like gliclazide have synergistic action as for insulinotropic effect is concerned. An extra pancreatic hypoglycemic effect of Nigella sativa has been observed in the study of Le et al⁶⁰ with an insulin-sensitizing action of Nigella sativa extracts by enhancing the activity of the two major intracellular signal transduction pathways of the hormone's receptor and decrease in hepatic gluconeogenesis. In a study, Ahmad Bilal et al⁶¹ reported that Nigella sativa showed the change in insulin level but the change was not statistically significant.

2.3.3. Nigella sativa and Histopathology of Pancreatic Beta-cells

Kanter et al⁵⁵ investigated the effect of *Nigella sativa* on histopathology of pancreatic β -cells, in streptozotocin-induced diabetic rats. Blood insulin and glucose concentrations were also measured. The results of this study reported that *Nigella sativa* treatment caused decrease in the elevated serum glucose, increase in the lowered serum insulin concentrations and partial regeneration or proliferation of pancreatic beta cells in STZ-induced diabetic rats. This study concluded that the hypoglycemic action of *Nigella sativa* could be partly due to amelioration in the β -cells of pancreatic islets causing increase in insulin secretion. Another study⁵⁶ of same researchers evaluated the possible protective effects of *Nigella sativa* against β -cell damage in streptozotocin induced diabetic rats. Oxidative stress is believed to play a role in the pathogenesis of diabetes mellitus. To assess changes in the cellular antioxidant defense system, they measured the activities of antioxidant enzymes such as glutathione peroxidase (GSHPx), superoxide dismutase (SOD) and catalase (CAT)) in pancreatic homogenates. They also measured serum nitric oxide (NO) and erythrocyte and pancreatic tissue malondialdehyde (MDA) levels, a marker of lipid peroxidation, to determine whether there is an imbalance between oxidant and antioxidant status. Pancreatic beta-cells were examined by immunohistochemical methods. Streptozotocine induced a significant increase in lipid peroxidation and serum NO concentrations and decreased antioxidant enzyme activity. *Nigella sativa* treatment provided a protective effect by decreasing lipid peroxidation and serum NO and increasing antioxidant enzyme activity. In immunohistochemical study of Kanter M et al⁵⁶, cells islet of Langerhans shown weak insulin immunohistochemical staining and degeneration was observed in untreated STZ-induced diabetic rats.

Increased intensity of staining for insulin and preservation of beta-cell numbers were apparent in the *Nigella sativa* treated diabetic rats. This study stated that *Nigella sativa* treatment decreasing oxidative stress and preserving pancreatic beta-cell integrity due to this *Nigella sativa* showing the therapeutic protective effect in diabetes. It was also suggested that *Nigella sativa* may be clinically useful for protecting β -cells against oxidative stress.

2.3.4. Effect of *Nigella sativa* on Lipid Profile, Lipid Peroxidation and Anti-oxidant Defense System

Dahri et al⁶² observed significant decrease in serum low density lipoprotein cholesterol level and increase in serum high density lipoprotein cholesterol level when rats were treated with *Nigella sativa*. The study of Bahram et al⁶³ showed significant decrease in the development of hyperlipidemia in *Nigella sativa* seed treated group and serum lipid profile and malondialdehyde were significantly lower, compared to control group. Some studies have mentioned different beneficial properties of *Nigella sativa* as extract, oil or active compounds such as thymoquinone. But only a few have studied the effects of whole or crushed seed, including its hypolipidemic and antioxidant properties. One study assessed the effect of crushed black seed on some blood parameters including serum levels of cholesterol and triglyceride⁶⁴. Study of Ibraheim⁶⁵ showed significant decrease in the concentration of total cholesterol and triglycerides. Study of Zaoui et al⁶⁶ indicated that oral treatment with *Nigella sativa* decreased serum cholesterol and triglycerides. In another study *Nigella sativa* administration to rats significantly decreased serum total cholesterol, LDL-C and triglycerides and increased HDL-C⁴³.

Le et al⁶⁰ reported a significant decrease in plasma triglycerides and an increase in HDL-C levels in black seed extract-oral treated rats, compared to the control group. In the study of Dehkordi and Kamkhah⁶⁷ a significant reduction was observed in serum TC and LDL-C of patients with mild hypertension after 8 weeks of oral administration of *Nigella sativa* seed extract. The results of Bamosa et al⁶⁸ demonstrated a decrease in serum total cholesterol, LDL-C, HDL-C and triglycerides during intraperitoneal injection of thymoquinone in rats. Morikawa et al⁶⁹ in an invitro study investigated hypotriglyceridemic effect of nigellamines, that is black seed diterpene alkaloids, equivalent to the hypolipidemic agent, clofibrate. Ali and Blunden⁷⁰ stated in their study that the hypolipidemic effect of black seed does not seem to be due only to one component, but rather to the synergistic action of its different constituents including thymoquinone and nigellamine, soluble fiber - mucilage, sterols, flavonoids and high content of polyunsaturated fatty acids. The hypolipidemic action of thymoquinone and its mechanism is not fully established, however it is proposed that the main reason of hypolipidemic action of thymoquinone may due to its antioxidant property. In a studies of Elrehany M⁷¹, Sabzghabae AM et al⁵⁰ reported that *Nigella sativa* treatment in diabetic groups not showed significant change in parameters of lipid profile.

Regarding the effect of black seed on lipid peroxidation and antioxidant defense system, Kanter et al⁵⁵ found that treatment with *Nigella sativa* decreased blood MDA levels and increased the antioxidant defense system activity in carbon tetrachloride treated rats. In an another study conducted by same authors in the experimental spinal cord injury in rats proved that *Nigella sativa* treatment can reduce the spinal cord MDA and treatment also prevented from inhibition of CAT,

SOD and GPX enzyme activities⁵⁶. The study of Meral et al⁷² indicated that *Nigella sativa* extract decreased the elevated blood MDA concentration and increased the lowered glutathione and ceruloplasmin concentrations in diabetic group. The antioxidant effect of black seed seems to be due to thymoquinone, flavonoids and antioxidant vitamins like ascorbic acid. It has been shown that *Nigella sativa* and TQ inhibit non-enzymatic lipid peroxidation in liposomes and both work as a scavenger of various reactive oxygen species including superoxide anion and hydroxyl radicals⁷³. In addition flavonoids are a class of polyphenolic compounds that seem to have antioxidant properties by suppressing reactive oxygen and nitrogen species formation, scavenging reactive oxygen and nitrogen species and protecting the antioxidant defense system⁷⁴. The sequels of diabetes mellitus are deranged lipid and carbohydrate metabolism leading to their increased levels. *Nigella sativa* decreases triglycerides, total cholesterol and increases the healthy cholesterol i.e. HDL cholesterol^{66,26,35}. These effects potentate when *Nigella sativa* is given in combination with gliclazide. The combination significantly decreases cholesterol, triglyceride and total lipids, while a significant increase in serum insulin, total protein and liver glycogen levels was observed^{60,75}.

Meral et al⁷² observed *Nigella sativa* decreased the elevated glucose and MDA concentrations, increased the lowered glutathione and ceruloplasmin concentrations and prevented lipid peroxidation induced liver damage in diabetic rabbits. Thus *Nigella sativa* might be used in diabetic patients to prevent lipid peroxidation, increase anti-oxidant defense system activity and also to prevent the liver damage. Hosseinzadeh et al⁷⁵ reported that thymoquinone and *Nigella sativa*

may have protective effects on lipid peroxidation process during ischemia-reperfusion injury in rat hippocampus.

A comprehensive study was conducted by Moneim et al⁵⁹ to evaluate the effects of *Nigella sativa* and gliclazide on serum glucose, insulin, total lipids, triglyceride, cholesterol, total protein and liver glycogen levels in diabetic rats. The results indicated that treatment with gliclazide significantly decreased the raised fasting blood glucose level as well as blood glucose while treatment with *Nigella sativa* significantly decreased blood glucose level during OGTT when compared to diabetic control. Combined treatment with gliclazide and *Nigella sativa* significantly decreased cholesterol, triglyceride and total lipids, while a significant increase in serum insulin, total protein and liver glycogen levels was observed.

2.3.5. Effect of *Nigella sativa* on Liver Function Tests

El-Dakhkhny et al⁴³ investigated the effects of weeks oral intake of *nigella sativa* on some liver function tests in D-galactosamine or carbon tetrachloride-induced hepatotoxicity male albino rats. In another experiment, the effect of the *Nigella sativa* on serum lipid profile was examined in male spontaneously hypertensive rats of stroke prone strain and Wistar Kyoto rats. The study showed that daily administration of *Nigella sativa* did not adversely affect the serum transaminases (ALT and AST), alkaline phosphatase and serum bilirubin or prothrombin activity in normal albino rats. When *Nigella sativa* was given for four weeks prior to induction of hepatotoxicity by D-galactosamine or carbon tetrachloride, it was able to give complete protection against d-galactosamine and partial protection against carbon tetrachloride hepatotoxicity. *Nigella sativa* showed

a favorable effect on the serum lipid pattern, where the administration of *Nigella sativa* caused a significant decrease in serum total cholesterol, low density lipoprotein, triglycerides and a significant elevation of serum high density lipoprotein level. In another investigation by Al-Jishi and Hozaifa⁷⁶ the effects of *Nigella sativa* on liver function tests on male albino rats were studied and favorable results were shown by *Nigella sativa*. Many previous studies concluded that the active constituents of *Nigella sativa* are thymoquinone, dithymoquinone, thymohydroquinone and thymol⁷⁷. Several studies have shown the various therapeutic actions of *Nigella sativa*. It has activity against diabetes^{54,62} radical scavenging activity^{78,79}, prevents lipid peroxidation and increases the antioxidant defense system⁷².

2.3.6. Effect of *Nigella sativa* on Kidney, Liver and Nerve

Renal dysfunction is a common complication in diabetes that is involved in oxidative stress changes^{80,81}. The amelioration of renal hemodynamic and function changes in diabetics has been elucidated by supplementation with antioxidants. *Nigella sativa* seed was believed to be responsible for restoration in renal dysfunction in nephrotoxic rats through the antioxidant effect^{82,83}. The diabetic nephropathy has been considered an important cause of mortality and morbidity and many of the end stage renal failure results are due to diabetic nephropathy⁸³. Streptozotocin and Alloxan-induced diabetic rodents develop nephropathy similar to the early stage of human diabetic nephropathy⁸⁴. In the diabetic animals, a significant increase in the kidney weight was observed^{85,86}. The factors like glucose over-utilization and subsequent increased uptake, glycogen accumulation, lipogenesis and protein

synthesis in the kidney tissue are may be attributing in kidney enlargement in diabetes. *Nigella sativa* extract administered to the diabetic rats successfully prevented the enlargement of the kidney. Histological studies investigated on the induced diabetic rat kidneys showed the damage to the glomerulus as it is degenerated or necrotized, thickened basement membrane and edematous renal convoluted tubules with increase in mucopolysaccharide deposits which were found to be absent or reduced in the diabetic kidneys treated with *Nigella sativa* extract. The treated diabetic rats however showed healing features which resembled that of a normal kidney^{87,88}. Advanced histopathological studies on human diabetic nephropathy showed arteriolar hyalinosis and tubular atrophy coupled with an increase in the interstitial volume. These features are largely absent in normal and *Nigella sativa* treated animals. The tubular changes noted in the kidney of diabetic rats primarily consist of vacuolization of tubular cells with evidence of tubular atrophy, tubulointerstitial fibrosis and alteration of the medullary structure^{89,90}.

According to the study of Samad A et al⁹¹ effect of *Nigella sativa* on gluconeogenesis and liver glucose production helps to clarify part of the hypoglycemic mechanism since hepatic glucose production through gluconeogenesis is known to contribute to hyperglycemia in diabetic patients. Research on isolated hepatic cells showed a significant decrease in glucose production from gluconeogenic elements like glycerol, alanine and lactate in *Nigella sativa* treated animals as compared to the untreated animals⁹². This significant decrease in liver glucose output and ameliorative effect on regeneration of pancreatic islets suggests that the observed antidiabetic action of *Nigella sativa* is at least partially mediated through an effect on hepatic gluconeogenesis.

EL-Kholy WM et al⁹³ observed no toxicity and no histopathology of liver tissue of *Nigella sativa* treated rats. Mohammad A D et al⁹⁴ observed that oral administration of *Nigella sativa* has no toxic effect on liver to the parameters used, ALT and aspartate aminotransferase AST. Histopathology examination showed no hepatic vacuolization, degeneration, inflammation and necrosis in liver tissue. Almost all the studies suggested a hepatoprotective effects of *Nigella sativa* due to some component such thymoquinone and monoterpenes or tocopherols, phytosterols and phenols⁹⁵. Antioxidant and anti-inflammatory properties of *Nigella sativa* are the main features of preventing and protecting liver from injury. Several studies have shown the protective effects of *Nigella sativa* against liver injury produced by ROS with its free radical scavenger properties and enhanced antioxidant defences in body. Thymoquinone is the main active ingredient of *Nigella sativa* seed responsible for it. The effect of *Nigella sativa* to postpone progression in chronic liver diseases should be considered as preventive medicine in patients with hepatic disorders^{96,97,98,99,100}. Rakesh Jadhav¹⁰¹ observed that administration of anti-tubercular resulted in degeneration, necrosis and fibrosis. Administration of *Nigella sativa* showed significant reduction in the scores in degeneration and necrosis.

Previous studies showed the repairing ability of CCl₄ induced centrilobular hepatocellular vacuolar degeneration and necrosis by *Nigella sativa*. Treatment with *Nigella sativa* seeds significantly declined the effects of CCl₄ induced damage and it was evidenced by the decreased level of liver enzymes and lipid profile and restoration of hepatocellular architecture^{102,103}. Al-Razzuqi et al¹⁰⁴ reported protective effect of oil extract of *Nigella sativa* seeds against carbon tetrachloride induced acute liver injury in experimental rabbit models. Protective effect of *Nigella sativa* on lead

acetate-induced hepatic tissue damage in mice was investigated by Alarifi et al¹⁰⁵. Thymoquinone, the active constituent of *Nigella sativa*, has been well documented as a potent antioxidant, particularly against the CCl₄-induced free radical species¹⁰⁶. Thymoquinone restores liver cellular architecture and prevents leakage of its enzymes through preventing the formation of toxic stable complex by a combination of CCl₃, O₂ free radical and the glycolipid component of cell membrane¹⁰⁷. Amina E.E et al¹⁰⁸ in their bio-chemical and histological study proved that *Nigella sativa* seeds possess potential to protect the liver tissue against oxidative damages and could be used as an effective protector against CCl₄ induced liver damages. There are very few studies on histopathology of liver of streptozotocine induced diabetic rats treated with *Nigella sativa* and thymoquinone.

In a histopathological study of Kanter M¹⁰⁹ studied on the sciatic nerves of streptozotocin induced diabetic rats and they evaluated the possible beneficial effect of *Nigella sativa* and thymoquinone on STZ induced diabetic changes in sciatic nerve. Histological evaluation of the tissues in diabetic animals treated with thymoquinone and *Nigella sativa* showed fewer morphologic alterations. Myelin breakdown decreased significantly after treatment with *Nigella sativa* and thymoquinone. The ultra-structural features of axons also showed remarkable improvement suggesting the utility of *Nigella sativa* and thymoquinone as a potential treatment for peripheral neuropathy in streptozotocine induced diabetic rat. Improvement of the diabetic peripheral nerve injury in the rat by administration of *Nigella sativa* was reported by Kazim et al¹¹⁰. Beuch et al¹¹¹ reported the regeneration of injured peripheral nerves after three months. Many previous studies are showing

the beneficial effect of *Nigella sativa* in biochemical parameters and histopathological changes in induced diabetes and other induced injuries.

BIBLIOGRAPHY

1. Barach, J. H. Historical facts in Diabetes. *Annals of Medical History*. 1928;36 (10): 324-326.
2. Leibowitz, J. O. The concept of diabetes in historical perspective. *Israel J. Medical Sci*. 1972;8 (3): 469-475.
3. Sanders, L. J. *The philatelic history of diabetes: in search of a cure* Alexandria, American Diabetes Association.2001.
4. <http://www.webmd.boots.com/diabetes/type-2-diabetes-guide/type-2-diabetes>. Retrieved on 02/04/2017.
5. <http://www.nhs.uk/conditions/Diabetes-type2/Pages/Introduction.aspx>. Retrieved on 02/04/2017.
6. NationalDiabetes Information Clearinghouse (NDIC):"National Diabetes Statistics, 2011".
7. Insel, P. M. and W. T. Roth. *Diabetes: Core concepts in health*. 9th Edition. M.C. Graw Hills, New York. 2002;397p.
8. Vorhaus, L. J. "Cholesterol." Microsoft® Encarta® 2006 [DVD]. Redmond, WA: Microsoft Corporation.
9. BNF. (British National Formulary). British Medical association: Royal Pharmaceutical Society of Great Britain. Bemrose Security Derby UK. 2003;46.
10. Zohary, Daniel; Hopf, Maria. *Domestication of plants in the Old World* (3 ed.). Oxford University Press. 2000;206p.

11. Saliha B, Sipahib T, Oybak Dönmez, E. "Ancient nigella seeds from Boyalı Höyük in north-central Turkey". *Journal of Ethnopharmacology*. 2009;124 (3): 416–20.
12. Kotb, T. F. *Medicinal Plants in Libya*. Arab Encyclopedia House.Tripoli-Libya.1985.
13. Warriar,P.K. Nambiar,V.P.K. & Ramankutty C.,Vaidya, Sala A. *Indian Medicinal Plants Orient Longman, Kottakal, India*.1961;1:163-72.
14. Rathee P.S, Mishra S.-H, and Kaushal R. Anti microbial activity of essential oil, fixed oil and unsaponifiable matter of *Nigella sativa* L. *Indian J. Pharm Sci*.1982; 44, 8-10.
15. Aqel M. Effects of *Nigella sativa* seeds on intestinal smooth muscle. *Int. J. Pharmacogn*.1993; 31:55-60.
16. <http://theblessedseed.blogspot.com/2012/01/for-energy-and-improved-immune-system.html>
17. Toama MA, Taha S El-Alfy and El-Fatatry HM, Antimicrobial Activity of the Volatile Oil of *Nigella sativa* Linneaus Seeds. *Antimicrob Agents Chemother*. 1974; 6(2): 225-226.
18. Al-Hader A., Aqel M., and Hasan Z. Hypoglycemic effects of the volatile oil of *Nigella sativa*. *Int. J. Pharmacogn*.1933; 31: 96-100.
19. Dwivedi S et. al., Relivance of medicinal herbs used in traditional system of medicine, *Farmavita. Net*.2007.
20. Dwivedi, S.N. "Traditional health care among the tribals of Rewa District of Madhya Pradeshwith special reference to conservation of endangered and vulnerable species", *Econ. Taxon. Bot*. 1999;23(2): 315-320.

21. Malcolm Stuart. The Encyclopedia of Herbs and Herbalism, Macdonald and Co. Turin, Italy. 1987.
22. John Lust. The Herb Book. Bantam Books, New York, USA. 1984.
23. Said, H. M. Pharmacographia Indica. Hamdard. 1972;15: 28-29.
24. Ghaznavi, K. Tibb-e-Nabvi aur Science. 8th Ed. Lahore: Alfaisal. 1992;246-54.
25. Bukhari, M. Sahih Bukhari Sharif. Reprint. Lahore Pakistan: Maktaba Rehmania Urdu Bazar. 1985;3:312.
26. El-Dakhakhny, M., N. I. Mady and M. A. Halim. Nigella sativa L. oil protects against induced hepatotoxicity and improves serum lipid profile in rats. *Arzneimittelforschung*. 2000;50 (9): 832-836.
27. Blatter, E., J. F. Caius and K. S. Mhaskar. 1984. Indian Medicinal Plants. 2nd Ed. Allahabad, India: Lalit Mohan Basu. 1984;11-12.
28. Al-Jassir MS. Chemical composition and microflora of black cumin (*Nigella sativa* L.) seeds growing in Saudi Arabia. *Food Chem*. 1992; 45: 239-242.
29. Ahmad, A., Husain, A., Mujeeb, M., Alam Khan, Sh., Najmi, Abul., Siddique, N., et al. A review on therapeutic potential of *Nigella sativa*: A miracle herb. *Asian Pac J Trop Biomed*. 2013; 3(5): 337-352.
30. Atta-Ur-Rahman. Nigellidine-a new indazole alkaloid from the seed of *Nigella sativa*. *Tetrahedron Lett*. 1995; 36(12): 1993-1994.
31. Cheikh-Rouhou S, Besbes S, Lognay G, Blecker C, Deroanne C, Attia H. Sterol composition of black cumin (*Nigella sativa* L.) and Aleppo pine (*Pinus halpensis* Mill.) seed oils. *J Food Comp Anal*. 2008; 21(2): 162-168.

32. Mehta BK, Verma M, Gupta MJ. Novel lipid constituents identified in seeds of *Nigella sativa* Linn. *Braz Chem Soc.* 2008; 19(3): 458-462.
33. Bourgou S, Ksouri R, Bellila A, Skandrani I, Falleh H, Marzouk B. Phenolic composition and biological activities of Tunisian *Nigella sativa* L. shoots and roots. *C R Biol.* 2008; 331(1): 48-55.
34. Morikawa T, Xu F, Ninomiya K, Matsuda H, Yoshikawa M. N.mines A3, A4, A5 and C, new dolabellane-type diterpene alkaloids with lipid metabolism-promoting activities from the Egyptian medicinal food black cumin. *Chem Pharm Bull.* 2004; 52(4): 494-497.
35. Ali Z, Ferreira D, Carvalho P, Avery MA, Khan IA. Nigellidine-4- O-sulfite, the first sulfated indazole-type alkaloid from the seeds of *Nigella sativa*. *J Nat Prod.* 2008; 71(6): 1111-1112.
36. Mehta BK, Pandit V, Gupta M. New principles from seeds of *Nigella sativa*. *Nat Prod Res.* 2009; 23(2): 138-48.
37. Abdel-Aal, E. S. and R. S. Attia. 1993. Characterization of black cumin seeds proteins. *Alexandria Sci. Exch.* 1993;14 (4): 483-496.
38. Haq, A., N. Remo, and S. T. A1-Sedairy. Fractionation of black seed (*Nigella sativa* Linn.) proteins by using rotofor. *J. Liquid Chromatography and Related Technologies.* 1996;19: 593-599.
39. Siong, T. E., K. S. Choo and S. M. Shahid. Determination of calcium in foods by the atomic absorption spectrophotometric and titrimetric methods. *Pertanika.* 1989;12 (3): 303-311.
40. Takruri, H. R. H. and M. A. E. Dameh. Study of the nutritional value of black cumin seeds. *J. Science of Food and Agriculture.* 1998;76: 404-410.

41. Al-Yahya, M. A. Phytochemical studies of the plants used in traditional medicine of Saudi Arabia. *Fitoterapia*. 1986;57 (3): 179-182.
42. Rchid, H., H. Chevassus, R. Nmila, C. Guiral, P. Petit, M. Chokairi and Y. Sauvaire. 2004. *N. sativa* seed extracts enhance glucose-induced insulin release from rat-isolated Langerhans islets. *Fundam. Clin. Pharmacol.* 2004;18 (5): 525-529.
43. El-Dakhakhny M, Mady N, Lembert N, Ammon HP: The hypoglycemic effect of *Nigella sativa* oil is mediated by extrapancreatic actions. *Plant Med.* 2002;68(5):465–6.
44. Alsaif MA: Effect of *Nigella sativa* oil on impaired glucose tolerance and insulin insensitivity induced by high-fat-diet and turpentine-induced trauma. *Pak J Biol Sci.* 2008; 11(8):1093–9.
45. Abdelmeguid NE, Fakhoury R, Kamal SM, Al Wafai RJ: Effects of *Nigella sativa* and thymoquinone on biochemical and subcellular changes in pancreatic β -cells of streptozotocin-induced diabetic rats. *Diabetes.* 2010;2(4):256–66.
46. Geng D, Zhang S, Lan J: Analysis on chemical components of volatile oil and determination of thymoquinone from seed of *Nigella glandulifera*. *Zhongguo Zhong Yao Za Zhi.* 2009;34(22):2887–90.
47. Khanam M. Dewan F. Effects of the crude and the n-hexane extract of *Nigella sativa* Linn (kalajira) upon diabetic rats. *Bangla J Pharmacol.* 2008;4:17–20.
48. Salama RH. Hypoglycemic effect of lipoic Acid, carnitine and *nigella sativa* in diabetic rat model. *Int J Health Sci (Qassim).* 2011 Jul; 5(2):126-34.

49. Qidwai W, Hamza HB, Qureshi R, Gilani A. Effectiveness, safety, and tolerability of powdered *Nigella sativa* (kalonji) seed in capsules on serum lipid levels, blood sugar, blood pressure, and body weight in adults: results of a randomized, double-blind controlled trial. *J Altern Complement Med.* 2009 Jun; 15(6):639-44.
50. Sabzghabae AM, Dianatkah M, Sarrafzadegan N, Asgary S, Ghannadi A. Clinical evaluation of *Nigella sativa* seeds for the treatment of hyperlipidemia: a randomized, placebo controlled clinical trial. *Med Arch.* 2012; 66(3):198-200.
51. Datau EA, Wardhana, Surachmanto EE, Pandelaki K, Langi JA, Fias. Efficacy of *Nigella sativa* on serum free testosterone and metabolic disturbances in central obese male. *Acta Med Indones.* 2010 Jul; 42(3):130-4.
52. Fararh, K. M., Y. Atoji, Y. Shimizu, T. Shiina, H. Nikami and T. Takewaki. Mechanisms of the hypoglycaemic and immunopotentiating effects of *Nigella sativa* L. oil in streptozotocin-induced diabetic hamsters. *Res. Vet. Sci.* 2004;77 (2): 123-129.
53. Omar, Nesreen M.; Atia, Ghalia M. Effect of *Nigella sativa* on pancreatic β -cell damage in streptozotocin-induced diabetic rats: histological and immunohistochemical study. *The Egyptian Journal of Histology:* 2012;35:106–116.
54. Rchid, H., H. Chevassus, R. Nmila, C. Guiral, P. Petit, M. Chokairi and Y. Sauvair. 2004. *Nigella sativa* seed extracts enhance glucose-induced insulin release from rat-isolated Langerhans islets. *Fundam. Clin. Pharmacol.* 2004;18 (5): 525-529.

55. Kanter M., I. Meral, Z.Yener, H. Ozbek and H. Demir. Partial regeneration proliferation of β -cells in islets of Langerhans by *Nigella sativa* L in streptozotocin induced diabetic rates. *Tohoko. J.Exp. Med.* 2003; 201: 213-219.
56. Kanter, M., O. Coskun, A. Korkmaz and S. Oter. Effects of *Nigella sativa* on oxidative stress and beta-cell damage in streptozotocin-induced diabetic rats. *Anat. Rec. . Discov. Mol. Cell. Evol. Biol.* 2004; 279 (1): 685-691.
57. Badary, O. A. Thymoquinone attenuates ifosfamide-induced Fanconi syndrome in rats and enhances its antitumor activity in mice. *J. Ethnopharmacol.* 1999;67(2): 135-142.
58. Hajhashemi, V., A. Ghannadi and H. Jafarabadi. *Phytother Res.* 2004;18 (3): 195-199.
59. Moneim, A. A., M. El-Feki and E. Salah. Effect of *Nigella sativa*, fish oil and gliclazide on alloxan diabetic rats 1- biochemical and histo-pathological studies. *J. Egypt. Ger. Soc. Zool.* 1997;23: 237-265.
60. Le, P.M., Benhaddou-Andaloussi, A., Elimadi, A., Settaf, Cherrah, Y., Haddad, P.S. The petroleum ether extract of *N.sativa* exerts lipid-lowering and insulin-sensitizing action in the rates. *J. Ethnopharmacol.* 2004;94 (2): 251-259.
61. Ahmad Bilal, Tariq Masud, Arshad Mahmood Uppal, Abdul Khaliq Naveed. Effects of *Nigella sativa* Oil on Some Blood Parameters in Type 2 Diabetes Mellitus Patients. *Asian Journal of Chemistry Vol. 21, No. 7 (2009), 5373-5381.*

62. Dahri, A. H., M. C. Atta, A. R. Ali and A. M. Rafique. Effect of *Nigella sativa* (kalonji) on serum cholesterol of albino rats. 2005.
63. Bahram Pourghassem-Gargari, Vahideh Ebrahimzadeh-Attary, Maryam Rafraf1 and Abolfazl Gorbani. Effect of dietary supplementation with *Nigella sativa* L. on serum lipid profile, lipid peroxidation and antioxidant defense system in hyperlipidemic rabbits. *J. Med. Plant. Res.* 2009;3(10):815-821.
64. Ramlah Mohamad Ibrahim, Nurul Syima Hamdan, Maznah Ismail, Suraini Mohd Saini, Saiful Nizam Abd Rashid, Latiffah Abd Latiff, Rozi Mahmud. Protective Effects of *Nigella sativa* on Metabolic Syndrome in Menopausal Women. *Adv Pharm Bull.* 2014 Mar; 4(1): 29–33.
65. Ibraheim ZZ. Effect of *Nigella sativa* seeds and total oil on some blood parameters in female doxorubicin volunteers. *Saudi Pharm. J.* 2002;10: 54–59.
66. Zaoui A, Cherrah Y, Alaoui K, Mahassine N, Amarouch H, Hassar M. Effects of *Nigella sativa* fixed oil on blood homeostasis in rat. *J. Ethnopharmacol.* 2002;79 (1): 23-6.
67. Dehkordi FR, Kamkhah AF. Antihypertensive effect of *Nigella sativa* seed extract in patients with mild hypertension. *Fundam. Clin. Pharmacol.* 2008;22 (4): 447-52.
68. Bamosa AO, Ali BA, al-Hawsawi ZA. The effect of thymoquinone on blood lipids in rats. *Indian. J. Physiol. Pharmacol.* 2002;46 (2): 195-201.
69. Morikawa T, Xu F, Ninomiya K, Matsuda H, Yoshikawa M. Nigellamines A3, A4, A5, and C, new dolabellane-type diterpene alkaloids, with lipid metabolism-promoting activities from the Egyptian medicinal food black cummin. *Chem. Pharm. Bull.* 2004;52 (4): 494-7.

70. Blunden G, Ali BH,. Pharmacological and toxicological properties of *Nigella sativa*. *Phytother. Res.* 2003;17 (4): 299–305.
71. Elrehany M, Elbawb Elsaid ME, Younis HA, Mhmoud AM. Therapeutic effect of *Nigella sativa* on patients with coronary artery disease. *AAMJ.* 2012;10:12–25.
72. Meral, I., Z. Yener, T. Kahraman and N. Mert. Effect of *Nigella sativa* on glucose concentration, lipid peroxidation, anti-oxidant defence system and liver damage in experimentally-induced diabetic rabbits. *J. Vet. Med. A. Physiol. Pathol. Clin. Med.* 2001;48 (10): 593-599.
73. S. Padhye, S. Banerjee, A. Ahmad, R. Mohammad, F.H. Sarkar. From here to eternity – the secret of Pharaohs: therapeutic potential of black cumin seeds and beyond *Cancer Ther.*, 2008;6:495–510.
74. Moyers SB, Kumar NB. Green tea polyphenols and cancer chemoprevention: multiple mechanisms and endpoints for phase II trials. *Nutr. Rev.* 2004;62(5): 204-211.
75. Hosseinzadeh H., S. Parvardeh, M. N. Asl, H. R. Sadeghnia, T. Ziaee. Effect of thymoquinone and *Nigella sativa* seed oil on lipid peroxidation level during global cerebral ischemia-reperfusion injury in rat hippocampus. *Phytomedicine.* 2007;14(9): 621-627.
76. Al-Jishi, S. A. and B. A. Hozaiifa. Effect of *Nigella sativa* on blood hemostatic function in rats. *J. Ethnopharmacol.* 2003;85(1): 7-14.
77. Ghosheh OA, Houdi AA, Crooks PA. High performance liquid chromatographic analysis of the pharmacologically active quinones and

- related compounds in the oil of the black seed (*Nigella sativa* L.). *J Pharm Biomed Anal.* 1999;19:757–762.
78. Burits M, Bucar F. Antioxidant activity of *Nigella sativa* essential oil. *Phytother Res.* 2000;14:323–328.
79. Ramadan MF, Kroh LW, Mörsel JT. Radical scavenging activity of black seed (*Nigella sativa* L.), coriander (*Coriandrum sativum* L.), and niger (*Guizotia abyssinica* Cass.) crude seed oils and oil fractions. *J Agric Food Chem.* 2003;51:6961–6969.
80. Heidland A, Sebekova K, Schinzel R. Advanced glycation end products and the progressive course of renal disease. *Am J Kidney Dis.* 2001;38: S100–S106.
81. Lee HB, Yu MR, Yang Y, Jiang Z, Ha H. Reactive oxygen species regulated signaling pathways in diabetic nephropathy. *J Am Soc Nephrol.* 2003;14(8 Suppl 3):S241–S245.
82. Yusuksawad MS, Chaiyabutr N. Changes in renal hemodynamics in streptozotocin-induced diabetic rats with L-ascorbic acid supplementation. *Clin Hemorheol Microcirc.* 2006;34:391–399.
83. Kuhad A, Sachdeva AK, Chopra K. Attenuation of renoinflammatory cascade in experimental model of diabetic nephropathy by sesamol. *J Agric Food Chem.* 2009; 57:6123–6128.
84. Boon NA, Colledge NR, Walker BR, Hunter JA (eds), *Davidson's Principles and Practice of Medicine*, 20 th edition, Churchill Livingstone–Elsevier Publishers, Philadelphia. 2006; 843–844.

85. Grover J.K., Yadav S.P., Vats V., Effect of feeding *Murraya koeingii* and *Brassica juncea* diet on kidney functions and glucose levels in streptozotocin diabetic mice, *J Ethnopharmacol.* 2003, 85(1):1–5.
86. Yadav U.C., Moorhy K., Baquer N.Z., Combined treatment of sodium orthovanadate and *Momordica charantia* fruit extract prevents alterations in lipid profile and lipogenic enzymes in alloxan diabetic rats, *Mol Cell Biochem.* 2005;268(1–2):111–120.
87. Grover J.K., Vats V., Rathi S.S., Dawar R., Traditional Indian anti-diabetic plants attenuate progression of renal damage in streptozotocin induced diabetic mice, *J Ethnopharmacol.* 2001;76(3):233–238.
88. Sun L., Halaihel N., Zhang W., Rogers T., Levi M., Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus, *J Biol Chem.* 2002;277(21):18919–18927.
89. Sugano M., Yamato H., Hayashi T., Ochiai H., Kakuchi J., Goto S., Nishijima F., Iino N., Kazama J.J., Takeuchi T., Mokuda O., Ishikawa T., Okazaki I. R., High-fat diet in lowdose-streptozotocin-treated heminephrectomized rats induced all features of human type 2 diabetic nephropathy:a new rat model of diabetic nephropathy, *Nutr Metab Cardiovasc Dis.* 2006;16(7):477–484.
90. Mogyorosi A, Ziyadeh FN. Diabetic nephropathy. in *Textbook of Nephrology*, eds MassrySG, GlassockRJ. (Lippincott, Williams and Wilkens, Philadelphia), 4th ed. 2001;845–895.

91. Samad Alimohammadi^{1*}, Rahim Hobbenaghi², Javad Javanbakht³, Danial Kheradmand⁴, Reza Mortezaee⁵, Maryam Tavakoli⁶, Farshid Khadivar⁷ and Hamid Akbari⁸. Protective and antidiabetic effects of extract from *Nigella sativa* on blood glucose concentrations against streptozotocin (STZ)-induced diabetic in rats: an experimental study with histopathological evaluation. Alimohammadi et al. Diagnostic Pathology 2013, 8:137.
92. Houghton PJ, Zakara R, Heras B, Hoult JR: Fixed oil of *Nigella sativa* and derived thymoquinone inhibit eicosanoid generation in leukocytes and membrane lipid peroxidation. *Planta Med* 1995, 61:33–36.
93. EL-Kholy WM, Hassan HA, Nour SE, Abe Elmageed ZE, Matrougui K. effects of *Nigella sativa* and bees' honey on hepatotoxicity induced by administration of sodium nitrite and sunset yellow. *FASEB J* 2009;23: 733.
94. Mohammad Aziz Dollah, Saadat Parhizkar, Latiffah Abdul Latiff, Mohamad Hafanizam Bin Hassan. Hepatoprotective Toxicity Effect of *Nigella Sativa* on the Liver Function of Rats *Advanced Pharmaceutical Bulletin*, 2013, 3(1), 97-102.
95. Ramadan MF, Kroh LW, Morsel JT. Radical scavenging activity of black cumin (*nigella sativa* l.), coriander (*coriandrum sativum* l.), and niger (*guizotia abyssinica* cass.) crude seed oils and oil fractions. *J Agric Food Chem* 2003;51(24):6961-9.
96. Abdel-Moneim A, Morsy BM, Mahmoud AM, Abo- Seif MA, Zanaty MI. Beneficial therapeutic effects of *Nigella sativa* and/or *Zingiber officinale* in HCV patients in Egypt. *EXCLI J* 2013; 12: 943-955. 48.

97. Seronello S, Sheikh MY, Choi J. Redox regulation of hepatitis C in nonalcoholic and alcoholic liver. *Free Radic Biol Med* 2007; 43:869–882. 49.
98. Melhem A, Stern M, Shibolet O, Israeli E, Ackerman Z, Pappo O, et al. Treatment of chronic hepatitis C virus infection via antioxidants: results of a phase I clinical trial. *J Clin Gastroenterol* 2005; 39:737–742. 50.
99. Al-Okbi SY, Mohamed DA, Hamed TE, Edris AE. Potential protective effect of *Nigella sativa* crude oils towards fatty liver in rats. *Eur J Lipid Sci Technol* 2013; 115:774–782. 51.
100. Danladi J, Abdusalam A, Timbuak JA, Miriga AA, Dahiru AU. Hepatoprotective effect of black seed (*Nigella sativa*) oil on carbon tetrachloride (ccl4) induced liver toxicity in adult wistar rats. *J Dental Med Sci* 2013; 4:56-62.
101. Rakesh Jadhav, M. Mateenuddin. Effect of *Nigella Sativa* Oil on Hepatotoxicity Induced by Antitubercular Drugs in Albino Rats *Indian Medical Gazette — APRIL 2013*. 141-147.
102. Balahoroglu R., Dulger H., Ozbek H., Bayram I. and Sekeroglu, M. Protective effects of antioxidants on the experimental liver and kidney toxicity in mice . *Eur J Gen Med*. 2008; 5 (3): 157-164.
103. Brandao, C., Ferreira, H., Piovesana, H., Polimeno, N., Ferraz, J., DE Nucci, G. Developmental model of liver cirrhosis in rabbits. *Clin Exp Pharma Physiol*. 2000; 27: (12): 987-990.
104. Al-Razzuqi, R. Hussaini,J. and Al-Jeboori, A. Protective effect of *Nigella sativa* against carbon tetrachlorideinduced acute liver injury in experimental rabbit models. *Int J Green Pharm*. 2011; 5(3): 198-200.

105. Alarifi, S., Aldahmash, B., El-Nagar, D. and Dkhil, M. Effect of corn oil, flaxseed oil and black seed oil on lead acetate-induced hepatic tissue damage: A histological study. *J Med Plants Res.* 2012; 6(24): 4128-4134.
106. Al-Ghamdi, M. Protective Effect of *Nigella sativa* Seeds Against Carbon Tetrachloride-induced Liver Damage. *The American Journal of Chinese Medicine.* 2003; 31(5): 721–728.
107. Al-Ali, A., Alkhawajah, A., Randhawa, M. and Shaikh, N. Oral and intraperitoneal LD50 of thymoquinone, an active principle of *Nigella sativa*, in mice and rats. *J. Ayub. Med. Coll. Abbottabad.* 2008 ;20(2): 25-27.
108. Amina E. Essawy, Ashraf M. Abdel-Moneim, Latifa I. Khayyat, Aglal A. Elzergy. *Nigella sativa* seeds protect against hepatotoxicity and dyslipidemia induced by carbon tetrachloride in mice. *Journal of Applied Pharmaceutical Science.* 2012;2(10):021-025.
109. Kanter M, Effects of *Nigella sativa* and its major constituent, thymoquinone on sciatic nerves in experimental diabetic neuropathy, *Neurochem Res*, 2008, 33(1), 87-96.
110. Kazim, T., Ayad, H. and Abdul-Ghani, M.A. 2005. Regeneration of the peripheral nerve in experimentally induced diabetes using oil of *Nigella sativa* L. *Tikrit Medical Journal*, 11 (1): 35 -45. Beuch, W. and Friede, R.L. 1984.
111. Beuch and Friede: The role of non-resident cell in wallerian degeneration. *Journal of Neurology and Cytology*, 13: 767–796.

CHAPTER 3

HYPOTHESIS

AIMS & OBJECTIVES

HYPOTHESIS

Both *Nigella sativa* seed powder and thymoquinone can reduce diabetes induced alterations in various biochemical parameters and histopathological changes of metabolic organs in albino rats.

AIMS & OBJECTIVES

- a. To evaluate the effect of Nigella sativa seed powder and thymoquinone in normal and streptozotocin(STZ) induced diabetic rats on various biochemical parameters and morphological effect on metabolic organs.
 - i. Biochemical parameters (Serum)
 - Glucose, Insulin, Oral Glucose Tolerance Test,
 - MDA,
 - Endogenous antioxidant -SOD,
 - Exogenous antioxidants –Vitamin C and E.
 - Lipid Profile
 - Liver function tests
 - ii. Histopathological changes – Pancreas, Liver, Kidney and Nerve.
- b. Purpose of the present study was to address the issues to support to the existing information pertaining to the effect of Nigella sativa seed powder and thymoquinone in treating diabetes.

CHAPTER 4

MATERIALS & METHODS

4.1. Procurement and Rearing of Experimental Animal

Laboratory inbred adult albino Wister rats fed with laboratory stock diet and water *ad libitum*, and weighing 175- 250g were used in the study. Rats are acclimatized a week to the laboratory conditions at 22- 24° C and a 12 h light: dark (circadian) cycle. The acclimatized rats were housed in polypropylene cages (32x40x18 cm) three animals in each. The experimental protocols were approved by the Institutional Animal Ethical Committee (IAEC) Shri B M Patil Medical College, Vijayapura and the experiments were performed as per norms of Committee for the Purpose of Control and Supervision of Experimentation on Animals (CPCSEA).

4.2. Preparation of Nigella sativa seed powder

Seed of Nigella sativa were procured from Safa Honey co Ltd, Bangalore (recognized Nigella sativa seed seller), authenticated by botanist from DRM Science college, Davangere. The Nigella sativa seeds were grained in to the fine powder with help of the department of pharmacognigence, Bapuji College of Pharmacy, Davangere. The powder was stored in to vacuum tight containers. Nigella sativa seed powder administrated orally^{1,2} (300mg / kg body weight).

4.3. Thymoquinone

Thymoquinone is a phytochemical compound found in the Nigella sativa seed. Thymoquinone procured from Sigma – Aldrich, Bangalore. Its stock solution was prepared by dissolving 1g in 10mL ethanol. Diluted solution of thymoquinone at

concentration of 4mg mL^{-1} was prepared by dissolving $400\ \mu\text{L}$ of stock solution in 10mL sterile distilled water. This freshly prepared solution was administered to rats through intraperitoneal injection³ (4mg / kg body weight).

4.4. Streptozotocin Induced Diabetes

Streptozotocin

Streptozotocin is a naturally occurring chemical that is particularly toxic to the insulin-producing beta cells of the pancreas. In medicine streptozotocin is used for treating certain cancers of Islets of pancreas and used in medical research to produce an animal model for diabetes. Streptozotocin is a glucosamine-nitrosourea compound. Like other alkylating agents it is in class of nitrosourea, it is toxic to cells by causing damage to the DNA, though other mechanisms may also contribute. DNA damage of pancreas beta cells induces activation of poly ADP-ribosylation, which is very important role for diabetes induction than DNA damage itself. Streptozotocin is similar enough to glucose to be transported into the cell by the GLUT2, but is not recognized by the other glucose transporters. This explains its relative toxicity to beta cells, since these cells have relatively high levels of GLUT2^{4,5,6}.

Citrate Buffer

- Citric acid – Dissolve 2.101gm of citric acid in 100ml of distilled water.
- Sodium citrate solution 0.1M : Dissolved 2.941gm of sodium citrate in 100ml distilled water.

- Preparation of Citrate Buffer with 4.4 PH – 49.5ml of citric acid solution add with 50.5 ml of sodium citrate solution.




Figure 2: Mechanism of Streptozotocin⁷

Streptozotocin induced diabetes

- Streptozotocin procured from SRL lab, Hyderabad. 50mg/kg body weight streptozotocin used for inducing diabetes into albino rats with single rapid intraperitoneal injection.
- Preparation – 15mg of streptozotocin dissolved in 1ml of citrate buffer

$$= 50\text{mg}/1000 \times \text{body weight (gm)} = \text{Result} / 1.5 = \text{result in ml}$$
- Confirmed Diabetes after 24 hrs $>180\text{mg/dl}^1$, repeated fasting glucose checkup first 7 days, after 1 week of induction, confirmed diabetic($>180\text{mg/dl}$) rats only taken for study⁸.

4.5. Gravimetry

Effect on body weight, metabolic organs (Liver, kidney and pancreas) of all the groups was evaluated. Animals are anesthetized by euthanasia where in animals are placed in sealed chambers where high levels of aesthetic gas are introduced by soaking cotton in 40 ml of diethyl ether. Once after loss of righting reflex approximately after 60 sec rats will be removed from the chambers and continued for further process. Liver, kidney and pancreas were carefully removed and weighted using digital electronic balance. The organosomatic index was calculated.

$$\text{Organosomatic index} = \frac{\text{Weight of organ (One side/both sides)} \times 100}{\text{Body weight of rats}}$$

4.6 Method of euthanasia

Euthanasia is the act of humanely putting an animal to death or allowing it to die. Euthanasia methods are designed to cause minimal pain and distress. Euthanasia is distinct from animal slaughter and pest control, which are performed mainly for the purpose other than an act of mercy, although in some cases the procedure is the same. Gas anaesthetic such as diethyl ether can be used for euthanasia of rats. The animals are placed in sealed chambers where high levels of aesthetic gas introduced by soaking cotton in 40ml of diethyl ether. Death may also be caused using carbon dioxide once unconsciousness has been achieved by inhaled anaesthetics. Once after loss of righting reflex approximately after 60 sec will be removed from the chamber and continued for further process.

4.7. Blood & Tissue collection

4.7.1. Blood collection

Blood samples were collected by the retro-orbital route on 46th day and processed for biochemical assay.

Procedure for retro orbital venous blood collection⁹

Also referred to as periorbital, posterior-orbital and orbital venous plexus bleeding

- The animal is anaesthetized and at an appropriate depth of anesthesia prior to commencement or even can be euthanize, signs that indicate a satisfactory plane of anesthesia include a lack of response to a toe pinch and respiration that are regular and relaxed.
- The anaesthetized rat made to lie on its back, the head of the rat toward the edge of table.
- Fix the head with thumb and forefinger, tightening the skin over the sides of the face. This leads to retraction of the eyelids and protracts the eye ball.
- Insert a micro hematocrit (capillary) tube into the medial canthus and twist, it leads to break through the bulbar conjunctiva. Capillary tube should pass toward the medial aspect of the bony orbit.
- Collect the blood into test tubes and seal. Continue until unable to collect. If difficulty arise changes to other eye.

- Blood flow can be controlled or stopped by applying finger pressure gently to the soft tissue. A finger should be placed over the closed eyelid for approximately 30 seconds. The rat should be checked for post-operative pre-orbital lesions approximately 30 minutes after blood sampling and on at least one more occasion with two hours of the sampling.

Advantages of retro orbital venous blood collection

- Rapid – large number of animals can be bled within short period of time.
- Obtained volume: medium to large.
- Good sample quality. Potential contamination with topical anesthetic, if used should be taken into account.
- A minimum of 10 days should be allowed for tissue repair before repeat sampling from the same orbit. Otherwise it may interfere in the healing process with blood flow.
- Alternating orbit should not be attempted until the phlebotomist is proficient in obtaining samples from the orbit accessed most readily by the dominant hand that is a right handed person should withdraw samples from the right orbit before attempting to obtain samples from the left orbit.

4.7.2. Tissue collection

After euthanasia rats were kept in supine position and dissected. Metabolic organs liver, kidney, pancreas and nerve were collected and washed in normal saline. Histopathology of all the collected organs was done. For the evolution of histopathology

specimens were kept in 10% formalin. By following routine histological techniques, the samples were put into paraffin and serial sections of 5µm were taken from tissue blocks.

4.7.3. Analysis of Biochemical assay

Glucose

GOD-POD Method¹⁰

Principle:

The reaction sequence employed in this assay is as follows:

Glucose is oxidized by glucose oxidase and produces gluconate and hydrogen peroxide. The hydrogen peroxide is oxidatively coupled with 4-aminoantipyrine and phenol. The intensity of the coloured complex (quinoneimine) is proportional to the glucose concentration in the sample and can be measured photometrically at 505nm (500-540nm).

Reagent composition:

<u>Active ingredients</u>	<u>Concentration</u>
Phosphate buffer	100 mmol/L
Glucose oxidase	7000 U/L
Peroxidase	6700 U/L
4-Aminoantipyrine	0.7 mmol/L
Phenol	0.1mmol/L

Procedure:

Pipette into test tubes labelled Blank (B), Standard (S) and Test (T) as follows:

	B	S	T
ERBA Glucose reagent	1.0ml	1.0ml	1.0ml
Glucose Standard	-----	1.0ml	-----
Specimen	-----	-----	1.0ml

Table 1: Procedure of Glucose estimation

Mix and incubate for 10 minutes at 37⁰ C (or) 15 minutes at R.T.

Mix and read absorbance of Standard (S) and Test (T) against Blank (B) 505 nm or with green filter (500-540nm). The final colour is stable for 1 hour at R.T

Calculations:

$$\text{Glucose Conc. in mg/dl} = \frac{\text{Abs. of T} \times 100}{\text{Abs. of S}}$$

Estimation of Serum Malondialdehyde (MDA) (Nadiger et al method 1986)¹¹

Principle - Auto oxidation of unsaturated fatty acids lead to the information of semi stable peroxides which then undergo a series of reaction to form short chain aldehydes like malondehyde(MDA). Two molecules of thiobarbituric acid (TBA) react with one molecule of MDA with the elimination of 2 molecule of water to yield pink crystalline pigment with an absorption maximum at 530nm.

Reagents

1. 10% trichloroacetic acid(TCA)

10gm of trichloroacetic acid in 100ml distilled water

2. 0.67% thibarbituric acid in 100ml distilled water

Reagents	Blank(ml)	Test(ml)
Distilled water	0.5	-----
Serum	-----	0.5
0.67% Thiobarbituric acid(TBA)	1.5	1.5
10% Trichloroacetic acid	3.6	3.6
Keep in water bath and boil for 10-15 min and cool. Centrifuge for 10-15 min		
Absorbance of supernatant at 530nm		

Table 2: Procedure of MDA estimation

Calculation:

Concentration of serum MDA

$$= \frac{\text{Absorbance of test}}{\text{Nanomolar extin non co- efficient}} \times \frac{\text{Total Volume}}{\text{Sample Volume}}$$

$$= \frac{\text{Absorbance of test} \times 5.6}{1.5 \times 10^5 \times 0.5} \times \frac{10^9}{1000}$$

= Absorbance of test X 73.33

=.....nmol/ml

Estimation of serum Superoxide Dismutase (SOD) (Marklund and Marklund method 1974)¹²

Principle – Superoxide anion is involved in auto oxidation of pyrogallol at alkaline pH(8.5). The superoxide dismutase(SOD) inhibits auto-oxidation of phyrogallol, which can be determined as an increase in absorbance at 420nm.

Reagents –

1. Tris buffer, 0.05M, pH 8.5 containing 1mM EDTA

50ml of tris buffer(50mM of Tris buffer and 1mM of EDTA) was prepared to this 50ml HCL was adjust the pH 8.5 and volume was made upto 100ml.

2. Pyrogallol(20mM): 25mg pyrogallol dissolved in 10ml distilled water.

Procedure

	Tris Buffer(ml)	Serum(ml)	Pyrogallol(ml)	OD at 420 nm after 1 min, 30 sec	OD at 420 nm after 3 min, 30 sec
Control	2.9	0	0.1		
Test	2.8	0.1	0.1		
<p>The contents of the above tube were mixed and the absorbance at 420nm was measured</p> <p style="text-align: center;">Absorbance at 3 min 30sec – Absorbance at 420nm Was measured</p> <p style="text-align: center;">A/min =</p> <p style="text-align: center;">2</p>					

Table 3: Procedure of SOD estimation

Calculation:

Serum SOD activity

$$= \frac{A/\text{min of control} - A/\text{min of Test}}{A/\text{min of control} \times 50} \times 100 \times \frac{1}{\text{Sample Volume}}$$
$$= \frac{C - T}{C \times 50} \times 1000$$

=.....**U/ml**

one unit of SOD is defined as the amount of enzyme required to cause 50% inhibition of phyrogallol auto oxidation.

Vitamin C Estimation

By Roe & Kuether Method¹³

Vitamin C includes standardization of chemicals & analysis vitamin C in sample.

Standardization of vitamin C (Ascorbic acid)

Principle

The ascorbic acid is oxidized to diketogulonic acid in presence of strong acid solution reacts with 2,4, dinitrophenyl hydrazine to form diphenylhydrazone which dissolves in strong H₂ So₄ solution to produce red colour which can be measure at 505nm(range of vitamin C 500-520nm) spectrophotometrically.

Reagents:

1. **TCA (10%):** 10 gm TCA dissolved in distilled water(DW) and make volume up to 100ml.
2. **2,4-DNPH:** 2gm 2,4-DNPH dissolved in 9N H_2SO_4 & make volume up to 100ML. 9N H_2SO_4 preparation : MW: 98(2+32+64); Density:1.83gm/cc (i.e.1830gm in 1000cc) Molarity= density/MW; 1830/98=18.67M, but here each mole contribute 2 H^+ so conc. H_2SO_4 is approx.. 37 Normal. To make 9N H_2SO_4 solution in 100ml DW: $V_1N_1=V_2N_2$; $100 \times 9 = V_2 \times 37$; $V_2 = 24.324\text{ml}$; i.e. 24.32ml H_2SO_4 added in DW up to 100ml.
3. **Thiourea :** 10gm thiourea dissolved in 100ml of 50% ethanol (store in 4°C).
4. **1.5% CuSO_4 :** 1.5 gm CuSO_4 dissolved in DW upto 100ml.
5. **Combined C. R. (freshly):** 5ml 2,4-DNPH+0.1 ml $\text{Cu}(\text{SO}_4)$ + 1ml thiourea.
6. **85% H_2SO_4 :** 85 ml H_2SO_4 added in DW upto 100ml.
7. **1% Stock Solution of Vitamin C :** 1gm Vit. C makes it 100 ml with DW.
8. **Working standard:** 1ml stock diluted upto 100ml DW to 500DW

Standard Curve Preparation:

Standardization: 100ml DW = 1gm vit. C

1ml = 0.01gm, 0.1=0.001gm.

Stock(ml)	DW(ml)	TCA(ml)	Colour Reagent(ml)	Mixed & kept at 56 ⁰ C in warm water bath for 1hr then cooled in ice bath for 5 min.	85% H ₂ SO ₄ (cold)(ml)
Blank	--	0.5	0.4		2
0.1	0.5	0.5	0.4		2
0.2	0.4	0.5	0.4		2
0.3	0.3	0.5	0.4		2
0.4	0.2	0.5	0.4		2
0.5	0.1	0.5	0.4		2
All test tubes are mixed and after 20min OD of Stock Std was read against B at 500nm.					
Stock(ml)		Concentration(g/ml)		OD	
0.1		0.001			
0.2		0.002			
0.3		0.003			
0.4		0.004			
0.5		0.005			

Table 4: Procedure for standardization of vitamin -C

Estimation

1. Principle

Ascorbic Acid is oxidized to diketoglutoxic acid in presence of strong acid solution, which reacts with 2, 4-DNPH to form diphenylhydrazine which dissolves in strong H₂SO₄ solution to produce red colour which can be measure at 500 nm (range of vit. C 500-520 nm) spectrophotometrically.

2. Depolarization:

For plasma / serum sample: 1ml sample+ 1ml 10% TCA (1.1 v/v)

1ml plasma / serum in dry centrifuge + 1ml 10% TCA

Mix well (10-15 sec.)

Centrifuge (10min at 3500 rpm)

Take supernatant

Sl.no	Reagents	T(ml)	S(ml)	B(ml)
1	Supernatant	1	--	--
2	Working standard(g/ml)	--	(Stock: DDW)	--
3	10% TCA	--	0.5	0.5
4	DDW	--	----	0.5
5	Colour reagent (Fresh)	0.4	0.4	0.4
Mix & all test kept in warm water bath at 56 degree C for 1hr then cooled in ice bath for 5min.				
6	85% cold H ₂ SO ₄	2	2	2

All test tubes are mixed and after 20min OD of T& S was read against B at 500nm. T= test, S= standard, B= blank

Table 5: Vitamin C estimation Procedure

Vitamin E estimation

By Das et al (2012)¹⁴

Reagents

Absolute ethanol (aldehyde free), N-propanol, Xylene (extra pure), Ferric chloride (%), Distilled water, DL - tocopherol acetate, & 2, 2' - Bipyridyl.

Preparation of reagents

Stock standard of α -tocopherol (0.27% w/v): 270mg of α -tocopherol acetate dilute in 100ml absolute ethanol and mix thoroughly.

2, 2' - Bipyridyl (0.12% w/v): 120 mg 2, 2' - bipyridyl dissolved and made volume up to 100ml of n-propanol & kept in brown bottle.

Ferric chloride (0.12% w/v): 120mg $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$ dissolved in 100ml ethanol & kept in brown bottle. All the solutions are stable at room temperature.

Preparation of standard curve

Working standard of α -tocopherol (27 $\mu\text{g}/\text{mL}$): Dilute 1ml of stock standard to 100mL absolute ethanol to obtain concentration 27 $\mu\text{g}/\text{mL}$ (2.7 $\mu\text{g}/100\text{mL}$). This solution is stable at room temperature. In six centrifuged tubes labelled as (blank) B, S₁, S₂, S₃, S₄ and S₅ place 00, 150, 300, 450, 600 and 750 μL of working standard α -tocopherol (27 $\mu\text{g}/\text{mL}$) in respectively and add absolute ethanol to make the volume of each tube equal as 750 μL . These solutions (S₁-S₅) are equivalent to 4 $\mu\text{g}/\text{mL}$, 8 $\mu\text{g}/\text{mL}$, 12 $\mu\text{g}/\text{mL}$, 14 $\mu\text{g}/\text{mL}$, 16 $\mu\text{g}/\text{mL}$ and 20 $\mu\text{g}/\text{mL}$ of α -tocopherol respectively. Use these solutions in the routine procedure shown in following table(Table 6). Read the absorbance by using 200 μl of solutions prepared above including blank putting on plain ELISA micro plate (non-antibody coated) and read in ELISA reader at 492nm. Plot standard curve absorbance vs α -tocopherol ($\mu\text{g}/\text{mL}$).

S. no	Working standard		DW (μL)	Xylene (μL)	Centrifuge Xylene at 3000 rpm. 500 μL Xylene layer taken out	2,2` - Bipyridyl (μL)	FeCl ₃ (μL)	After 2 min read OD at 492 nm
	- tocopherol (μL)	Ethanol (μL)						
B	0	750	750	750		500	100	
S ₁	150	600	750	750		500	100	
S ₂	300	450	750	750		500	100	
S ₃	450	300	750	750		500	100	
S ₄	600	150	750	750		500	100	
S ₅	750	0	750	750		500	100	

Table 6: Procedure for standardization of vitamin E

The curve is drawn to determine the extent of adherence to the Beer-Lambert law with various photoelectric instruments.

Analysis of serum - tocopherol

Sample preparation: Allow the 3ml blood to clot in centrifuge tube for hrs at room temperature and centrifuge at 3000rpm for 15 min to get serum. Serum for the analysis of - tocopherol should be protected from sunlight and undue agitation. - tocopherol darkens on exposure to light and slowly oxidized by atmospheric oxygen. - tocopherol was found stable in separated serum at 25° C for 1day, at 4°C for 2 weeks and at -20°C for 2 months.

Procedure Step -1: two centrifuge tubes label as T and B (i.e. sample and blank). To the sample tube add 750 μ L absolute ethanol and 750 μ L serum. Add the serum slowly with shaking to obtain a finely divided protein precipitate. To the blank tube add 750 μ L distilled water and 750 μ L absolute ethanol. Stopper the tubes tightly by wrap paper and shake vigorously for at least 30sec. To all these tubes add 750 μ L xylene. Again stopper the tubes tightly by wrap paper and shake vigorously for at least 30sec and centrifuge all tubes for 10 min at 3000rpm (Table 7).

Step-2: Transfer 500 μ L of the xylene layer (supernatant) into properly ladled clean small size test tubes. To each tube add 500 μ L of 2, 2- bipyridyl solution and 100 μ L ferric chloride solution and wait for 2 min (Table 8).

Step-3: Transfer 200 μ L solutions from these tubes to uncoated micro wells respectively. Readings are made in ELISA Reader (Erba, Lisa Scan II), with the rapid measure mode. Set the primary wavelength as 492 and measure the absorbance within 4 min (Table 9).

	T(μL)	B(μL)	Mix for 30 sec & centrifuge for 10 min at 3000 rpm
Serum	750	---	
DW	---	750	
Ethanol	750	750	
Mix for 30 sec			
Xylene	750	750	

Table 7: Analysis of - tocopherol procedure

	T(μL)	B(μL)	Wait for 2 min
Supernatant	500	500	
2,2-bipyridyl	500	500	
FeCl ₃	100	100	

Table 8: Analysis of - tocopherol procedure

	T(μL)	B(μL)
ELISA	200	200
Read the absorbance at 492nm within 2min		

Table 9: Analysis of - tocopherol procedure

Note: we can take the serum 350μL (in case less availability) by reducing all other reagents by half.

Calculation:

$$\text{Concentration of Vitamin E } \mu\text{g/ml} = \frac{\text{OD of test} - \text{OD of Blank}}{\text{Slope}} \times \text{Dilution factor}$$

$$\text{Where Slope} = \frac{Y_2 - Y_1}{X_2 - X_1}$$

X & Y are concentration and absorbance of standards respectively.

Oral glucose tolerance test (OGTT) ^{15,16}

Oral glucose tolerance test (OGTT) for rats were performed according to the standard method. Group I served as untreated normal control and the oral 2 h glucose tolerance test was carried out via estimating glucose of blood sample collected at 0, 30, 60, 90 and 120 min. An oral glucose load of 3.5 g/kg body weight was administered for the test². Group II rats were normal rats treated with *Nigella sativa* seed powder (300mg/kg BW) for 45days and similar OGTT was conducted on these animals. Group III normal rats treated with thymoquinone(4mg/ kg BW) for 45days followed by OGTT. Group IV served as untreated diabetic control rats followed by OGTT. Group V diabetic rats received a dose of 300 mg/kg BW of *Nigella sativa* seed powder for 45days and followed by OGTT and Group VI diabetic rats received a dose of 4mg/kg BW of thymoquinone for 45days and followed by OGTT.

Insulin

By Chemiluminescence immunoassay (CLIA) ^{17, 18, 19}

Principle of the Assay

The insulin CLIA Kit is based on a solid phase enzyme-linked immunosorbent assay. One anti-Insulin antibody utilizes by the assay system for solid phase (microliter wells) immobilization and another anti-Insulin antibody in the antibody-enzyme (horseradish peroxidase) conjugate solution. The test specimen (serum) and standards are added to the insulin antibody coated microliter wells. Then anti-Insulin antibody labeled with horseradish peroxidase (conjugate) is added. If Insulin present in the

specimen, it will combine with the antibody on the well and the enzyme conjugate resulting in the insulin molecules being sandwiched between the enzyme-linked antibodies and solid phase. After incubation of one hour at room temperature, the wells are washed with water to remove unbound labeled antibodies. A solution of chemiluminescent substrate is then added and read relative light units (RLU) in an illuminometers. The intensity of the emitting light is proportional to the amount of enzyme present and is directly related to the amount of Insulin in the serum. By reference to a series of insulin standards assayed in the same way, the concentration of Insulin in the unknown sample is quantified.

Assay Procedure

Reagent Preparation

- All reagents should be at room temperature (18-25°C) and mixed by gently inverting or swirling prior to use.
- To prepare substrate solution, make a 1:1 mixing of reagent A with reagent B before using of it. Mix gently till complete mixing. Discard excess after use.
- Dilute 1 volume of wash buffer concentrate (50x) with 49 volumes of distilled water. 750 ml of washing buffer (1x) can be prepared by diluting of 15 ml of wash buffer concentrate (50x) with 735 ml of distilled water, mix well before use.
- Reconstitute each lyophilized standard with 0.5 ml distilled water. Allow the material of reconstituted to stand for at least 20 minutes. Reconstituted standards should be stored sealed at 2-8°C.

Procedure

- Secure the desired number of coated well in the holder. Dispense 50 µl of insulin standards, specimens, and controls into the appropriate wells. Gently but thoroughly mix for 10 seconds.
- Dispense 100 µl enzyme conjugate reagent into each well. Mix well for 30 seconds and incubate at room temperature for 60 minutes.
- Remove the mixture of incubation by emptying the plate content into a waste container. Rinse and empty the microliter plate 5 times with 1 x wash buffer (300 µl each well). Strike the microliter plate sharply onto absorbent paper or paper towels to remove all residual water droplets.
- Dispense 100 µl of Chemiluminescence substrate reagent into each well. Gently mix for 10 seconds. Incubate at room temperature, in the dark, for 20 minutes.
- Stop the reaction by adding 100 µl of stock solution to each well. Gently mix for 10 seconds until the blue color completely changes to yellow.
- Read the optical density at 450 nm with a microliter plate reader within 15 minutes.


LIPID PROFILE

Total Cholesterol

by modified Roeschau`s Method^{20, 21}

Principle

The estimation of cholesterol involves the following enzyme catalysed reactions.



Procedure

Reagents	Blank	Standard	Test
Working reagent	1000 μ l	1000 μ l	1000 μ l
Distilled water	20 μ l	-----	-----
Standard	-----	20 μ l	
Test	-----	-----	20 μ l



Table 10: Procedure for Cholesterol estimation



Triglycerides

This reagent is based on the method of *Wako* and the modified by *McGowan et al* ²²,
23,24,25

Principle

The triglycerides are determined after enzymatic hydrolysis with lipases. The indicator for this is a quinoneimine formed from hydrogen-peroxide, 4-aminophenazone and 4-chlorophenol under the catalytic influence of peroxidase.





Reagents	Blank	Standard	Test
Working reagent	1000 μ l	1000 μ l	1000 μ l
Distilled water	10 μ l	-----	-----
Standard	-----	10 μ l	-----
Test	-----	-----	10 μ l

Table 11: Procedure for Triglycerides

Mix and incubate for 10 min at 37°. Read the absorbance of standard and each test at 505 nm (500-540nm) against reagent blank.

Calculation

$$\text{Triglycerides (mg/dl)} = \frac{\text{Abs of test}}{\text{Abs. of standard}} \times \text{Conc. Of standard}$$




HDL Cholesterol

By Phosphotungstic Acid Method, End point^{26,27}.

Principle

Chylomicrons, LDL and VLDL (low and very low density lipoprotein) are precipitated from serum by phosphotungstate in the presence of divalent cations such as

magnesium. The HDL cholesterol remains unaffected in the supernatant and is estimated using ERBA cholesterol reagent. Serum / plasma phosphotungstate (HDL + LDL + chylomicrons).



Absorbance of quinoneimine is directly proportional to the HDL cholesterol concentration, when measured at 505nm.

Procedure

Reagents	Blank	Standard	Test
Cholesterol	1000 μ l	1000 μ l	1000 μ l
Working reagent			
Distilled water	50 μ l	-----	-----
Standard	-----	50 μ l	-----
Test	-----	-----	50 μ l

Table 12: Procedure for HDL Cholesterol

Mix well; incubate for 10min. at 37°C, or 12 min. at 30° C. Read the absorbance of the standard and each test at 505nm.

Calculation

$$\text{HDL cholesterol of Test} = \frac{\text{Abs of test}}{\text{Abs. of standard}} \times \text{Conc. Of standard} \times \text{dilution factor Abs.}$$

$$\text{HDL cholesterol} = \frac{\text{Abs of test}}{\text{Abs. of standard}} \times 25 \times 3$$

$$\text{HDL cholesterol} = \frac{\text{Abs of test}}{\text{Abs. of standard}} \times 75$$

LDL Cholesterol²⁸

LDL-C, usually called as 'bad cholesterol' transports cholesterol to the tissues and is linked to the development of cardiovascular diseases. Accurate measurement of LDL-C is therefore of very importance in therapies which focus on reduction of lipid content to reduce or prevent the progress of atherosclerosis and to avoid plaque rupture.

Calculation

$$\text{LDL} = \text{Total Cholesterol} - \text{HDL Cholesterol} - \frac{\text{Triglycerides}}{5}$$

Where [TG] / 5 is an estimate of VLDL-cholesterol.

Calculation

Perform calculations in units per litre. Multiplying the delta A/min by the factor.

Activity in U/L = delta A/min X 3376

SI conversion factor: 1U/L X 0.017 = 1 μ Kat /L


Alkaline Phosphatase (ALP)

By King & King's Method^{27, 32}

Alkaline phosphatase (ALP) catalyses the hydrolysis of a wide variety of non-physiological and physiological phosphoric acid esters in alkaline medium). The liver and biliary tract is the source of normal sera.

Principle:

Serum ALP hydrolyzes phenyl phosphate into phenol and disodium hydrogen phosphate at pH 10.0 the phenol so formed reacts with 4-Aminoantipyrine in presence of oxidizing agent potassium ferricyanide in alkaline medium to form a red colored complex whose absorbance is proportional to the enzyme activity.



Specimen serum

Procedure:

Pipette into clean dry tubes labeled Blank (B), Standard (S), Control (C) and Test (T) and add the reagents in the following order.

	B	S	C	T
Working Buffered Substrate	1.0ml	1.0ml	1.0ml	1.0ml
Deionized water	3.1ml	3.0ml	3.0ml	3.0ml
Incubate at 3 min at 37°C				
Serum	-----	-----	-----	0.1ml
Phenol Standard	-----	0.1ml	-----	-----
Incubate for 15 minutes at 37°C				
Color Reagent	2.0ml	2.0ml	2.0ml	2.0ml
Serum	-----	-----	0.1ml	-----

Table 13: Procedure for ALP estimation

Mix well after each addition of reagent and measure absorbance (A) for Blank (B), Standard (S), Control (C) and Test (T) against deionized water on photocolorimeter using a green filter or on spectrophotometer at 510 nm.

Calculations:

$$\text{Serum ALP in KA units/dl} = \frac{A(T)-A(C)}{A(S)-A(B)} \times 10 \text{ (Std. Conc.)}$$

1KA unit/dl = 7.1 U/l.

4.7.4. Histopathology

Manual tissue processing

Procedure is followed as per the Bancroft procedure³³

Fixation: Fixation is the first step towards the preparation of a histological section from a dead biological specimen. The substances used for fixation are called as fixatives. Tissue will be kept in fixative for 24hrs.

Common fixatives - Formalin, Zenker`s fluid.

Washing: After fixation tissue is washed under running tap water one to two hours. It removes fixative from tissue.

Dehydration, clearing and Impregnation: Our aim is imbibe tissue with paraffin; this cannot be done directly because paraffin is not mixable with water of tissue. Dehydration is done in stages, first the tissue is immersed in alcohol which replaces water of tissue (dehydration). Paraffin is not mixable with alcohol also; Xylene benzene, chloroform and toluene are substances which get mixed both the alcohol and paraffin therefore after alcohol the tissue is treated with one of these liquids (called clearing agents) and then tissue is impregnated in melted paraffin. Following is the list of time for manual tissue processing.

Step	Treatment	Hours
Fixation	Formalin (10%)	24
Dehydration	30%	1
	50%	1
	80%	1
	90%	1
	100%	1
	100%	1
	100%	1
Clearing	Xylene	1
	Xylene	1
Infiltration	Paraffin at 50-56°C	1
	Paraffin at 50-56°C	1
	Paraffin at 50-56°C	1

Table 14: Procedure for manual tissue processing

Embedding: The process of embedding enables specimens too small and / or too delicate to be surrounded with some suitable material example paraffin that will support them on all sides with firmness but without producing any injurious effect on the specimen the embedded tissue may then be section into sufficiently thin slices without distortion.

Preparation of Blocks: It is done with the help of L-blocks; L-blocks are L-shaped metallic pieces. Two L-blocks are placed on glass plate, so that enclose a rectangular

space. The tissue is put in it over which the melted paraffin is poured which solidifies slowly. The L-blocks are removed.

Section cutting: For histological preparation tissue cut (sectioned) into thin slices trim the upper or cutting surface of the block parallel to the knife edge until the surface of the tissue get exposed. Attach the block holder to the microtome. Clamp the knife firmly in position in microtome. Adjust the desired thickness scale in the microtome. Move the microtome fairly constant and fast. Pick up the end of short ribbon with a soft brush and gently pull it away from the knife as you continue sectioning.

Hematoxylin and Eosin Staining

1. Xylene 2 Minutes
2. Xylene 2 Minutes
3. Absolute alcohol 1 Minutes
4. Absolute alcohol 1 Minutes
5. 90% Alcohol 2 Minutes
6. 70% Alcohol 2 Minutes
7. 50% Alcohol 2 Minutes
8. Distilled water 5 Minutes
9. Hematoxylin 2 to 5minutes depending on which of the above types of Hematoxylin Solution is used (Stain for 20 minutes with Erlich`s and for 2-5 minutes with Harris` Hematoxylin.
10. Wash well in running tap water for 2-3 minutes section may be examined with microscope to confirm a sufficient degree of staining.

11. Remove excess stain by differentiation in acid alcohol (1% HCL in 70% alcohol) for a few seconds. Blue staining of hematoxylin stained section is changed to red by action of acid.
12. Immediately wash in alkaline tap water for at least 5 minutes to regain the blue colour (‘bluing section’) (a few drops of saturated lithium carbonate may be added to the tap water in a large beaker and bluing of section done in this. After bluing, the slides should be thoroughly washed in running tap water to remove excess lithium carbonate). If necessary, examine microscopically.
13. 1 % aqueous Eosin 1 to 3 minutes
14. Wash the surplus eosin water
15. Examine the sections microscopically. Cytoplasm and muscle cell should be deep pink, collagen fibers a lighter pink, erythrocytes and eosinophil granules should be bright orange red.
16. 90% alcohol for 10 to 15 min
17. Absolute alcohol I for 10 to 15 seconds
18. Absolute alcohol II for 10 to 15 seconds
19. Xylene I – 1 to 2 min
20. Xylene I – 1 to 2 min or until completely clear
21. Mount in D.P.X. or any other synthetic resin medium.

Results

Muscle cell – deep pink, Collagen fibres – lighter pink, erythrocytes and Eosinophil granules – bright orange red, Cytoplasm – pink, Nuclei – blue of blue –back.

4.8. Grouping of Animals

Laboratory bred adult albino Wister rats weighing between 175 - 250gm were used in the study. The acclimatized animals were divided into six groups of six rats each. Group I rats were normal control rats; group II were normal rats treated with *Nigella sativa* seed powder (300mg/kg body weight); group III were normal rats treated with thymoquinone(4mg/kg body weight); group IV were streptozotocin induced diabetic control rats; group V were streptozotocin induced diabetic rats treated with *Nigella sativa* seed powder(300mg/kg body weight) and group VI were streptozotocine induced diabetic rats treated with thymoquinone(4mg/kg body weight).

4.9. Statistical Analysis

Data obtained from all control and experimental samples has been subjected to statistical analysis for evaluating the range of significance. After collecting all data was filled in Microsoft excel, data was presented with tables and diagrams. Mean \pm SD (standard deviation) values were calculated for each group.

To determine the significance of inter-group differences, each parameter will be analysed separately. All the parameters were compared by using proper statistical tests using software SPSS V 20 32bit, values were analysed by one-way analysis of variance (ANOVA) using post hoc Turkey HSD test to study the differences between the groups. The level of statistical significance was set at $P < 0.05$.

BIBLIOGRAPHY

1. Matira K. Dewan F. Effects of the crude and the n-hexane extract of *Nigella sativa* Linn (kalajira) upon diabetic rats. *Bangla J Pharmacol.* 2008;4:17–20.
2. Abdelmeguid, N.E.; Fakhoury, R.; Kamal, S.M.; AlWafai, R.J. . Effect of *Nigella sativa* L. and Thymoquinone on Streptozotocin Induced Cellular Damage in Pancreatic Islets of Rats. *Asian Journal of Cell Biology*; 2011; 6:1-21.
3. Zubaida A. Hawsawi, Basil A. Ali, Abdullah O. Bamosa. Effect of *Nigella sativa* (black seed) and thymoquinone on blood glucose in albino rats. *Annals of Saudi Medicine.* 2001; 21:3-4.
4. Szkudelski T. "The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas.". *Physiol Res.* 2001; 50 (6): 537–46.
5. Wang Z, Gleichmann H. "GLUT2 in pancreatic islets: crucial target molecule in diabetes induced with multiple low doses of streptozotocin in mice".*Diabetes.* 1998;47 ;(1):50-6.
6. Schnedl WJ, Ferber S, Johnson JH, Newgard CB. "STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells".*Diabetes.* 1994;43 (11): 1326–33.
7. Jinzi Wu, Liang-Jun Yan. Streptozotocin-induced type 1 diabetes in rodents as a model for studying mitochondrial mechanisms of diabetic cell glucotoxicity. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy* 2015;8 181–188.

8. Amar B Singh, J P Chaturvedi, T Narender and Arvind K Srivastava. Preliminary studies on the hypoglycemic effect of peganum harmala l. Seeds ethanol extract on normal and streptozotocin induced diabetic rats. *Indian Journal of Clinical Biochemistry*, 2008; 23 (4): 391-393.
9. Van Herck H, Baumas V, Bandit C J, Hesp A. P, Strurkenboom J H, Van Lith H A et al. Orbital sinus blood sampling in rats as performed by different techniques: the influence of technique & expertise. *Lab Anim*.1998; 32:377-86.
10. Barham D, and Trinder,P. *Analyst* . 1972;97:142.
11. Nadiger Ha, Marcus Sr, ChandrakalaMv, Kulkarni Dd. Malondialdehyde Levels In Different Organs Of Rats Subjected To Acute Alcohol Toxicity. *Indian Journal of Clinical Biochemistry* 1986; 133-136.
12. Marklund, S., Marklund, G. Involvement of the superoxyde anion radical in the auto oxidation of pyrogallol and a convenient assay for superoxyde dismutase. *Eur. J. Biochem*. 1974; 47:469-474.
13. Roe & Koether, Estimation of serum Ascorbic Acid by DNPH Method. 1943.
14. Jameel G. Jargar, Shaheenkousar H, Hattiwale, Swastika Das, Salim. Dhundasi, Kusal K. Das. A modified simple method for determination of serum - tocopherol (vitamin E). *J Basic Clin Physiol Pharmacol* 2012; 23(1):45-48.
15. Vigneaud V, Karr W. Carbohydrate utilization: I. Rate of disappearance of d-glucose from the blood. *J Biol Chem* 1925; 66:281-300.

16. Das KK, Razzaghi-Asl N, Tikare SN, Di Santo R. Hypoglycemic activity of curcumin synthetic analogues in alloxan- induced diabetic rats. *Journal of enzyme inhibition and medicinal chemistry*, 31(1), 2016, 99-105.
17. National Committee for Clinical Laboratory Standards. Procedures for the collection of diagnostic blood specimens by venipuncture: approved standards. 4th Ed. NCCLS Document H3-A4, Wayne, PA: 1998.
18. Sacks BD: Carbohydrates in Burtis, C.A. and Ashwood, AR (Eds) *Tietz Textbook of Clinical Chemistry*. 2nd Ed. Philadelphia. W.B. Saunders Co. 1994.
19. Eastham, R.D.: *Biochemical Values in Clinical Medicine*, 7th Ed. Bristol. England. John Wright & Sons, Ltd, 1985.
20. Allain C.C, Poon L.S, Chan C.S.G, Richmond W, Fu P. *Clin. Chem.*1974; 20:470.
21. Roeschlau P, Bernt E, Gruber W A. *ClinBiochem.* 1974; 12:226.
22. McGown M W et al. Product data sheet, Triglycerides- G code no. 997-69801 WAKO pure chemical industries Ltd. Dallas. *Clinichem* 1983;29:538.
23. Jacobs N. J., VanDenmark, P.J., *Arch. Biochem Biophys.* 1960; 88: 250-255.
24. Koditscheck L. K., Umbreit, W. W., *J. Bacteriol* 1969; 98: 1063-1068.
25. Trinder. P., *Ann. Clin. Biochem.* 1969; 6: 24-27.
26. Rusterin M, Scholnic H.R, Morfin R. L. *Lipids res.*1970.
27. Tietz NW. *Clinical guide to laboratory tests*, 2nd ed. Saunders Co., 1991.
28. NCEP expert panel, *Arch Inter Med.* 1998; 148: 26-69.

29. Burtis C.A, Ashwood E.R. editors. Tietz textbook of clinical chemistry. 2nd ed. Philadelphia. W.B. Saunders Company. 1994; 790-5.
30. Young, D. S., Effects of Preanalytical Variables on Clinical Laboratory Tests, AACCC Press, Washington, DC. (1993).
31. International Federation of Clinical Chemistry, Scientific Committee. J. Clin. Chem. Clin. Biochem. 1980; 18:521-534.
32. King. P.R.M & King, E.J. Clin Path 7.322.
33. John D Bancroft, Mariyab Gamble –Theory and Practice of Histological Technique. 6th edition Chulchil Livingstone Elsevier.

CHAPTER 5

RESULTS

5.1. Gravimetry

5.1.1. Weight gain

Regular weight of the rat was recorded during dosage period. Initial and final weights were considered to calculate the weight gain. All the rats in group I, II and III remained healthy and active with normal behaviour. However, rats of group IV acted as diabetic control, where the diabetic induced without any treatment were found to be lethargic and their body weight gain was found to be negative among all groups. This was statistically significant when compared with normal control rats, normal rats treated with *Nigella sativa* seed powder, normal rats treated with thymoquinone, diabetic induced rats treated with *Nigella sativa* seed powder and diabetic induced rats treated with thymoquinone. However, in case of group V(diabetic induced rats + *Nigella sativa* seed powder) and group VI (diabetic induced rats + thymoquinone) an improvement in body weight was observed, as compared with the group IV (diabetic induced control) rats (Table 15).

5.1.2. Organosomatic Index

Organosomatic index was calculated by weight of organ multiplied by 100 and divided by total body weight.

Pancreas – Pancreaticosomatic index was increased significantly in diabetic untreated rats compared with normal control rats, in diabetic treated rat groups it was decreased, but no statistical significance change was found between diabetic untreated and diabetic treated groups (Table 16).

Liver - Hepatosomatic index was increased significantly in diabetic untreated rats compared with normal control rats, in diabetic treated rat groups it was decreased and it was statistically significance change (Table 16).

Kidney – Renalsomatic index was increased significantly in diabetic untreated rats compared with normal control group, in diabetic treated rat groups it was decreased, but no statistically significance change was found between diabetic untreated and diabetic treated groups (Table 16).

Groups ↔	I	II	III	IV	V	VI	F - Value	P- Value
Parameter ↓	Normal Rats– Control	Normal Rats – Nigella sativa seed powder	Normal Rats – Thymo quinone	Diabetic Rats– Control	Diabetic Rats – Nigella sativa seed powder	Diabetic Rats – Thymo quinone		
Initial Body weight (g)	234.67± 11.55 ^a	225.67± 16.62 ^a	229.17± 13.75 ^a	173.17± 8.18 ^b	164.67± 10.95 ^b	168.83± 14.54 ^b	40.79	0.05
Final Body weight (g)	345.50± 15.83 ^a	339.17± 11.02 ^a	332.82± 20.35 ^a	144.17± 9.17 ^b	225.17± 13.08 ^c	241.33± 20.52 ^c	162.89	0.001
Change in Body Weight(%)	47.72± 12.97 ^a	51.15± 14.62 ^a	45.66± 12.00 ^a	-16.65± 5.49 ^b	37.28± 12.40 ^{a,c}	43.23± 9.73 ^{a,c}	29.32	0.003
Values with superscripts in each row among various groups are statistically significant with each other(P<0.05)								

Table 15: Results of initial, final body weight & weight gain in each group



Groups 	I	II	III	IV	V	VI	F - Value	P- Value
Parameter 	Normal Rats– Control	Normal Rats – Nigella sativa seed powder	Normal Rats – Thymoquinone	Diabetic Rats– Control	Diabetic Rats – Nigella sativa seed powder	Diabetic Rats – Thymoquinone		
Pancreaticosomatic index (%)	0.18± 0.02 ^a	0.21± 0.03 ^a	0.20± 0.04 ^a	0.34± 0.07 ^b	0.27± 0.04 ^b	0.26± 0.08 ^b	7.55	0.04
Hepatosomatic index (%)	2.14± 0.14 ^a	2.08± 0.16 ^a	2.25± 0.21 ^a	3.81± 0.27 ^b	3.15± 0.32 ^c	2.86± 0.23 ^c	54.3	0.002
Renalsomatic index (%)	0.43± 0.06 ^a	0.39± 0.05 ^a	0.41± 0.07 ^a	0.58± 0.04 ^b	0.49± 0.12 ^b	0.46± 0.07 ^b	5.07	0.02
Values with superscripts in each row among various groups are statistically significant with each other (P<0.05).								

Table 16: Results of organosomatic index of Pancreas, Liver and Kidney.

5.2. Biochemistry

5.2.1. Glucose - Levels of glucose were increased significantly in diabetic control (group IV) rats compared with normal control (group I) rats, normal rats treated with Nigella sativa seed powder (group II) and thymoquinone (group III). The levels of glucose were reduced significantly in diabetic rats treated with Nigella sativa seed powder (group V) and thymoquinone (group VI). There was no significant change between normal control (group I) rats and normal rats treated with Nigella sativa seed powder (group II) and thymoquinone (group III) (Table 17).

Groups →	I	II	III	IV	V	VI	F - Value	P- Value
Parameter ↓	Normal Rats– Control	Normal Rats – Nigella sativa seed powder	Normal Rats – Thymoquinone	Diabetic Rats– Control	Diabetic Rats – Nigella sativa seed powder	Diabetic Rats– Thymoquinone		
Initial Glucose (mg/dl)	88.83± 11.72 ^a	79.83± 15.11 ^a	84.33± 18.61 ^a	215.50± 32.04 ^b	211.83± 14.84 ^b	220.17± 28.27 ^b	67.93	0.05
Final Glucose (mg/dl)	86.33± 14.61 ^a	83.17± 18.48 ^a	79.67± 13.22 ^a	241.33± 40.73 ^b	177.67± 33.79 ^c	162.33± 25.41 ^c	38.02	0.003
Values with superscripts in each row among various groups are statistically significant with each other(P<0.05)								

Table 17: Results of Glucose(mg/dl)

5.2.2. Insulin

Levels of insulin were decreased significantly in diabetic control (group IV) rats compared with normal control (group I) rats, normal rats treated with Nigella sativa seed powder (group II) and thymoquinone (group III). The levels of insulin were increased significantly in diabetic rats treated with Nigella sativa seed powder (group V) and thymoquinone (group VI). There was no significant change between normal control (group I) rats and normal rats treated with Nigella sativa seed powder (group II) and thymoquinone (group III) (Table 18).

Groups →	I	II	III	IV	V	VI		
Parameter ↓	Normal Rats– Control	Normal Rats – Nigella sativa seed powder	Normal Rats – Thymoquinone	Diabetic Rats– Control	Diabetic Rats – Nigella sativa seed powder	Diabetic Rats – Thymoquinone	F - Value	P- Value
Insulin (mu/L)	0.44± 0.14 ^a	0.41± 0.06 ^a	0.48± 0.11 ^a	0.16± 0.05 ^b	0.30± 0.04 ^c	0.33± 0.06 ^c	12.13	0.001
Values with superscripts in each row among various groups are statistically significant with each other(P<0.05)								

Table 18: Results of Insulin (mu/L)

5.2.3. Oral Glucose Tolerance Test (OGTT)

Diabetic control rats (group IV) did not show tolerance to Oral Glucose Tolerance Test compared with normal control (group I) rats, normal rats treated with Nigella sativa seed powder (group II) and thymoquinone (group III). Diabetic rats treated with Nigella sativa seed powder (group V) and thymoquinone (group VI) showed significant improvement in tolerance to Oral Glucose Tolerance Test. There was no significant change in tolerance to Oral Glucose Tolerance Test between normal control (group I) rats and normal rats treated with Nigella sativa seed powder (group II) and thymoquinone (group III) (Figure 3).




Figure 3: Graph – OGTT

^aFBS: Fasting blood suger

^{b,c,d,e} Horizontal values are the mean \pm SD of six observations in each group in every 0.5h interval till 2.0h in each row. Values with different superscription (a,b,c,d) are different significantly from each other (p<0.05). One way ANOVA of different groups in every 0.5h interval till 2.0h is referred below vertically.

5.2.4. Serum Malondialdehyde (MDA)

The MDA levels were increased significantly in diabetic control (group IV) rats compared with normal control (group I) rats, normal rats treated with *Nigella sativa* seed powder (group II) and thymoquinone (group III). The levels of MDA were reduced significantly in diabetic rats treated with *Nigella sativa* seed powder (group V) and thymoquinone (group VI). There was no significant change between normal control (group I) rats and normal rats treated with *Nigella sativa* seed powder (group II) and thymoquinone (group III) (Figure 4).




Figure 4: Graph – MDA (nmol/ml)

NC- Normal Control Rats, NNS- Normal rats treated with *Nigella sativa*, NTQ- Normal rats treated with Thymoquinone, DC- Diabetic Control Rats, DNS- Diabetic rats treated with *Nigella sativa*, DTQ- Diabetic rats treated with Thymoquinone.

5.2.5. Endogenous antioxidant - Serum Superoxide dismutase (SOD),

Exogenous antioxidants – Serum Vitamin C and E

The levels of Superoxide dismutase (SOD), Vitamin C and E were decreased significantly in diabetic control (group IV) rats compared with normal control (group I) rats, normal rats treated with Nigella sativa seed powder (group II) and thymoquinone (group III). The levels of Superoxide dismutase (SOD), Vitamin C and E increased significantly in diabetic rats treated with Nigella sativa seed powder (group V) and thymoquinone (group VI). There was no significant change between normal control (group I) rats and normal rats treated with Nigella sativa seed powder (group II) and thymoquinone (group III) (Figure 5,6,7).




Figure 5: Graph – SOD(U/ml)




Figure 6: Graph – Vitamin C (µg/ml)




Figure 7: Graph – Vitamin E (µg/ml)

5.2.6. Lipid profile

In case of Lipid profile parameters the levels of HDL –C was decreased significantly in diabetic control (group IV) rats, compared with normal control (group I) rats, normal rats treated with *Nigella sativa* seed powder (group II) and thymoquinone (group III). The levels of HDL –C were increased significantly in diabetic rats treated with *Nigella sativa* seed powder (group V) and thymoquinone (group VI). There was no significant change between normal control (group I) rats and normal rats treated *Nigella sativa* seed powder (group II) and thymoquinone (group III). The levels of TG, TC, LDL –C and VLDL –C were increased significantly in diabetic control rats compared with normal control (group I) rats, normal rats treated with *Nigella sativa* seed powder (group II) and thymoquinone (group III). The levels of TG, TC, LDL –C and VLDL –C were decreased significantly in diabetic rats treated with *Nigella sativa* seed powder (group V) and thymoquinone (group VI). There was no significant change between normal control (group I) rats and normal rats treated *Nigella sativa* seed powder (group II) and thymoquinone (group III) (Table 19).

Groups →	I	II	III	IV	V	VI	F - Value	P- Value
Parameter ↓	Normal Rats– Control	Normal Rats – Nigella sativa seed powder	Normal Rats – Thymo quinone	Diabetic Rats– Control	Diabetic Rats – Nigella sativa seed powder	Diabetic Rats – Thymo quinone		
HDL (mg/dl)	36.83± 8.95 ^a	38.17± 17.36 ^a	41.17± 13.92 ^a	14.17± 5.38 ^b	28.50± 8.34 ^c	30.67± 11.33 ^c	7.19	0.002
TG (mg/dl)	128.83± 25.89 ^a	106.83± 13.59 ^a	122.7± 20.91 ^a	204.33± 36.97 ^b	162.17± 30.97 ^c	151.83± 16.55 ^c	12.85	0.001
TC (mg/dl)	139.17± 29.18 ^a	126.67± 25.91 ^a	118.50± 19.60 ^a	255.33± 43.36 ^b	197.17± 21.96 ^c	173.67± 23.24 ^c	18.38	0.003
LDL (mg/dl)	76.57± 27.70 ^a	67.13± 24.12 ^a	52.90± 17.86 ^a	199.63± 42.99 ^b	136.57± 36.30 ^c	112.63± 23.45 ^c	20.24	0.005
VLDL (mg/dl)	25.77± 5.18 ^a	21.37± 2.72 ^a	24.43± 4.18 ^a	40.87± 7.39 ^b	32.43± 4.39 ^c	30.37± 3.31 ^c	12.85	0.001
Values with superscripts in each row among various groups are statistically significant with each other(P<0.05)								

Table 19: Results of HDL, TG, TC, LDL and VLDL Cholesterol (mg/dl).

5.2.7. Liver function tests

In case of Liver function tests the levels of serum AST, ALT and ALP were increased significantly in diabetic control rats (group IV), compared with normal control (group I) rats, normal rats treated with *Nigella sativa* seed powder (group II) and thymoquinone (group III). The levels of AST, ALT and ALP were decreased significantly in diabetic rats treated with *Nigella sativa* seed powder (group V) and thymoquinone (group VI). There was no significant change between normal control (group I) rats and normal rats treated with *Nigella sativa* seed powder (group II) and thymoquinone (group III). The levels of total protein were decreased significantly in diabetic control rats (group IV), compared with normal control (group I) rats, normal rats treated with *Nigella sativa* seed powder (group II) and thymoquinone (group III). The levels of total protein were increased significantly in diabetic rats treated with *Nigella sativa* seed powder (group V) and thymoquinone (group VI). There was no significant change between normal control (group I) rats and normal rats treated *Nigella sativa* seed powder (group II) and thymoquinone (group III) (Table 20).

Groups →	I	II	III	IV	V	VI	F - Value	P- Value
Parameter ↓	Normal Rats – Control	Normal Rats – Nigella sativa seed powder	Normal Rats – Thymo quinone	Diabetic Rats – Control	Diabetic Rats – Nigella sativa seed powder	Diabetic Rats – Thymo quinone		
Total Protein(g/dl)	10.03± 2.07 ^a	8.45± 0.79 ^a	9.30± 1.58 ^a	3.80± 0.74 ^b	6.47± 0.97 ^c	7.02± 1.55 ^c	16.24	0.01
AST (IU/L)	83.83± 11.05 ^a	79.17± 7.99 ^a	74.67± 9.24 ^a	153.33± 13.71 ^b	125.67± 9.71 ^c	106.50± 15.69 ^c	44.16	0.003
ALT (IU/L)	53.67± 10.61 ^a	45.33± 6.28 ^a	48.67± 9.44 ^a	96.50± 15.62 ^b	73.33± 10.46 ^c	65.33± 8.02 ^c	20.23	0.006
ALP (IU/L)	69.50± 13.41 ^a	56.67± 7.50 ^a	62.67± 10.32 ^a	129.67± 17.37 ^b	97.67± 11.69 ^c	85.17± 13.67 ^c	27.37	0.002
Values with superscripts in each row among various groups are statistically significant with each other(P<0.05)								

Table 20: Results of Liver Function Tests (Total Protein, AST, ALT, ASP)

5.3. Histopathology

5.3.1. Histopathology of Pancreas

Normal control rats (group I): Sections studied under H&E stain showed the normal islet cells with classical histological features. Cells of the pancreas were all present in their usual proportions. The acinar cells with prominent nuclei strongly

stained were arranged in lobules. The islet cells were seen surrounded by a fine capsule. The islet of Langerhans showed the clear - cells with nuclei (Figure 8,14).

Normal rats treated with Nigella sativa seed powder (group II): Sections studied under H&E stain showed the same architecture as normal control rats. There were no pathological changes (Figure 9).

Normal rats treated with thymoquinone (group III): Sections studied under H&E stain showed the same architecture as normal control rats. There were no pathological changes(Figure 10).

Diabetic control rats (Group IV): Sections studied under H&E stain showed the degenerative and necrotic changes and shrinking of the islets of Langerhans. The nucleus showed either marginal hyperchromasia or pyknosis. There was mostly hydropic degeneration and degranulation in the cytoplasm, while some of the cells had a dark eosinophilic cytoplasm (Figure 11,15).

Diabetic rats treated with Nigella sativa seed powder (Group V): Section studied under H&E stain showed the decreased severity of necrotic and degenerative changes in the islets of pancreas. The parenchyma was more in amount than in the diabetic group. A few cells were with pyknotic nuclei, but the majority of cells showed significantly light hydropic degeneration, partly indicating regranulation of islet cells. The islets of Langerhans were distinctly increased in size (Figure 12,16).

Diabetic rats treated with thymoquinone (group VI): Sections studied under H&E stain showed the same features as diabetic rats treated with Nigella sativa seed powder (Group V) (Figure 13,17).




Figure 8: Pancreas of normal control rats showing normal acinar cells and Islet of Langerhans (H&E10X)




Figure 11: Pancreas of STZ diabetic control rats showing the degenerative changes in islet of Langerhans (H&E -10X)




Figure 9: Pancreas of normal rats treated with Nigella sativa seed powder showing normal acinar cells and Islet of Langerhans (H&E -10X)




Figure 12: Pancreas of STZ diabetic rats treated with Nigella sativa seed powder showing few diabetic changes and improved architecture of islet of Langerhans (H&E-10X).




Figure 10: Pancreas of normal rats treated with thymoquinone seed powder showing normal acinar cells and Islet of Langerhans (H&E -10X)




Figure 13: Pancreas of STZ diabetic rats treated with thymoquinone showing few diabetic changes and improved architecture of islet of Langerhans (H&E-10X).




Figure 14: Pancreas of normal control rats showing normal acinar cells and Islet of Langerhans (H&E-20X)




Figure 15: Pancreas of STZ diabetic control rats showing the degenerative changes in islet of Langerhans (H&E -20X).




Figure 16: Pancreas STZ diabetic rats treated with Nigella sativa seed powder showing few diabetic changes and improved architecture of islet of Langerhans (H&E -20X)




Figure 17: Pancreas of STZ diabetic rats treated with thymoquinone showing few diabetic changes and improved architecture of islet of Langerhans (H&E -20X).

5.3.2. Histopathology of Liver

Normal control rats (group I): Sections studied under H&E stain showed normal parenchymal tissue composed of numerous hexagonal to pyramidal lobules. Each lobule consisted of central vein from which the hepatic plates radiated outwards. 3 to 5 portal triads were located at the periphery of the lobule, containing branches of bile duct, portal vein and hepatic artery and occasional mononuclear cells. The sinusoids were lined by both endothelial cells and Kupffer cells both of which with inconspicuous

flattened nuclei and ill-defined cytoplasmic margins. The central veins were lined by endothelial cells surrounded by ring of collagen fibres. The hepatocytes were polygonal in shape with well-defined borders. The nucleus was single, round and has a fine chromatin pattern with 1 to 2 clearly defined amphiphilic prominent nucleoli. The cytoplasm was eosinophilic and finely granular (Figure 18,24).

Normal control rats treated with Nigella sativa seed powder (group II):

Section studied under H&E stain showed the same architecture as normal control rats. There were no pathological changes (Figure 19).

Normal control rats treated with thymoquinone (group III): Section studied under H&E stain showed the same architecture as normal control rats. There were no pathological observations (Figure 20).

Diabetic control rats (Group IV): Section studied under H&E stain showed distortion in the arrangement of cells around the central vein, periportal fatty infiltration (fatty steatosis) with focal necrosis of hepatocytes, hydropic changes and aggregation and infiltration of lymphocytes between hepatocytes (Figure 21,25).

Diabetic rats treated with Nigella sativa seed powder (Group V): Sections studied under H&E stain showed the normal cellular arrangement around the central vein and reduced necrotic changes and the blood vessels in normal condition (Figure 22,26).

Diabetic rats treated with thymoquinone (group VI): Section studied under H&E stain showed the same features as diabetic rats treated with Nigella sativa seed powder (Group V) (Figure 23,27).




Figure 18: Liver of normal control rat showing normal architecture with central vein, hepatocytes and hepatic sinusoids (H&E-10X).




Figure 21: Liver of STZ diabetic control rat showing distortion in the arrangement of cells around the central vein, and fatty steatosis (H&E -10X).




Figure 19: Liver of normal rats treated with *Nigella sativa* seed powder showing normal architecture with central vein, hepatocytes and hepatic sinusoids (H&E 10X).




Figure 22: Liver sections of diabetic rats treated with *Nigella sativa* seed powder showing normal cellular arrangement around the central vein and reduced necrotic changes (H&E10X).




Figure 20: Liver of normal rats treated with thymoquinone showing normal architecture with central vein, hepatocytes and hepatic sinusoids (H&E -10X).




Figure 23: Liver sections of diabetic rats treated with thymoquinone showing normal cellular arrangement around the central vein and reduced necrotic changes (H&E 10X).




Figure 24: Liver section of normal control rat showing normal architecture of portal triad (H&E-20X).




Figure 25: Liver section of STZ diabetic control rat showing destructed architecture of portal triad with monocyte infiltration (H&E-20X).




Figure 26: Liver section of STZ diabetic rat treated with *Nigella sativa* showing the portal triad as near to normal (H&E 20X).




Figure 27: Liver section of STZ diabetic rat treated with thymoquinone showing the portal triad as near to normal (H&E 20X).

5.3.3. Histopathology of Kidney

Normal control rats (group I): Sections studied under H&E stain showed normal renal parenchymal tissue composed of glomeruli and tubules separated by small amount of interstitial connective tissue containing peritubular capillaries. Each glomerulus was a spherical collection of interconnected capillaries within Bowman`s space lined by flattened parietal cells. The outer aspects of the glomerular capillaries

were covered by a layer of visceral epithelial cells (podocytes). The capillary tufts were supported by the mesangial cells. Tubules and glomeruli appear normal in morphology and in cellularity, interstitium appears normal, vessel appear normal (Figure 28,34).

Normal control rats treated with Nigella sativa seed powder and thymoquinone (group II and III): Sections studied under H&E stain showed the same architecture as normal control rats. There were no pathological observations (Figure 29,30,35,36).

Diabetic control rats (Group IV): Sections studied under H&E stain showed deposits of hyaline material diffuse and evenly spread in the mesangium of the glomeruli. There was a diffuse infiltration of the glomerular tuft with eosinophilic material and also heavy focal deposition. The diffuse infiltrate appeared to be in the basement membranes of the capillaries and the capillary bed had been obliterated and this deposition caused complete hyalinization of many glomeruli. In many of the glomeruli, lesions characteristic of diabetic glomerulosclerosis were present and these glomeruli consisted of round, practically acellular, hyalinized nodule in their tuft. There was a considerable deposit of hyaline material thickening in Bowman's capsule. Both afferent and efferent arterioles appeared as narrow ovals and also showed strong eosinophilic hyaline thickening. In most of the sections, areas of lymphocytic infiltrate were seen in the interstitium (Figure 31,37).

Diabetic rats treated with Nigella sativa seed powder (Group V) and thymoquinone (group VI): Sections showed features of normal glomerulus, very less number of inflammatory cells, normal basement membrane and capillaries and decrease in the hyaline deposit (Figure 32,33,38,39).




Figure 28: Kidney section of normal control rat showing normal renal parenchymal tissue which is composed of glomeruli and tubules (H&E-10X).




Figure 31: Kidney section of STZ diabetic control rat showing deposits of hyaline material and diffuse infiltration in the mesangium of the glomerulus (H&E-10X).




Figure 29: Kidney section of normal rat treated with *Nigella sativa* seed powder showing normal renal parenchymal tissue which is composed of glomeruli and tubules (H&E-10X).




Figure 32: Kidney section of STZ diabetic rats treated with *Nigella sativa* seed powder showing normal glomerulus, very less number of inflammatory cells, normal basement membrane and capillaries, decrease in the hyaline deposit (H&E-10X).




Figure 30: Kidney section of normal rat treated with thymoquinone showing normal renal parenchymal tissue which is composed of glomeruli and tubules (H&E-10X).




Figure 33: Kidney section of STZ diabetic rats treated with thymoquinone showing normal glomerulus, very less number of inflammatory cells, normal basement membrane and capillaries, decrease in the hyaline deposit (H&E-10X).




Figure 34: Kidney section of normal control rat showing normal renal parenchymal tissue which is composed of glomeruli and tubules (H&E-20X).




Figure 37: Kidney section of STZ diabetic control rat showing deposits of hyaline material and diffuse infiltration in the mesangium of the glomerulus (H&E-20X).




Figure 35: Kidney section of normal rat treated with *Nigella sativa* seed powder showing normal renal parenchymal tissue which is composed of glomeruli and tubules (H&E-20X)




Figure 38: Kidney section of STZ diabetic rats treated with *Nigella sativa* seed powder showing normal glomerulus, very less number of inflammatory cells and decrease in the hyaline deposit(H&E-20X).




Figure 36: Kidney section of normal rat treated with thymoquinone showing normal renal parenchymal tissue which is composed of glomeruli and tubules (H&E-20X).




Figure 39: Kidney section of STZ diabetic rats treated with thymoquinone showing normal glomerulus, very less number of inflammatory cells and decrease in the hyaline deposit (H&E-20X).

5.3.4. Histopathology of Nerve

Sections tibial nerve of normal control rats showed normal nerve architecture. Fine myelinated nerve fibres were found with nuclei of Schwann cells and connective tissue coverings (endoneurium, perineurium, and epineurium). There was no pathological observations in normal rats treated with *Nigella sativa* seed powder (group II) and thymoquinone (group III). The diabetic control (group IV), diabetic rats treated with *Nigella sativa* seed powder (group V) and thymoquinone (group VI) also showed architecture similar to normal control rats (Figure 40,41,42,43,44,45).




Figure 40: Nerve section of normal control rat showing normal architecture, fine myelinated nerve fibres are found with nucleus of Schwann cells and connective tissue coverings (H&E-10X).




Figure 42: Nerve section of normal rat treated with thymoquinone showing normal architecture, fine myelinated nerve fibres are found with nucleus of Schwann cells and connective tissue coverings (H&E-10X).




Figure 41: Nerve section of normal rat treated with *Nigella sativa* seed powder showing normal architecture, fine myelinated nerve fibres are found with nucleus of Schwann cells and connective tissue coverings (H&E-10X).




Figure 43: Nerve section of STZ diabetic control rat showing normal architecture, fine myelinated nerve fibres are found with nucleus of Schwann cells and connective tissue coverings (H&E 10X) .




Figure 44: Nerve section of STZ diabetic rat treated with *Nigella sativa* seed powder showing normal architecture, fine myelinated nerve fibres are found with nucleus of schwann cells and connective tissue coverings (H&E-10X).




Figure 45: Nerve section of STZ diabetic rat treated with thymoquinone showing normal architecture, fine myelinated nerve fibres are found with nucleus of schwann cells and connective tissue coverings (H&E-10X).

CHAPTER 6

DISCUSSION

6.1. Gravimetry

6.1.1. Weight gain

Results of the present study showed negative weight gain in case of streptozotocin induced diabetic rats. It clearly indicates diabetes interfering with metabolic pattern of experimental animals. This may be due to increased hyperglycaemia leads protein wasting due to inaccessibility of carbohydrate¹. A significant improvement of body weight gain in case of *Nigella sativa* seed and thymoquinone treated induced diabetic rat groups indicates a beneficial role of both the compounds to overcome the effect of diabetes². A possible explanation for this might be that *Nigella sativa* seed and thymoquinone reduce hyperglycaemia and therefore protein wasting due to inaccessibility of carbohydrate³. There was no significant change in normal rats treated with *Nigella sativa* seed powder and thymoquinone compared with normal control rats. Our results are in agreement with the findings of Samad Alimohammadi et al² study. A significant weight loss was observed in the diabetic untreated group, while *Nigella sativa* seed powder and thymoquinone treated rat groups exhibited significant increase in the body weight in comparison with diabetic untreated group but lower than in the normal controls. In the study of Kanter et al³ *Nigella sativa* markedly improved body weight gain in STZ-induced diabetic rats.

6.1.2. Organosomatic index

Increase in organosomatic index of pancreas, liver and kidney of streptozotocin induced diabetic group may be due to decreased bodyweight. Similarly, significant

decrease in pancreas, liver and kidney weight in induced diabetic group rats indicates an alteration of metabolism in those organs. The improvement of organ weight in pancreas, liver and kidney in groups of *Nigella sativa* seed powder and thymoquinone treated induced diabetic rats indicates a beneficial effect in this regard, possibly by resorted altered metabolism of those organs⁴. There was no significant change in normal rat groups treated with *Nigella sativa* seed powder and thymoquinone compared with normal control rat group. Our results are in agreement with findings of Kaleem M et al⁴ that streptozotocin induced diabetic rats showed significant decrease in body, kidney and liver weights and after treatment with *Nigella sativa* significant improvement in the body, kidney and liver weight was observed.

6.2. Biochemistry

6.2.1. Glucose hemostasis

Glucose, Insulin and Oral Glucose Tolerance Test

The level of glucose was increased significantly in induced diabetic rats. The level of glucose was reduced significantly in diabetic rat groups treated with *Nigella sativa* seed powder and thymoquinone. The level of insulin was decreased significantly in induced diabetic rats. This may be due to toxic effect of streptozotocin to β -cells of islets of Langerhans which leads to insufficient secretion of insulin¹. The treated groups of induced diabetic rats with *Nigella sativa* seed and thymoquinone showed significant increase in insulin levels. There was no significant change in normal rats treated with *Nigella sativa* seed powder and thymoquinone compared with normal control rats. The

anti-hyperglycaemic effect of *Nigella sativa* seed and its active component, thymoquinone may be due to reduction of oxidative stress, thus preserving pancreatic beta cell integrity leading to insulin level increase^{2,5}. This is supported by our histopathological observations of pancreas. In the study of Kaleem M et al⁴ treatment of *Nigella sativa* seed resulted in elevation of glutathione(GSH) level which is present in the beta cells of islets and protects the membranes against oxidative damage by regulating the redox status of protein in the membrane⁶. In the study of Kanter et al³ *Nigella sativa* caused a sharp decrease in the elevated serum glucose and increase in serum insulin concentration in streptozotocin diabetic rats and in addition *Nigella sativa* treatment protected the majority of the Langerhans islet beta cells. In another study of same researchers where the *Nigella sativa* in streptozotocin diabetic albino rats caused a decrease in the elevated serum glucose and an increase in the lowered serum insulin concentrations as well as an improvement in histological appearance of islets of Langerhans of diabetic rats. They stated that hypoglycemic effect of *Nigella sativa* could be partly due to amelioration in beta cells of pancreatic islets causing an increase in insulin secretion⁷.

According to Alsaif MA⁸ the other possible reason of blood glucose lowering effect of *Nigella sativa* may be due to improved insulin insensitivity in diabetic rats. Furthermore, the *Nigella sativa* contains many bioactive constituents such as thymoquinone, p-cymene, pinene, dithymoquinone and thymohydroquinone, which act as antioxidants⁹.

In the present study streptozotocin induced diabetic rats showed impaired oral glucose tolerance. The treated groups of diabetic rats with *Nigella sativa* seed powder and thymoquinone showed significant improvement in glucose tolerance. The normal control rats, normal rats treated with *Nigella sativa* seed powder and normal rats treated with thymoquinone showed tolerance to OGTT and there was no significant change between groups of normal control rats and normal rats treated. In the study of Labhal et al¹⁰ *Nigella sativa* alone was very effective at restoring glucose homeostasis. They showed in another study that *Nigella sativa* seed given by intragastric gavage was able to correct diabetes. The *Nigella sativa* reduced blood glucose within one month¹¹. Le et al¹² confirmed the reduction of intestinal transport in vivo and are increased insulin sensitivity. They are in agreement with Al-Awadi et al¹³, who obtained an improved OGTT response in streptozotocin rats treated with a mixture of plants containing *Nigella sativa*. Bouchra M et al¹⁴ showed that *Nigella sativa* aqueous extract directly affected intestinal absorption of glucose. Moreover inhibition of electrogenic sodium dependent glucose transport occurred. Thus inhibition of intestinal glucose absorption by *Nigella sativa* is significant and may participate in the recognized hypoglycemic effect of the plant. Most of the previous studies showed that *Nigella sativa* hypoglycemic activity in streptozotocine induced diabetic rats because of its rich components mainly thymoquinone and nigellone antioxidant nature helping in preserving integrity of beta cells of islets^{1,2,3,4,5}. The study of El-Dakhakhny et al¹⁵ proved that hypoglycemic activity of *Nigella sativa* and thymoquinone. *Nigella sativa* and thymoquinone may

also be acting to increase peripheral insulin sensitivity or glucose utilization or to decrease intestinal glucose absorption.

6.2.2. Oxidative stress (MDA) and Anti-oxidative (SOD, Vitamin C & E) markers

The level of malondialdehyde(MDA) was increased significantly in induced diabetic rats. The level of malondialdehyde(MDA) was reduced significantly in diabetic rat groups treated with *Nigella sativa* seed powder and thymoquinone. The levels of superoxide dismutase(SOD), vitamin C and E were decreased significantly in induced diabetic rats. The treated groups of induced diabetic rats with *Nigella sativa* seed and thymoquinone showed significant increase in SOD, vitamin C and E levels. There was no significant change in normal rats treated with *Nigella sativa* seed powder and thymoquinone compared with normal control rats. Lipid peroxidation may bring about protein damage and inactivation of membrane-bound enzymes either through chemical modification by its end products or through direct attack by free radicals, MDA and 4-hydroxynonenal¹⁶. Our results are in agreement with the findings of Wolf¹⁷, El-Missiry et al¹⁸ and Mahmood et al¹⁹. These studies reported an increase in lipid peroxides and a decrease in antioxidant enzymes in diabetes. These studies also have results as ours showing improvement in reduced antioxidants after treatment with *Nigella sativa*. In the study of Bahram Pourghassem-Gargari et al²⁰, *Nigella sativa* seed powder showed a significant decrease in serum MDA level. The antioxidant effect of black seed seems to be due to its oil, thymoquinone, flavonoids and also antioxidant vitamins like ascorbic acid and tocopherols. It has been shown that *Nigella sativa* and thymoquinone inhibit

non-enzymatic lipid peroxidation in liposomes and both work as a scavenger of various reactive oxygen species including superoxide anion and hydroxyl radicals²¹. In addition flavonoids present in *Nigella sativa* are a class of polyphenolic compounds that seem to have antioxidant properties by suppressing reactive oxygen and nitrogen species formation, scavenging reactive oxygen and nitrogen species and protecting the antioxidant defense system^{22,23}. In the study of A A Sayed²⁴ it was observed that thymoquinone has antioxidative properties as evidenced by the significant increase in glutathione and SOD activity and reduction of lipid peroxidation and NO levels in the diabetic treated groups. So it might improve the function of beta cells in the diabetic rats and influence insulin effects by directly acting on specific components of the insulin-signaling transduction pathway. Kanter et al²⁵ studied the effect of black seed on lipid peroxidation and antioxidant defense system and found that treatment with *Nigella sativa* decreased MDA level and increased the antioxidant defense system activity in carbon tetrachloride treated rats. The study of Kanter et al²⁶ showed that *Nigella sativa* treatment reduced the spinal cord tissue MDA and prevented inhibition of SOD, GPX and catalase enzyme activities, following the experimental spinal cord injury in rats. Schettler et al²⁷ suggested that the reduced antioxidant production was due to increased oxygen metabolites causing a decrease in the activity of the antioxidant defence system. Kennedy and Baynes²⁸ stated that non-enzymatic glycosylation of the enzymes leading to decreased antioxidant enzyme activity in diabetes. In diabetic rats decreased vitamin C and E was observed. Because of more oxidative stress the utilization of Vitamin C and E is more and when treated with *Nigella sativa* and thymoquinone the utilization of

vitamin C and E is becoming less which leads to increase in their levels in diabetic rat groups treated with *Nigella sativa* seed powder and thymoquinone. In addition there are many fatty acids in *Nigella sativa*, the most important of which are linoleic acid (55.6%), oleic acid (23.4%) and palmitic acid (12.5%)²⁹, tocopherols (, , and) and vitamin C³⁰ which lead to increase in vitamin C and E levels. Hence *Nigella sativa* may have antioxidant properties that will be useful for therapeutic purposes. The results of the present study indicate that the preventive effects of *Nigella sativa* may be due to inhibition of lipid peroxidation as a result of its antioxidant nature. These findings suggest that *Nigella sativa* treatment has a therapeutic protective effect against diabetes by preserving pancreatic beta cell integrity through decreasing oxidative stress. Consequently *Nigella sativa* may be clinically useful for protecting β -cells against oxidative stress.

6.2.3. Lipid Profile

The level of HDL-cholesterol was decreased significantly in induced diabetic rats. The level of HDL-cholesterol was increased significantly in diabetic rat groups treated with *Nigella sativa* seed powder and thymoquinone. The levels of total cholesterol(TC), triglycerides(TG), LDL-cholesterol and VLDL- cholesterol were increased significantly in induced diabetic rats. The treated groups of induced diabetic rats with *Nigella sativa* seed and thymoquinone showed significant decrease of all these parameters. There was no significant change in normal rats treated with *Nigella sativa* seed powder and thymoquinone compared with normal control rats. The results of our

study showed a promising hypolipidemic effect produced *Nigella sativa* and thymoquinone supplementation separately in induced diabetic rats. It has been reported that LDL-C positively and HDL-C negatively correlate with cardiovascular disease³¹. Circulating LDL-C can pass into the arterial wall from the blood where it may be oxidized and engulfed by macrophages forming foam cells. Thereafter a complex interplay of cell necrosis, collagen deposition and smooth muscle recruitment lead to the forming of atherosclerotic plaques. However HDL-C possesses antioxidant and anti-inflammatory activities and promotes the efflux of cholesterol to liver from the peripheral tissue, thereby reducing the uptake of cholesterol by macrophages and providing a protective effect against atherosclerosis³².

The present study showed a decrease in TC, TG and LDL-C in diabetic treated groups with *Nigella sativa* seed powder and thymoquinone. The changes in lipid profile monitor an improvement in the dyslipidemia in diabetic rats. The decrease in LDL-C is sufficiently enough predictor for the beneficial effect of *Nigella sativa* on lipid pattern. American Diabetic Association has identified LDL-C as the primary target of lipid lowering in diabetic dysfunction³³. Baharam Pourghassem-Gargari et al²⁰ showed significant decrease in the concentration of TC and TG. The study of Zaoui et al³⁴ indicated that treatment with *Nigella sativa*, decreased serum cholesterol and TG levels. El-Dakhakhny et al¹⁵ observed that *Nigella sativa* administration to rats significantly decreased serum TC, LDL-C and TG and increased HDL-C. Le et al¹² reported a significant decrease in plasma TG and an increase in HDL-C level in *Nigella sativa* seed treated rats, compared to the control group.

The results of Bamosa et al³⁵ demonstrated a decrease in serum TC, LDL-C, TG and increased HDL-C during intraperitoneal injection of thymoquinone in rats. Morikawa et al³⁶ studied the hypotriglyceridemic effect of *Nigella sativa* seed and diterpene alkaloids nigellamines was reported. Nigellamines are equivalent to the hypolipidemic agent, clofibrate. The hypolipidemic effect of *Nigella sativa* seed was due to the synergistic action of its different constituents including thymoquinone and nigellamine, soluble fiber like mucilage, sterols, flavonoids and high content of polyunsaturated fatty acids (PUFAs)³⁷.

Mechanism of hypolipidemic action of thymoquinone may help in decreased cholesterol synthesis because of its antioxidant role. Lipid lowering effects of dietary soluble fibers^{38,39} are probably related to decreased dietary cholesterol absorption, increased primary bile acid synthesis and its fecal losses. Flavonoids may act by making liver cells more efficient to remove LDL-C from blood. To do this, flavonoids increase LDL receptor densities in liver and by binding to apolipoprotein B^{40,41}.

Hamdy NM et al⁴² reported that thymoquinone, the active constituent of *Nigella sativa* has attenuate oxidative stress in streptozotocin induced diabetic rats. Ismail M⁴³ reported thymoquinone hypolipidimic effect in hypercholesterolemic rats. Kaleem et al⁴ confirmed the antidiabetic activity of *Nigella sativa* and its efficiency in controlling the dyslipidemia due to its antioxidant effects. Therefore the antioxidant activity of *Nigella sativa* may also be implicated in ameliorating the dyslipidemia associated with diabetes through decreasing insulin resistance.

6.2.4. Liver function tests

In present study the level of total protein was reduced significantly in diabetic control rats. The level of total proteins was increased in groups of diabetic rats treated with *Nigella sativa* and thymoquinone. The levels of AST, ALT and ALP were increased significantly in diabetic control rats. The treatment of *Nigella sativa* and thymoquinone separately helped in lowering of AST, ALT and ALP levels. The decrease in serum total protein observed in diabetic rats is coinciding with the findings of Ayed Al-Logmani⁴⁴, Wanke et al 1991⁴⁵, Tragl et al⁴⁶. This decline may be due to the inhibited oxidative phosphorylation processes which lead to decrease of protein synthesis, increase in the catabolic processes and reduction of protein absorption. Ayed Al-Logmani et al⁴⁴ found *Nigella sativa* treatment improved the lowered levels of total protein in diabetic rats. This effect of the *Nigella sativa* is presumably due to its ability to increase insulin secretion⁴⁷.

In streptozotocin induced diabetic rats the activities of blood AST, ALT and ALP were significantly elevated compared to their normal levels. These results indicated that liver dysfunction may be inducing the diabetes⁴⁸ and liver was necrotized in STZ induced diabetic rats. Therefore increase in the activities of liver enzymes in blood may be mainly due to the leakage of these enzymes from the liver cytosol into the blood stream⁴⁹ which gives an indication on the hepatotoxic effect of streptozotocin. These findings are supported by histopathological observations of liver sections. On the other hand, treatment of the diabetic rats with *Nigella sativa* seed caused reduction in the activity of these enzymes in blood compared with the mean values of diabetic group and

consequently may alleviate liver damage caused by streptozotocin induced diabetes. Thymoquinone treated diabetic rats also produced similar results and histopathological observations are in support of these findings. Findings of Ayed Al-Logmani et al⁴⁴ and Ayed Sh. AL-logmani⁴⁷ are similar to our results. A study was performed on rat model to evaluate the hepato protective effect of Nigella sativa alcoholic extract against D-Galactosamine (D-GalN) / Lipo polysaccharide induced hepatotoxicity and found that D-GalN/LPS showed significant rise in AST, ALT and ALP. Nigella sativa maintained the levels of AST, ALT and ALP close to normal⁵⁰. Another study based on carbon tetrachloride induced rats has shown that CCl₄ treatment increased the lipid peroxidation and liver enzymes and decreased the antioxidant enzyme level and further Nigella sativa treatment decreased the elevated lipid peroxidation, AST, ALT and ALP levels and increased the reduced antioxidant enzyme levels²⁵. Mansour MA⁵¹ reported that thymoquinone, chief constituent of Nigella sativa seed showed a vital role as antioxidant and may efficiently act as a protective agent against chemically induced hepatic damage. Studies in vitro using isolated rat hepatocytes have shown that preincubation of hepatocytes with thymoquinone showed protection of isolated hepatocytes against TBHP induced toxicity evidenced by decreased leakage of ALT and AST⁵². Another study showed that thymoquinone is efficient cytoprotective agent against CCl₄-induced hepatotoxicity, possibly via inhibition of the production of oxygen free radicals that cause lipid peroxidation⁵³.

Thymoquinone treatment showed similar significant improvement in liver function parameters in diabetic rats of our study. These results are similar to the results

of Adel Abdel Moneim et al⁵⁴. Bashandy et al⁵⁵ observed that AST and ALT levels were significantly decreased in the thymoquinone treated diabetic group as compared to diabetic control group. Thymoquinone is associated with beneficial changes in hepatic enzyme activities and thereby exerts potential antihyperglycemic effect⁵⁶. In the study of Abdel-Moneim A⁵⁷ Nigella sativa administration to rats with aflatoxin induced toxicity caused a significant amelioration of the activities of AST and ALT. In another study Abdel Moneim A⁵⁸ Nigella sativa administration to diabetic rats exhibited amelioration effect in serum ALT and AST. This study showed that in control diabetic group there was significant decrease in serum total protein which may be due to structural distortion and functional impairment of the hepatic cells which associated with low serum protein and albumin levels⁵⁹. A possible explanation for the differential effects of Nigella sativa and thymoquinone on the activities of AST and ALT in blood is that these treatments may inhibit the liver damage induced by streptozotocin⁴⁸. In the present study there was no significant change in normal rats treated with Nigella sativa seed powder and thymoquinone compared with normal control rats, indicating that Nigella sativa seed powder or its major biochemical component, thymoquinone do not show any toxic effect. Our histopathological observation also confirmed this.

6.3. Histopathology

6.3.1. Pancreas

H&E stained sections of pancreas of normal control rats showed normal islet cells with classical histological features. Cells were present in their normal proportions. The pancreatic acinar cells were strongly stained and arranged in lobules with prominent nuclei. The islet cells were seen embedded within the acinar cells and surrounded by a fine capsule. The islet of Langerhans showed clear β - cells with nuclei. H&E sections of pancreas of normal rat groups treated with *Nigella sativa* seed powder and thymoquinone showed the same architecture as normal control rats. There were no pathological observations. These findings indicate non-toxic effect of *Nigella sativa* seed and thymoquinone.

H&E stained of pancreas of diabetic control rats sections showed degenerative and necrotic changes and shrinking of the islets of Langerhans. The nuclei of necrotic beta cells showed either marginal hyperchromasia or pyknosis. There was mostly degranulation in the cytoplasm of the degenerative and necrotic cells and also hydropic degeneration. Our findings are similar to the results of studies of Aughsteeen A.A⁶⁰ and Azza Attia A⁶¹. H&E sections of pancreas of diabetic rat groups treated with *Nigella sativa* seed powder and thymoquinone showed the severity of degenerative and necrotic changes in the islet of Langerhans. Parenchyma was less than those in the diabetic control group. In treated groups few cells were with pyknotic nuclei but the majority of cells showed significantly light hydropic degeneration as compared to islet cells of

untreated diabetic rats, indicating regranulation of islet cells. The islets of Langerhans were distinctly increased in size.

The study of Afaf Jamal⁶² clearly indicated that in diabetic rats many histological changes were observed in the pancreatic islets as compared with the normal control. The islets were small and atrophied. Degenerative, necrotic changes and shrinking of the islets of Langerhans vaculation of cytoplasm and degranulation were observed. Our findings are similar to this study.

Results of current study are similar to the findings of Kanter et al³ who showed that the use of *Nigella sativa* reduced the severity of degenerative and necrotic changes in islets of streptozotocin induced diabetic rats. Sections of pancreatic tissues of treated rats with *Nigella sativa* showed that the majority of cells had slight degeneration compared to the diabetic group with no treatment. Sections of pancreatic tissue of diabetic treated rats with thymoquinone showed similar findings. Findings from the other study suggested that the active ingredient of *Nigella sativa* seed thymoquinone is the most effective against streptozotocin diabetes as its administration ameliorated most of the pathological changes⁵. The study of A. A. Albajali⁶³ showed the histological abnormalities caused by diabetic induction and improvement after treatment with *Nigella sativa*. In the study of Kanter M⁷ immunohistochemical labeling of the pancreatic tissue of control rats revealed strong insulin antigen positivity in the beta cells of the islets. In untreated diabetic rat, the cells were negative for insulin-immunoreactivity and only a few beta cells in some islets displayed slight insulin immunopositivity in small granules. In diabetic rats with thymoquinone treatment, both

the number of insulin-immunoreactive beta cells and the immunopositivity of their granules increased in comparison with those seen in diabetic control rats. The same study suggested that thymoquinone treatment has a therapeutic protective effect against diabetes by preserving pancreatic beta cell integrity and decreasing oxidative stress. It is concluded that all our histological findings support the antioxidant nature of *Nigella sativa* seed and thymoquinone which help in preserving pancreatic beta cell integrity.

6.3.2. Liver

Sections of liver of normal control rats studied under H&E stain showed normal liver parenchymal tissue composed of hexagonal lobules. Each lobule consists of central vein from which the hepatocytes radiate outwards. The portal triads 3 to 5 number are located at the periphery of the lobule, containing branches of bile duct, portal vein and hepatic artery. Cords of hepatocytes and sinusoids radiate from central vein to the peripheral portal triads. The sinusoids are lined by both Kupffer cells and endothelial cells, both of which have ill-defined cytoplasmic margins and inconspicuous flattened nuclei. The central veins are lined by endothelial cells surrounded by ring of collagen fibres. The hepatocytes are polygonal in shape with well-defined borders. Sections of liver of normal control rats treated with *Nigella sativa* seed powder showed the same architecture as normal control rats. There were no pathological observations. Normal control rats treated with thymoquinone also showed same features as normal control rats. These findings supports nontoxic effect of *Nigella sativa* seed powder and thymoquinone.

Section of liver of diabetic control rats studied under H&E stain showed the distortion in the arrangement of hepatocytes around the central vein, focal necrosis of hepatocytes with periportal fatty infiltration, hydropic changes, infiltration and aggregation of lymphocytes between hepatocytes. Our findings are similar to the findings of Morfologia et al⁶⁴, Das et al⁶⁵ and Degirmenchi et al⁶⁶, who showed dilatation of veins, loss of usual concentric arrangement of hepatocytes and liver fibrosis in their studies. Sections of liver of diabetic rats treated with *Nigella sativa* seed powder studied under H&E stain showed the normal hepatocyte arrangement around the central vein, reduced necrotic changes near to normal cellular architecture and the blood vessels in some places coming near to normal appearance. Diabetic rats treated with thymoquinone also showed the same beneficial effect as *Nigella sativa* seed treatment. These beneficial findings of *Nigella sativa* and thymoquinone may be due to antioxidant effect and hepatorepairing ability. These histological findings are in support to our biochemical parameters, that is lowered liver enzymes in diabetic rats by *Nigella sativa* seed powder and thymoquinone treatment.

Studies of Das AV⁶⁵, Elmarakby⁶⁷, Evelson P⁶⁸ and Badary OA⁶⁹ also reported the similar histopathological finding of present study, in their study showed congestion in blood sinusoids as well as the central and the portal veins in the liver sections of diabetic untreated rats. Dilatation of the hepatic veins in diabetic rats as well as hepatic sinusoids also observed. In their studies, an increase in mononuclear cellular infiltration was observed in the periportal areas. In study of Elmarakby⁶⁷, Badary OA⁶⁹ and El-Tawil O⁷⁰ studies showed that diabetic rats treated with *Nigella sativa* treatment had

preserved hepatic tissues compared with diabetic untreated group. The hepatocytes were relatively normal, with vesicular nuclei. The portal areas were not apparently infiltrated with inflammatory cells in *Nigella sativa* treated group, the present study also observed similar findings. The present study shows *Nigella sativa* seed and thymoquinone having hepatoprotective nature against liver damaged by STZ induced diabetes.

6.3.3. Kidney

The H&E stained sections of kidney of normal control rats showed classical histological features of normal renal parenchymal tissue. The renal sections of normal rat groups treated with *Nigella sativa* and thymoquinone showed all classical features of renal tissue as normal control rats. This indicates nontoxic effect of *Nigella sativa* seed powder and its phytochemical component thymoquinone on renal tissue. Our observations are similar to the observations of Le et al.¹² in normal rats treated with *Nigella sativa*. Mohammad Aziz Dollah⁷¹ showed that oral administration of *Nigella sativa* has no toxicity by different doses used. These results are similar to the observations of EL-Kholy et al⁷² and AL Ameen et al⁷³.

The renal H& E stained sections of streptozotocin induced diabetic untreated rats observed the mesangium of the lobules of the glomerulus deposited with hyaline material. There was a diffuse infiltration of the glomerular tuft and also heavy focal deposition. The diffuse infiltrate appeared to be in the basement membrane of the capillaries and the capillary bed had been obliterated in places. In many of the glomeruli, lesions characteristic of diabetic glomerulosclerosis were present. In diabetic control rats renal sections showed that the nodules scattered among some non-affected normal

glomeruli and it is considered as a characteristic of diabetes mellitus. In most of the diabetic control rats renal sections showed areas of lymphocytic infiltrate in the interstitium. The S. L. Teoh et al⁷⁴ observed the damage in the glomerulus, thickened basement membrane and mucopolysaccharide deposits in proximal convoluted tubule of diabetic untreated kidneys. Sugano M et al⁷⁵ also observed similar findings in diabetic rats. The groups that were treated with *Nigella sativa* seed powder and thymoquinone showed features of normal glomerulus, normal basement membrane and capillaries, very less number of inflammatory cells and decrease in the hyaline deposit. Overall the kidney of treated diabetic rats appears to have normal histological architecture. The beneficial effect of *Nigella sativa* seed and thymoquinone may be due to antioxidant effect of these. In the study of Abdul Karim Salim Mahood⁷⁶ similar results were found in streptozotocin diabetic rats treated with *Nigella sativa* showed features of healing that are normal glomerulus with normal basement membrane and capillaries, decrease in the mucopolysaccharides, hyaline deposit and absence of inflammatory cells. The tissue necrosis was also observed to decrease. In the study of Kanter M⁷ treatment of thymoquinone repaired degenerated glomerular size, glomerular and tubular basement membranes, thickening of capsule, increased amounts of mesangial matrix and tubular dilatation and renal function as compared with diabetics untreated. This study concluded that thymoquinone therapy causes renal morphologic and functional improvement after streptozotocin induced diabetes in rats. The study of Ola Omran⁷⁷ found similar results and concluded that thymoquinone has protective effect on experimental diabetic nephropathy. All the above mentioned studies concluded that the antioxidant properties

of *Nigella sativa* seed and thymoquinone are the main reason to repairing ability of diabetic nephropathy.

6.3.4. Nerve

The nerve sections of normal control rats showed normal nerve architecture. Fine myelinated nerve fibres are found with nucleus of Schwann cells and connective tissue coverings. There was no pathological observations in normal rat groups treated with *Nigella sativa* seed powder and thymoquinone. The diabetic control rat nerve sections showed similar architecture as normal control rats. The diabetic rats treated with *Nigella sativa* seed powder and thymoquinone also showed similar architecture as normal control rats. There was no pathological changes between normal rats and streptozotocin induced diabetic rats. Our results similar to the findings of Guven A et al⁷⁸.

Histopathological architecture of pancreas, liver and kidney of diabetic rat groups treated with *Nigella sativa* and thymoquinone supports beneficial effect of *Nigella sativa* and its major bioactive component thymoquinone. This may be due to antioxidant properties of both phytochemical components.

BIBLIOGRAPHY

1. Akbarzadeh, D. Norouzian, M.R. Mehrabi, Sh. Jamshidi , A. Farhangi , A. Allah Verdi, S.M.A. Mofidian, B. Lame Rad. Induction of Diabetes by Streptozotocin In Rats. *Indian Journal of Clinical Biochemistry*, 2007; 22 (2):60-64.
2. Samad Alimohammadi, Rahim Hobbenaghi, Javad Javanbakht, Danial Kheradmand, Reza Mortezaee, Maryam Tavakoli, Farshid Khadivar, Hamid Akbari. Protective and antidiabetic effects of extract from *Nigella sativa* on blood glucose concentrations against streptozotocin (STZ)-induced diabetic in rats: an experimental study with histopathological evaluation. *Diagn Pathol*. 2013; 8: 137.
3. Kanter M, Coskun O, Korkmaz A. Effects of *Nigella sativa* on oxidative stress and β -cell damage in streptozotocin-induced diabetic rats. *Anat Rec A Discov Mol Cell Evol Biol*. 2004;279(1):685–691.
4. Kaleem M, Kirmani D, Asif M, Ahmed Q, Bano B. Biochemical effects of *Nigella sativa* L seeds in diabetic rats. *Indian J Exp Biol*. 2006 Sep;44(9):745-8.
5. Abdelmeguid NE, Fakhoury R, Kamal SM, Al Wafai RJ. Effects of *Nigella sativa* and thymoquinone on biochemical and subcellular changes in pancreatic β -cells of streptozotocin-induced diabetic rats. *Diabetes*. 2010;2(4):256–66.
6. Inove M, Saito Y, Hirato E, Morino Y, Nagase S. Regulation of redox status of plasma proteins by mechanism and transport of glutathione and related compounds. *J Protein Chem*, 1987;36: 169.

7. Kanter M, Akpolat M. Protective effects of the volatile oil of *Nigella sativa* seeds on β -cell damage in streptozotocin-induced diabetic rats: a light and electron microscopic study. *J. Government inf.* 2009; 40: 379-385.
8. Alsaif MA. Effect of *Nigella sativa* oil on impaired glucose tolerance and insulin insensitivity induced by high-fat-diet and turpentine-induced trauma. *Pak J Biol Sci.* 2008;11(8):1093–9.
9. Geng D, Zhang S, Lan J. Analysis on chemical components of volatile oil and determination of thymoquinone from seed of *Nigella glandulifera*. *Zhongguo Zhong Yao Za Zhi.* 2009;34(22):2887–90.
10. Labhal, A., Settaf, A., Bennani, N., Cherrah, Y., Slaoui, A., Hassar, M. Action anti-obésité et hypocholestérolémiant de *Nigella sativa* chez le rat des sables. *Caducee.* 1997; 27, 26–28.
11. Labhal, A., Settaf, A., Zalagh, F., Cherrah, Y., Hassar, M., Slaoui, A. Propriétés anti-diabétiques des graines de *Nigella sativa* chez le Meriones shawi obèse et diabétique. *Espérance Médicale.* 1999; 47, 72– 74.
12. Le, P.M., Benhaddou-Andaloussi, A., Elimadi, A., Settaf, A., Cherrah, Y., Haddad, P. The petroleum ether extract of *Nigella sativa* exerts lipid-lowering and insulin-sensitizing actions in the rat. *Journal of Ethnopharmacology.* 2004;94, 251–259.
13. Al-Awadi, F.M., Khattar, K.A., Guamaa, K.A. On the mechanism of the hypoglycaemic effect of a plant extract. *Diabetologia.* 1985;28, 432–434.

14. Bouchra Meddaha, Robert Ducrocq, Moulay El Abbas Faouzia, Bruno Etoc, Lahcen Mahraouic, Ali Benhaddou-Andaloussia,d, Louis Charles Martineaud, Yahia Cherraha, Pierre Selim Haddadd. Nigella sativa inhibits intestinal glucose absorption and improves glucose tolerance in rats. *Journal of Ethnopharmacology* 2009;121:419–424.
15. El-Dakhakhny, M., Mady, N., Lembert, N., Ammon, H.P., 2002. The hypoglycemic effect of Nigella sativa oil is mediated by extrapancreatic actions. *Planta Medica*. 2000;68(5):465-6.
16. Halliwell B, Gutteridge JMC. *Free radicals in biology and medicine*. 3rd ed. Oxford, UK: University Press. 1999; 20–37p.
17. Wolf SP. Diabetes mellitus and free radical. *Free radicals in medicine*. *Br Med Bull*. 1993;49:643–649.
18. El-Missiry MA, El-Gindy AM. Amelioration of alloxan induced diabetes mellitus and oxidative stress in rats by oil of Eruca sativa seeds. *Ann Nutr Metab*. 2000;44:97–100.
19. Mahmood MS, Gilani AH, Khwaja A, Rashid A, Ashfaq MK. The in vitro effect of aqueous extract of Nigella sativa seeds on nitric oxide production. *Phyther Res* 2003;17:921–924.
20. Bahram Pourghassem-Gargari¹, Vahideh Ebrahimzadeh-Attary^{1*}, Maryam Rafraf¹ and Abolfazl Gorbani. Effect of dietary supplementation with Nigella sativa L. on serum lipid profile, lipid peroxidation and antioxidant defense

system in hyperlipidemic rabbits *Journal of Medicinal Plants Research* Vol. 3(10), pp. 815-821, October, 2009.

21. Padhye S, Banerjee S, Ahmad A, Mohammad R, Sarkar FH. From here to eternity - the secret of Pharaohs: Therapeutic potential of black cumin seeds and beyond. *Cancer. Ther.* 2008;6 (b): 495-510.
22. Arts IC, Hollman PC. Polyphenols and disease risk in epidemiologic studies. *Am. J. Clin. Nutr.* 2005;81: 317-325.
23. Moyers SB, Kumar NB. Green tea polyphenols and cancer chemoprevention: multiple mechanisms and endpoints for phase II trials. *Nutr. Rev.* 2004;62 (5): 204-211.
24. A.A. Sayed. Thymoquinone and proanthocyanidin attenuation of diabetic nephropathy in rats. 2012; 16: 808-815.
25. Kanter M, Coskun O, Budancamanak M. Hepatoprotective effects of *Nigella sativa* L and *Urtica dioica* L on lipid peroxidation, antioxidant enzyme systems and liver enzymes in carbon tetrachloride- treated rats. *World. J. Gastroenterol.* 2005;11 (42):6684-8.
26. Kanter M, Coskun O, Kalayci M, Buyukbas S, Cagavi F. Neuroprotective effects of *Nigella sativa* on experimental spinal cord injury in rats. *Hum. Exp. Toxicol.* 2006;25 (3): 127.
27. Schettler V, Wieland E, Verwiebe R, Schuff-Werner P, Scheler F, Oellerich M. Plasma lipids are not oxidized during hemodialysis. *Nephron.* 1994;67:42-47.

28. Kennedy L, Baynes JW. Non-enzymatic glycosylation and the chronic complications of diabetes: an overview. *Diabetologia*. 1984;26:93–98.
29. Pari, L., S. Srinivasan and M. Saddiq. Preventive effect of diosmin, a bioflavonoid, on glycoprotein changes in streptozotocin-nicotinamide-induced type 2 diabetic rats. *Int. J. Pharmaceutical Sci. Res.* 2010;1: 89-95.
30. Amin B, Hosseinzadeh H. Black Cumin. Black Cumin (*Nigella sativa*) and Its Active Constituent, Thymoquinone: An Overview on the Analgesic and Anti-inflammatory Effects. *Planta Med* 2016; 82: 8–16.
31. Hausenloy DJ, Yellon DM. Enhancing cardiovascular disease risk reduction: Raising high-density lipoprotein levels. *Curr Opin Cardiol*.2009;24:473–82.
32. Badimón JJ, Ibáñez B. Increasing high-density lipoprotein as a therapeutic target in atherothrombotic disease. *Rev Esp Cardiol*. 2010;63:323–33.
33. American Diabetes Association: Standards of Medical Care in Diabetes. *Diabetes Care*. 2012;35:S11–63.
34. Zaoui A, Cherrah Y, Alaoui K, Mahassine N, Amarouch H, Hassar M. Effects of *Nigella sativa* fixed oil on blood homeostasis in rat. *J. Ethnopharmacol*. 2002;79 (1): 23-6.
35. Bamosa AO, Ali BA, al-Hawsawi ZA. The effect of thymoquinone on blood lipids in rats. *Indian. J. Physiol. Pharmacol*. 2002;46 (2): 195-201.
36. Morikawa T, Xu F, Kashima Y, Matsuda H, Ninomiya K, Oshikawam M. Novel dolabellane-type diterpene alkaloids with lipid metabolism promoting activities from the seeds of *Nigella sativa*. *Org Lett* 2004; 6(6): 869-872.

37. Ali BH, Blunden G. Pharmacological and toxicological properties of *Nigella sativa*. *Phytother. Res.* 2003;17 (4): 299–305.
38. Talati R, Baker WL, Pabilonia MS, White CM, Coleman CI. The effects of barley-derived soluble fiber on serum lipids. *Ann. Fam. Med.* 2009;7 (2): 157-163.
39. Moruisi KG, Oosthuizen W, Opperman AM. Phytosterols/stanols lower cholesterol concentrations in familial hypercholesterolemic subjects: a systematic review with meta-analyses. *J. Am. Coll. Nutr.* 2006;25 (1): 41-8.
40. El-Beshbishy HA, Singab ANB, Sinkkonen J, Pihlaja K. Hypolipidemic and antioxidant effects of *Morus alba* L. (Egyptian mulberry) root bark fractions supplementation in cholesterol-fed rats. *Life Sci.* 2006;78: 2724 – 2733.
41. Weggemans RM, Trautwein EA. Relation between soy-associated isoflavones and LDL and HDL cholesterol concentrations in humans: a Meta analyses. *Eur. J. Clin. Nutr.* 2003;57 (8): 940–946.
42. Hamdy NM, Taha RA. Effects of *Nigella sativa* oil and thymoquinone on oxidative stress and neuropathy in streptozotocin-induced diabetic rats. *Pharmacology.* 2009;84(3):127-34.
43. Ismail M, Al-Naqeep G, Chan KW. *Nigella sativa* thymoquinone-rich fraction greatly improves plasma antioxidant capacity and expression of antioxidant genes in hypercholesterolemic rats. *Free Radic Biol Med.* 2010;48:664–72.

44. Ayed Al-Logmani, Talal Zari. Long-term effects of *Nigella sativa* L. oil on some physiological parameters in normal and streptozotocin-induced diabetic rats. *Journal of Diabetes Mellitus*. 2011;1(3); 46-53.
45. Wanke, L. and Wong, N. (1991) Diabetes mellitus de-creases the activity of the albumin romotor in vitr Jour nal of Biological Chemistry, 266, 6068-6072.
46. Tragl, K.H., Reaven, G.M. Effect of insulin deficiency on hepatic ribosomal aggregation. *Diabetes*. 1972;21:84-88.
47. Ayed Sh. AL-Logmani and Talal A. ZARI2*Effects of *Nigella sativa* L. and *Cinnamomum zeylanicum* Blume oils on some physiological parameters in streptozotocin-induced diabetic rats. *Boletín Latinoamericano y del Caribe de Plantas Medicinales y Aromáticas* 2009;8(2):86–96.
48. Ohaeri, O. Effect of garlic oil on the levels of various enzyme in the serum and tissue of strediabetic rats. *Bioscience Reports*. 2001;21, 19-24.
49. Navarro C, Montilla P, Martin A, Jimenez J, Utrilla P. Free radicals scavenger and antihepatotoxic activity of *Rosmarinus*. *Planta Med*. 1993;59:312–314.
50. Gani MS, John SA. Evaluation of hepatoprotective effect of *Nigella Sativa* L. *Int J Pharm Pharm Sci* 2013;5:428-30.
51. Mansour MA, Ginawi OT, El-Hadiyah T, El-Khatib AS, Al-Shabanah OA, Al-Sawaf HA. Effects of volatile oil constituents of *Nigella sativa* on carbon tetrachloride-induced hepatotoxicity in mice: evidence for antioxidant effects of thymoquinone. *Res Commun Mol Pathol Pharmacol* 2001;110(3-4):239-51.

52. Daba MH, Abdel-Rahman MS. Hepatoprotective activity of thymoquinone in isolated rat hepatocytes. *Toxicol Lett* 1998;95(1):23-9.
53. Mansour MA. Protective effects of thymoquinone and desferrioxamine against hepatotoxicity of carbon tetrachloride in mice. *Life Sci* 2000;66(26):2583-91.
54. Adel Abdel Moneim, Hamdi Helmy, Eman S. Abdel-Reheim1 and Wsam Addaleel. Effect Of Thymoquinone And Camel Milk On Liver Function Of Streptozotocin Induced Diabetic Albino Rats. *EJBPS*. 2016, Volume 3, Issue 2, 65-71.
55. Bashandy S, Jaleel G, Abdallah H, Harraz S. Therapeutic Implications of Thymoquinone in the Management of Diabetes mellitus and its Complications. *Adv J of Phytomed and Clin Therap*, 2015; 3(3): 287-301.
56. Pari L, Sankaranarayanan C. Beneficial effects of thymoquinone on hepatic key enzymes in streptozotocin nicotinamide induced diabetic rats. *Life Sci.*, 2009; 85(23-26): 830-4.
57. Abdel-Moneim A. Effect of *Nigella sativa* on aflatoxinbi-induced oxidative stress in male albino rats. *J EGY GER SOC OF ZOOL*, 2004; 44: 301-22.
58. Abdel Moneim A, El-Feki M, Salah ES. Effect of *Nigella sativa*, fish oil and gliclazide on alloxan diabetic rats.1: biochemical and histopathological studies. *J EGY GER SOC OF ZOOL*, 1997; 23: 237-66.
59. Mahmoud MR, El-Abhar HS, Saleh S. The effect of *Nigella sativa* oil against the liver damage induced by *Schistosoma mansoni* infection in mice. *J Ethnopharmacol*, 2002; 79: 1–11.

60. Aughsteen, A.A., 2000. An ultrastructural study on the effect of STZ on the islet of Langerhans in mice. *Electric Microscope*, 49: 681-690.
61. Azza Attia, A., 2009. Histological and electron microscopic studies of the effect of -Carotene on the pancreas of streptozotocin (STZ)-induced diabetic rats. *Pak. J. Biol. Sci.*, 12: 301-314.
62. Afaf Jamal Ali Hmza, Effat Omar, Ariza Adnan and Muhamed T. Osman. *Nigella sativa* Oil Has Significant Repairing Ability of Damaged Pancreatic Tissue Occurs in Induced Type 1 Diabetes Mellitus *Global Journal of Pharmacology* 7 (1): 14-19, 2013.
63. A. A. Albajali¹, A. H. Nagi, M. Shahzad¹, M. Ikram Ullah and S. Hussain. Effect of *Allium sativa* L. on pancreatic β cells in comparison to *Nigella sativa* L. in streptozotocin induced diabetic rats. *Journal of Medicinal Plants Research*. 2011;5(24):5779-5784.
64. Morfología y Enzimas del Hígado Alteradas en Ratas con Diabetes Inducida por Estreptozotocina. *Altered Liver Morphology and Enzymes in Streptozotocin Induced Diabetic Rats. Int. J. Morphol.*, 27(3):719-725, 2009.
65. Das, A. V.; Padayatti, P. S. & Paulose, C. S. Effect of leaf extract of *Aegle Marmelose* (L.) Correa ex Roxb. On histological and ultrastructural changes in tissues of Streptozotocin induced diabetic rats. *Indian J. Exp. Biol.* 1996;34(4):341-5.
66. Degirmenchi, I.; Kalender, S.; Ustuner, M. C.; Kalender, Y.; Gunes, H. V.; Unal, N. & Basaran, A. The effects of acarbose and *Rumex patientia* on liver

- ultrastructure in streptozotocin-induced diabetic (type-II) rats. *Drugs Exp. Clin. Res.*, 28:229-34, 2002.
67. Elmarakby, Dalia M.^a; Sourour, Doaa A. The effect of *Nigella sativa* on the diabetic liver in male albino rats with a special focus on the role of hepatic oval cells. *The Egyptian Journal of Histology*: 2012;35(4):749–760.
68. Evelson P, Susemihl C, Villarreal I, Llesuy S, Rodríguez R, Peredo H, et al. Hepatic morphological changes and oxidative stress in chronic streptozotocin-diabetic rats. *Ann Hepatol*. 2005;4:115–120.
69. Badary OA, Taha RA, Gamal el-Din AM, Abdel-Wahab MH. Thymoquinone is a potent superoxide anion scavenger. *Drug Chem Toxicol*. 2003;26:87–98.
70. El-Tawil O, Moussa SZ. Antioxidant and hepatoprotective effects of thymoquinone against carbon tetrachloride-induced hepatotoxicity in isolated rat hepatocyte. *J Egypt Soc Toxicol*. 2006;34:33–41.
71. Mohammad Aziz Dollah¹, Saadat Parhizkar^{2*}, Mohammad Izwan¹. Effect of *Nigella sativa* on the kidney function in rats. *Avicenna Journal of Phytomedicine* Vol. 3, No. 2, Spring 2013, 152-158.
72. EL-Kholy WM, Hassan HA, Nour SE, Abe Elmageed ZE, Matrougui K. 2009. Hepatoprotective effects of *Nigella sativa* and bees' honey on hepatotoxicity induced by administration of sodium nitrite and sunset yellow. *FASEB J*. 2009;23: 733.
73. Al Ameen NM, Altubaigy F, Jahangir T, Mahday IA, Esmael Abdurrahman Mohammed EA and Musa OAA. Effect of *Nigella sativa* and bee honey on

pulmonary, hepatic and renal function in Sudanese in Khartoum state. *J Med Plant Res.* 2011;5: 6857-6863.

74. S. L. Teoh, Azian Latiff, S. Das. Histological changes in the kidneys of experimental diabetic rats fed with *Momordica charantia* (bitter gourd) extract *Romanian Journal of Morphology and Embryology* 2010, 51(1):91–95.
75. Sugano M, Yamato H, Hayashi T, Ochiai H, Kakuchi J, Goto S, Nishijima F, Iino N, Kazama JJ, Takeuchi T, Mokuda O, Ishikawa T, Okazaki R. High-fat diet in lowdose- streptozotocin-treated heminephrectomized rats induced all features of human type 2 diabetic nephropathy: a new rat model of diabetic nephropathy, *Nutr Metab Cardiovasc Dis*, 2006, 16(7):477–484.
76. Abdul Karim Salim Mahood. Histological study of the effect of *Nigella sativa* on diabetic nephropathy in rats. *Tikrit Medical Journal* 2012;18(2):154-168.
77. Ola Omran. Effects of Thymoquinone on STZ-induced Diabetic Nephropathy: An Immunohistochemical Study. *Ultrastructural Pathology.* 2013;38(1).
78. Guven, Aysel, Yavuz, Ozlem, Cam, Meryem, Comunoglu, Cem and Sevnc, Ozdemr(2009)'Central Nervous System Complications of Diabetes in Streptozotocin-Induced Diabetic Rats: A Histopathological and Immunohistochemical. Examination *International Journal of Neuroscience.* 119:8,1155-1169.

CHAPTER 7

Summary and Conclusion

Summary and Conclusion

Based on the results of the present study it may be concluded that *Nigella sativa* seed and thymoquinone have beneficial effect in treating the streptozotocin induced diabetic rats. It may be due to their antioxidant nature which helps to repair the damaged metabolic organs tissue like pancreas and liver.

- Glucose levels of induced diabetic rats were increased significantly and were lowered after treatment with *Nigella sativa* seed and thymoquinone. Insulin levels of induced diabetic control rats were decreased significantly and increased significantly in diabetic treated rat groups with *Nigella sativa* seed and thymoquinone. This may be due to preservation of integrity of β -cells by their antioxidant properties, which leads to increased secretion of insulin. Increased level of insulin in diabetic treated rat groups leading to lowering of higher glucose levels.
- Tolerance in oral glucose tolerance test is increased significantly in diabetic rat groups treated with *Nigella sativa* seed and thymoquinone compared with untreated diabetic rats. It may be due to increased insulin secretion or *Nigella sativa* seed and thymoquinone helping to increase peripheral glucose utilization or insulin sensitivity or decreased intestinal glucose absorption through extrapancreatic action.
- Streptozotocin caused shrinkage of islets of Langerhans and necrosis of β -cells in pancreas and increased oxidative stress due to toxic effect of streptozotocin on β -cells. This is supported by increased levels of MDA in streptozotocin induced diabetic rats and histopathological observations of pancreatic tissue.

- SOD levels of *Nigella sativa* seed and thymoquinone treated diabetic rat groups revealed that these components have antioxidant nature. This is also supported by histopathological observations of pancreatic tissue which showed reduced severity of degenerative and necrotic changes in islets of diabetic treated rat groups.
- In diabetic rats decreased levels of vitamin C and E were observed. It may be because of more oxidative stress and utilization of vitamin C and E. Increased levels of vitamin C and E in diabetic treated rat groups with *Nigella sativa* seed and thymoquinone indicating the antioxidant nature of both components. In addition there are many fatty acids in *Nigella sativa*, the most important of which are linoleic acid, oleic acid, palmitic acid, tocopherols and vitamin C which lead to increase in vitamin C and E levels.
- The levels of HDL-cholesterol were decreased significantly in induced diabetic untreated rats. The levels of HDL-cholesterol were improved significantly in diabetic treated rat groups with *Nigella sativa* seed and thymoquinone. The levels of total cholesterol(TC), triglycerides(TG), LDL-cholesterol and VLDL- cholesterol were elevated significantly in induced diabetic untreated rats. The treated groups of induced diabetic rats with *Nigella sativa* seed and thymoquinone showed significant decrease of all these parameters. The results of our study showed a promising hypolipidemic effect produced *Nigella sativa* and thymoquinone supplementation in induced diabetic treated rat groups. Flavonoids of *Nigella sativa* seed may be one of the reasons for hypolipidemic effect of it, as flavonoids helps liver cells to make more efficient to remove LDL-C from blood. To do this, flavonoids are acting to increase LDL receptor densities in liver by binding to apolipoprotein B.

- The level of total protein was reduced significantly in diabetic control rats. The levels of total proteins were improved in diabetic rat groups treated with *Nigella sativa* seed and thymoquinone. This effect is presumably due to its ability to increase insulin secretion.
- The levels of AST, ALT and ALP were increased significantly in diabetic control rats. Treatment with *Nigella sativa* seed and thymoquinone helped in lowering of AST, ALT and ALP levels. A possible explanation for the beneficial effects of *Nigella sativa* and thymoquinone on the activities of AST, ALT and ALP in blood is that these components may inhibit the liver damage induced by streptozotocin. The histopathological observation of liver sections of diabetic treated groups supporting this.
- There was no difference in any parameters between normal control rat group and normal rat groups treated with *Nigella sativa* and thymoquinone. This indicates non-toxic effect of *Nigella sativa* and thymoquinone. Our histopathological findings further support this observation as there were no pathological observations in normal rats groups treated with *Nigella sativa* seed and thymoquinone.
- *Nigella sativa* seed and thymoquinone give the same results. This suggests that the active ingredient thymoquinone is the most effective against streptozotocin diabetes as its administration ameliorated most of the pathological changes.
- All the results clearly indicate that there is beneficial effect in altered parameters which are affected by streptozotocin induced diabetes. As the beneficial effect of *Nigella sativa* seed and thymoquinone are seen in the present study, these phytochemical components may be considered as antidiabetic.

- The mechanism of beneficial effect of *Nigella sativa* seed and thymoquinone, probably through acted as antioxidant agents, which keep to rectify oxidant and antioxidant balance in tissues like liver, kidney and pancreas. Also it may be due to a cellular protective mechanism through cell signal pathways in pancreas with resultant amelioration of glucose homeostasis. Perhaps both *Nigella sativa* seed and thymoquinone improve cellular integrity especially in hepatocytes and cells of islets, this modulates pathophysiology of metabolically active tissue.

Limitations of the present study

- We could not evaluate the exact active compound of *Nigella sativa* seed which is acting as antidiabetic compound.
- Crude of seed was used directly.

Scope for future study


- More refine screening of *Nigella sativa* seed may be done for further conclusion.
- Different extractions of *Nigella sativa* seed may be used to evaluate its medicinal properties.
- Further evaluation of molecular factors, especially transcriptional factors need to be evaluated.

ANNEXURE - I

PUBLICATIONS

- Hepatoprotective effect of nigella sativa seed in sterptozotocin induced diabetic albino rats: histological observations. Int J Anat Res 2016,4(2):2459-63.
- Effect of Nigella sativa seed on streptozotocin induced diabetic reno toxicity: histological observations. Int J Anat Res 2016;4(3):2566-70.
- Antioxidant Effect of Nigella Sativa Seed Powder and Thymoquinone in Normal and Sterptozotocin Induced Diabetic Albino Rats. Int J Intg Med Sci 2016;3(3):242-47.
- Effect of Nigella Sativa Seed Powder on MDA and SOD levels in Sterptozotocin Induced Diabetis Albino Rats. J. Pharm. Sci. & Res. Vol. 7(4), 2015, 206-209.
- Effect of Thymoquinone on MDA and SOD levels in Sterptozotocin Induced Diabetic Albino Rats. J. Pharm. Sci. & Res. Vol. 7(4), 2015, 234-37.

Chairman,
Institutional Animal Ethics Committee (IAEC),
Prof. & HOD, Dept. of Pharmacology,
BLDEU's Shri. B.M.Patil Medical College,
BIJAPUR.



Mr. Shaik Hussain Saheb
Ph.D (Anatomy) Candidate,
BLDEU's Shri. B.M.Patil Medical College,
BIJAPUR.

ETHICAL CLEARANCE CERTIFICATE

The Institutional Animal Ethics Committee (IAEC) of this College met on 26.07.2013 at 10.30am to scrutinize the Research Project submitted by Ph.D candidate of this College.

The queries raised by the Ethics Committee have been satisfactorily answered by you, hence the Ethical Clearance is accorded for your Research project.

Title: "Effect of Nigella Sativa seed extract on glucose, lipid profile, liver function tests, oxidative stress and histological changes in pancreas, kidney, liver and tibial nerve in normal and streptozotocin induced diabetic rats".

Principal investigator: Mr. Shaik Hussain Saheb, PhD (Anatomy) Candidate.

11.09.2013

A handwritten signature in black ink, appearing to be 'R. S. Wali', written over a horizontal line. Below the signature is the date '11/9/2013'.

Dr. R. S. Wali
Chairman, (IAEC).
Professor & HOD
Dept. of Pharmacology
BLDEU's Shri B.M. Patil
Medical College, BIJAPUR



BLDE UNIVERSITY

Annexure-I

PLAGIARISM VERIFICATION CERTIFICATE

1. Name of Student: SHAIK HUSSAIN SAHEB Reg. No. 11PHD.0014
2. Title of the Thesis: EFFECT OF MIMELLA SATIVA SEED EXTRACT ON GLUCOSE, LIPID PROFILE, LIVER FUNCTION TESTS, OXIDATIVE STRESS AND HISTOPATHOLOGICAL CHANGES IN PANCREAS, KIDNEY, LIVER AND TIBIAL NERVE IN NORMAL AND STREPTOZOCCIN INDUCED DIABETIC RATS
3. Department: ANATOMY
4. Name of Guide & Designation: DR. S.D. DESAI, PRINCIPAL, SIMSARC, TUMKUR.
5. Name of Co Guide & Designation: DR. G.F. MAVISHETTAR, PROFESSOR OF ANATOMY, JJMCH, DAVANAGERE

The above thesis was verified for similarity detection. The report is as follows:

Software used TURNITIN Date: 15/07/2017
 Similarity Index (%): 12.7 Total word count 36424

The report is attached for the review by the Student and Guide.

The plagiarism report of the above thesis has been reviewed by the undersigned. The similarity index is below accepted norms.

The similarity index is above accepted norms, because of the following reasons:

.....

The thesis may be considered for submission to the University. The software report is attached.

DR. S.D. DESAI
PRINCIPAL
 Shridevi Institute of Medical Sciences
 & Research Hospital,
 NH-4, Sira Road, TUMKUR 3
 Signature of Guide
 Name & Designation

Dr. G. F. Mavishettar
 Signature of Co-Guide
 Name & Designation

Shaik Hussain Saheb
 Signature of Student

W. G. Patil
 Verified by (Signature)
 Name & Designation
Librarian
 B.L.D.E. University's
 Shri B.M. Patil Medical College
 Bijapur.

Dr. G. F. Mavishettar
 Professor of Anatomy
 J. J. M. Medical College
 DAVANGERE-577454